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Abstract
Germinal center (GC) responses are responsible for the protection provided by
immunizations but can also drive autoimmunity. B and T cells collaborate in the GC to
target the same antigen (Ag) to inform B cell differentiation; however, the properties of
Ags differ substantially in autoimmunity and foreign-Ag driven immunity. Currently, it is
not well understood how properties of the Ag itself influence the initiation or progression
of GC responses, limiting our ability to develop effective vaccinations and predict the
progression of autoimmune responses. The purpose of this thesis is to assess how GC
responses initiate and progress when immunizing with an autoAg relative to a model
foreign-Ag. It was hypothesized that autoreactive GCs would be relatively short-lived and
less productive than foreign-Ag driven GCs due to limiting properties of the autoAg. To
address this hypothesis, we developed a modular protein expression system to purify
large amounts of myelin oligodendrocyte glycoprotein (MOG), a commonly targeted
autoAg in Multiple Sclerosis (MS), and streamlined the modification of the MOG
protein’s properties. Relative to immunization with a model foreign-Ag, immunization
with MOG induces a short-lived GC that collapses early forming a large numbers of
memory B cells. Memory B cells generated from the MOG-induced GC are capable of
participating in secondary GCs, however, these memory cells are short-lived resulting in
a short window in which MOG-specific memory B cells can be engaged. The progression
of the MOG-induced GC is then shown to be limited by low T cell Ag-affinity. A
possible explanation for how Ag-properties affect GC progression, is that Ag-properties
influence how B and T cells communicate with each other. To address this hypothesis,
reporters capable of monitoring the activation status of B and T cells were generated
although, attempts to generate mice carrying these reporters were unsuccessful. Overall,
these results confirm that properties of Ags affect the progression of GC responses and
that the MOG-induced GC is limited by properties of the MOG autoAg. These results
have important implications for future vaccine design but also gives insight into how
autoreactive B cells may expand in MS.
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Chapter 1

1

Introduction
Our bodies are exposed to pathogens every day of our lives requiring the

combined efforts of the innate and adaptive immune systems to control infections. In the
modern world, the control of infectious diseases such as smallpox and polio has been
greatly facilitated through the use of vaccinations that induce protective antibody
responses by stimulating B cells from the adaptive immune system. Vaccinations are
invaluable in modern healthcare (1) yet there are still many diseases, such as human
immunodeficiency virus and malaria, that we have difficulty generating effective B cell
responses against due to insufficient understanding of how the immune system adapts
itself to properties of the immunizing antigen(s) (Ag) (2, 3).
Nonetheless, while the promotion of B cell responses may be beneficial in the
context of immunity against pathogens, it is problematic in the context of autoimmunity.
Indeed, the induction of B cell responses needs to be regulated heavily as B cells can
target Ags within our own bodies, known as autoAgs, resulting in the development and
progression of autoimmune diseases (4). Typically, the B cell’s contribution to disease
has been attributed to the production of autoantibodies that facilitate the destruction of
host tissue. However, evidence of B cells playing additional roles beyond antibody
production have created a great deal of interest in understanding how new subsets of B
cells are generated and how they influence ongoing autoimmune responses (5). Thus, not
only is there a need to better understand how B cell responses develop towards
pathogens, but a better understanding of factors that limit B cell responses directed
against our own bodies is required. In this thesis, I will address both of these needs by
investigating the basic rules that inform B cell differentiation in immune responses
directed towards a model autoAg and a model foreign-Ag.

1.1

B and T cells in immunity and autoimmunity
I will start by discussing the essential properties of B cells that define how these

cells participate in immune responses and how this may change in autoimmunity. In
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addition, I will similarly discuss another cell of the immune system, called a T cell, as the
B cell responses I will be studying in the thesis involve a necessary collaboration of these
two cells types (this will be discussed in more detail later).

1.1.1 The generation and function of Ag-specific receptors on B and T cells
As B and T cells develop in the bone marrow and thymus, respectively, they
rearrange genomic DNA through a random process to generate unique receptors specific
to each of these cells (6, 7). For B cells, they recombine DNA to generate a B cell
receptor (BCR) that is unique to each B cell clone. The BCR can be used to capture or
target a specific Ag, which can consist of any unique 3-dimensional (3-D) surface that
can be recognized by a BCR (8, 9). The recognition of Ags using the BCR is essential for
B cells to act as antigen presenting cells (APCs) and antibody secreting cells (ASCs) and
it is through these functions that the B cell contributes to immunity.
T cells similarly generate T cell receptors (TCRs) that are again unique to
particular T cell clones and recognize a specific Ag (8). However, unlike B cells, they do
not recognize Ag directly, instead they require APCs to collect and process full-length
proteins into smaller fragments, often referred to as peptides or peptide fragments. These
small peptide fragments are then loaded onto a specialized protein complex called the
major histocompatibility complex (MHC). The peptide is loaded into a binding cleft on
the MHC where molecular interaction between the MHC and peptide determine the
efficiency of peptide loading (10). Once loaded, the peptide can be recognized in the
binding cleft by TCR molecules. Classically, αβ-T cells (that rearrange α and β TCR
chains) have been divided in CD4+ and CD8+ T cells that recognize Ag presented on
MHC class II and MHC class I molecules, respectively (11). The ability of T cells to
recognize Ags through their TCR is essential for T cells to participate in the immune
response by either coordinating the activity of other cells (12, 13) or by acting as
cytotoxic cells to kill their targets (14). Although there are additional subsets of T cells
beyond αβ CD4+ T cells, for the purposes of this thesis, I focus on these T cells as they
are the primary drivers of B cell responses (15).
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Collectively, the B and T cell repertoires of Ag-specificity can recognize an
almost unlimited number of Ags (16). Although this is highly beneficial for the immune
system’s ability to recognize pathogens, this is also problematic as many of the BCRs and
TCRs generated also recognize autoAgs and can participate in autoimmunity. To limit
autoimmunity, the immune system has several systems that act on B and T cells during
development (central tolerance) that shape the peripheral B and T cell repertoires. One
important mechanism for controlling autoreactive B and T cell responses is to limit the
production of B and T cells that recognize autoAgs with high Ag-affinity, a key property
of BCRs and TCRs that influences several aspects of B and T cell biology. Antigenaffinity is a measure of how strongly a BCR or TCR forms a physical contact with its
target Ag. Antigen-receptor affinity affects not only the capacity of B and T cells to
execute their effector functions (17, 18), but of key interest to this thesis, it also affects B
and T cell activation and differentiation (17, 19). Thus, it is likely that the cumulative Agaffinities of the B and T cell receptors available in the periphery of the body can in large
part influence how an immune response initiates and progresses. Indeed, the idea that Agreceptor affinity affects the progression of B cell responses will be addressed in this
thesis. In this next section, I will discuss how tolerance mechanisms bias the peripheral
autoreactive B and T cell repertoires towards lower Ag-affinities and why this would not
occur for foreign-Ag specific B and T cell repertoires.

1.1.2 The influence of tolerance on autoreactive B and T cell receptors
As B and T cells progress through their development, they undergo a process
known as negative selection that is responsible for purging autoreactive B and T cells (6,
20). Upon presentation of autoAgs during negative selection, developing B and T cells
respond by triggering tolerance pathways that affect B and T cells differently. The fate of
B cells upon recognizing an autoAg is to undergo receptor editing, wherein the BCR
locus undergoes additional recombination events in an attempt to generate a new BCR
that no longer recognizes autoAgs (21). In the event that a B cell cannot recombine and
generate a non-autoreactive BCR, the B cell is induced to undergo apoptosis (22). Central
tolerance of B cells successfully eliminates the vast majority of autoreactive B cells (6,
23, 24), however, approximately 20-40% of the peripheral B cell repertoire remains
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autoreactive (25) although they typically recognize autoAgs with a low Ag-affinity (25,
26). Additionally, many of the leftover autoreactive B cells are anergic (a state of reduced
responsiveness to Ag-receptor signaling) (27). Anergic B cells typically have a shorter
life-span than non-anergic B cells leading to increased bias against the persistence of
autoreactive cells (28-30). Altogether, central tolerance eliminates high-affinity
autoreactive B cells thereby biasing the peripheral autoreactive B cell repertoire to B cells
of low enough Ag-affinity to pass through central tolerance.
Similarly, autoreactive T cells undergo negative selection by exposure to autoAg
in the thymus. In turn, the fate of an autoreactive T cell is determined by its Ag-affinity
(31). T cells that recognize autoAgs with high-affinity are induced to undergo apoptosis,
T cells that have low-affinity for autoAgs are unaffected, and T cells recognizing autoAgs
with intermediate-affinity are induced to become regulatory T (Tregs) cells (32).
Regulatory T cells are important as these intermediate-affinity cells would normally
potently induce autoimmune disease but are instead, functionally programed to become a
subset of T cells that potently inhibits autoimmune responses (33, 34). Overall, central
tolerance of T cells effectively removes higher-affinity autoreactive T cells that would
otherwise potently induce autoimmune disease by either deleting or converting them into
regulatory cells, leaving a relatively smaller pool of low-affinity autoreactive T cells.
As foreign-Ags are not expressed in organs where B and T cells are developing,
tolerance mechanisms do not appreciably affect the Ag-affinities of foreign-Ag specific B
and T cell repertoires. Thus, a major difference between foreign-Ag specific and autoAgspecific B and T cells, is the abundance of high-affinity B and T cells in the foreign Agspecific repertoire (35). Based upon the bias of autoreactive B and T cells towards low
Ag-affinities, and given that Ag-affinity affects B and T cell activation, it is likely that
the low Ag-affinities of autoreactive B and T cells will limit any immune response
directed against protein autoAgs. Thus, I hypothesize that B cell responses, in the form of
germinal center (GC) responses that are dependent on collaboration between B and T
cells, will be short-lived and generally less productive than foreign-Ag induced GC
responses as a result of the low Ag-receptor affinities of autoreactive B and T cells.
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1.2

B cell responses in Multiple Sclerosis
Despite tolerance mechanisms limiting the capacity of autoreactive B and T cells

to participate in autoimmune responses, it is still possible to engage these cells to do so.
In this section, I will describe the autoimmune disease MS that incorporates autoreactive
B and T cells into its pathology.

1.2.1 Multiple Sclerosis and experimental autoimmune encephalomyelitis
Multiple Sclerosis is an autoimmune disease where the myelin sheath surrounding
neurons in the central nervous system (CNS) is targeted for destruction by the immune
system. Damage to the CNS results in cognitive and physical disabilities that vary
depending on the region of the brain or spinal cord that has been damaged (36). Studies
looking for genetic signatures associated with MS have identified predominantly genes
that are associated with the immune system suggesting the immune system plays a key
role in the initiation of MS (37). Historically, MS has been thought of as a CD4+ T cell
mediated autoimmune disease as the induction of a myelin-specific CD4+ T cell response
is the minimum requirement to induce CNS autoimmunity in animals (38). Collectively,
animal models of CNS autoimmunity are known as experimental autoimmune
encephalomyelitis (EAE) (39). Typically, EAE is induced by immunizing animals with
short peptide fragments corresponding to immunodominant CD4+ T cell epitopes derived
from one of three major components of the myelin sheath: MOG, proteolipid protein, and
myelin basic protein. The disease course of EAE follows a predictable course of
ascending paralysis in mice and is characterized by the infiltration of T cells, B cells, and
various myeloid cells near regions of demyelination in the spinal cord and brain (40). As
MS research has evolved additional cells beyond CD4+ T cells have emerged as
important mediators of disease including cells of the myeloid lineage, CD8+ T cells and,
of key interest to this thesis, B cells.

1.2.2 Role of the B cell in Multiple Sclerosis
B cells had originally been thought to be of limited importance to disease
progression because the induction of a CD4+ T cell response was the minimum
requirement to induce EAE and B cell-deficient mice develop worse EAE than wild type
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mice (41). These results were misleading however, as B cell deficient mice develop
worse EAE as a result of lacking IL-10/IL-35 expressing regulatory B (Breg) cells that
potently inhibit T cell responses (42-44). Interest in B cells in MS was reignited when the
depletion of B cells in MS patients using an anti-CD20 antibody was shown to be one of
the most effective treatments for MS currently available (45, 46). Indeed, although Bregs
can be found in MS patients (47), it is now clear that the B cell compartment is overall
pro-inflammatory in MS and animal models (48, 49). Interestingly, CD20 is expressed on
all human B cell subsets except antibody-secreting plasma cells and the therapeutic
benefit of the anti-CD20 monoclonal antibodies occurs before any decrease in serum
antibody levels suggesting that non-plasma cell B cells may be the primary contributor to
MS (50, 51).
Engaging B cells to participate in immune responses directed against protein Ags,
such as those that are targeted in MS, typically occurs by inducing a GC, a structure that
normally forms in secondary lymphoid organs such as the spleen, peyers patches, or
lymph node (LN) (52). Within the GC, B cells can acquire high-affinity BCRs by
mutating their genomes, in particular the BCR locus, using enzymes such as activationinduced cytidine deaminase and uracil-DNA glycosylase in combination with DNA
repair pathways to mutate nucleotides in the BCR locus, a process known as somatic
hypermutation (SHM) (53). Nucleotide changes within the BCR then translate into amino
acid changes in the BCR that can affect the BCRs ability to bind Ag. Activation-induced
cytidine deaminase is also involved in another process where B cells undergo
immunoglobulin class-switch recombination (CSR) where IgM and IgD BCR isotypes
are switched for IgG, IgE, and IgA BCR isotypes (54). Class-switching is important as
BCR isotype affects the effector functions of secreted antibodies and also affects Aginduced signaling through the BCR (55-57). Overall, the GC supports these two
processes leading to the production of high-affinity and class-switched B cell subsets that
contribute to potent long-term immunity (58). Thus, if B cells are being engaged in an
Ag-specific manner in MS, we would expect that there should be evidence of myelinspecific B cells that have undergone CSR and SHM.
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In support of the idea that myelin-specific B cells are stimulated in MS, highaffinity MOG-specific IgG antibodies can be found in the serum of 67% of early onset
pediatric MS patients (59) and 20-42% of MS patients later in disease (60-62).
Furthermore, at the later stages of disease, IgG-antibodies directed against other myelinAgs are commonly seen (63, 64). As these antibodies are class-switched and of highaffinity, this is highly suggestive that the plasma cells that generated these antibodies
were derived from GCs. Myelin-specific B cells have also been seen to contribute to EAE
in several different models. The contribution of myelin-specific B cells to EAE is
partially through antibodies (65), however, it is clear that myelin-specific B cells also
contribute to the initiation and progression of EAE independently of antibody secretion
(49, 66, 67). Thus, there is evidence of myelin-specific GCs occurring in MS and there is
evidence of myelin-specific B cells contributing to the pathology of EAE suggesting
myelin-specific B cells in MS may also contribute to MS pathology.
Germinal centers directed against myelin-Ags could potentially occur within the
deep cervical LNs as they are connected to the lymphatic drainage of the brain and thus,
make autoAgs available to autoreactive B and T cells (68-70). Consistent with the idea
that B cell responses in the deep cervical LNs are contributing to MS pathology, there is
evidence that clonally expanded B cells in the deep cervical LNs are clonally related to B
cells found within the CNS of MS patients (71, 72). In particular, analysis of SHM in B
cells derived from the deep cervical LNs, peripheral blood, and cerebral spinal fluid of
MS patients identified B cell clones that were derived from the same GC. Thus, beyond
there being evidence of myelin-specific GCs in MS, there is also evidence of GCs
occurring outside of the CNS that are generating Ag-experienced B cells that are entering
the CNS.
A key assumption in the literature is that the B cell clonal relationships found
between the periphery and the CNS are due to myelin-specific B cells proliferating in the
periphery and entering the CNS. However, despite the evidence suggesting that GCderived myelin-specific B cells contribute to the pathology of MS, no study to date has
characterized how a GC response directed against a myelin autoAg would initiate or
progress. Furthermore, as no one has studied myelin-specific GC responses, we also do
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not have a good understanding of what immune cells are generated from myelin-specific
GCs or the properties of those cells. Indeed, based upon what is known about B and T
cell activation and the properties of autoreactive B and T cells (section 1.1), it is likely
that a GC directed against a myelin-autoAg will not progress in the same fashion as
foreign-Ag induced GCs. In this thesis, I address this need by studying GC responses
directed against the myelin protein, MOG, which is commonly used to induce EAE. In
the next sections, I will describe what is currently known about GCs and how Agproperties affect GCs.

1.3

Germinal center responses
The initiation and progression of GC responses has been classically defined in

context of GCs in LNs or the spleen. Germinal center responses proceed similarly in LNs
and the spleen despite being structurally different (73, 74). However, the experiments in
this thesis focus exclusively on LNs and thus, I will only describe the GC response in the
LN. Lymph nodes are found throughout the body where they collect excess lymph from
surrounding tissues and process pathogens/debris/Ags that filter through the LN to
activate Ag-specific B and T cells (75) (Figure 1.1). Lymph nodes have a thick outer
capsule that forms a conduit for incoming lymph in conjunction with the subcapsular
sinus. Lymph filters through the subcapsular sinus into the B cell follicle that is located
just below the subcapsular sinus (73). B cells reside in the B cell follicle where they can
interact with Ags draining through the B cell follicle through a variety of mechanisms
that will be described in more detail in section 1.3.1. Below the B cell follicles, CD8+ and
CD4+ T cells reside in the T cell zone that serves as the site of initial T cell activation.
Then, at the absolute center of the LN, are the medullary cords where macrophage and
plasma cells/plasmablasts reside. After lymph has passed through these sites, it is
collected in the efferent lymphatic duct and flows through the lymphatic system until it
connects back to circulating blood through the thoracic duct (75). These microstructures
are essential in directing B and T cells during immune responses and these structures will
be discussed in detail in the following sections.
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Figure 1.1. Summary of developing germinal center responses.
Immune responses in LNs start when mature Ag-presenting dendritic cells and soluble
Ags flow into the LN. (A) The Ag-specific T cell response is initiated through
interactions with mature Ag-presenting dendritic cells (76). (B) The B cell response is
initiated when B cells engage their Ag with their BCR, resulting in their activation (77).
(C) When these two events occur, approximately 1 day post-immunization, activated B
cells and pre-T follicular helper (pre-TFH) cells will migrate to the periphery of the B cell
follicle and form cognate interactions (78). These cognate interactions are responsible for
driving B cell differentiation into memory B cells, antibody-secreting plasmablasts, and
differentiation into GC B cells as well as finishing TFH cell differentiation. (D)
Approximately 4 days post-immunization, TFH cells and GC B cells then migrate into the
B cell follicle and seed a new GC where they again form cognate interactions. These
interactions are responsible for GC maintenance and differentiation of GC B cells into
antibody-secreting plasma cell subsets (E) and memory B cells which can participate in
secondary GC responses if induced to do so (F) (79).
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1.3.1 The initiation of B and T cell responses
At the initiation of immune responses, Ags flow into LNs through lymphatic
vessels which permeate surrounding tissues. Once Ag has arrived at the LN, it can diffuse
across the subcapsular sinus through small pores that allow small Ags to cross this layer.
Alternatively, B cells can actively collect Ag by extending membrane projections into
small channels carrying lymph through the B cell follicle (80). Larger Ags can be
actively collected in LNs by subcapsular sinus macrophage that shuttle complement
associated Ag from the subcapsular sinus into the B cell follicle (81). Moreover, dendritic
cells (DCs) that have collected Ag from the periphery of the body can exocytose whole
Ag into the B cell follicle (82). Through the BCR, B cells can recognize soluble Ags
directly in extracellular fluid (Figure 1.1B) or can recognize Ag deposited on specialized
follicular dendritic cells (FDCs), which collect Ags and are found at the center of the B
cell follicle (83). The FDC is important at this early stage of the immune response as they
retain Ags for long periods of time and can also collect insoluble or low affinity Ags that
B cells may have more difficultly responding to (84).
B cell receptor recognition of Ags results in the activation of B cells, culminating
in gene expression changes and altered surface expression of co-stimulatory molecules
that are important for the next stage of the B cell response, the pre-GC time point (see
section 1.3.2). This next stage of the B cell response is initiated when B cells upregulate
CCR7, a chemokine receptor, which directs cells to migrate towards the T cell zone as a
result of the expression of the CCL19 and CCL21 ligands by follicular reticular cells in
the T cell zone (85, 86). Additionally, B cells upregulate EBI2, a chemotactic receptor
that directs cells towards the periphery of the B cell follicle (87, 88) due to the expression
oxysterols at the periphery of the B cell follicle (89). This change in chemotactic receptor
expression ultimately directs B cells to move towards the border of the B cell follicle and
T cell zone where B cells await a cognate T cell partner to continue their differentiation
(77).
The T cell response occurs simultaneously with the B cell response. However T
cells are activated through an entirely different process. T cell responses are initiated by
resident DCs that collect Ags in the periphery of the body. Upon encountering a pathogen

12

and/or a signal indicating danger/tissue damage, DCs will begin to differentiate into
mature DCs. These DCs continue to mature and their activation commences as they
migrate from the periphery of the body into draining LNs and localize to the T cell zone
where they present Ags on MHC molecules to T cells (76). If a CD4+ T cell recognizes
one of the Ag peptides being presented on the DC, the T cell and the DC will form a
stable and long-lived interaction that is responsible for inducing T cell proliferation and
instructing T cell differentiation (Figure 1.1A) (90). The differentiation of CD4+ T cells is
instructed by a combination of cytokines and T cell Ag affinity that influence the choice
to become the various T helper subsets such as T helper 1, T helper 2, T helper 17 cells
and other T cell subsets (91-93). One of these other subsets, the pre-TFH cell, is essential
for the initiation and maintenance of the GC response and thus, is of the greatest
importance to this thesis (15). Pre-TFH cells undergo a transcriptional reprogramming as
part of their differentiation involving the expression of the transcription factor, Bcl6, a
key regulator directing TFH cell differentiation. The expression of Bcl6 is essential for
expressing the co-stimulatory receptors and ligands that are of critical importance to the
next stage of the immune response, the pre-GC time point (94). Similar to B cells, preTFH cells also modify their expression of chemokine receptors by upregulating CXCR5, a
chemokine receptor that directs cells towards the B cell follicle (88) as a result of
CXCL13 expression by follicular stromal cells and FDCs in the center of the B cell
follicle (95). Ultimately, this results in their localization to the border of the B cell follicle
and the T cell zone (78, 96). Once activated B cells and pre-TFH cells meet at the B cell
follicle-T cell zone border, the pre-GC time point begins.

1.3.2 The pre-germinal center time point
The pre-GC time point occurs approximately 1-1.5 days post-immunization and
begins once activated B cells begin to form physical interactions with pre-TFH cells.
During this time point, cognate B and T cells interact via their MHC class II and TCR
molecules, co-stimulatory/co-inhibitory receptors, and a variety of integrins whose
signaling is incorporated into decisions that result in cell differentiation, proliferation, or
initiation of cell death. For a more detailed description of these receptors and the timing
of their expression, see section 1.8. Interactions between B and T cells occur along the
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border between the B cell follicle and the T cell zone up to a region between B cell
follicles known as the interfollicular zone (78) (Figure 1.1C). Pre-GC interactions
between B and T cells are typically long-lived in nature, potentially lasting hours in
length (78, 97). During these interactions signals are exchanged between cognate B and T
cells that are essential for the pre-TFH cells to fully differentiate into T follicular helper
(TFH) cells, which are responsible for GC maintenance once they form (98). In addition to
TFH cell differentiation, pre-GC B-T interactions have a profound effect on the way that
the B cell response will progress.
At the pre-GC stage, B cells can differentiate into several different B cell subsets:
low-affinity short-lived plasmablasts, GC-independent memory B cells, and GC B cells.
Short-lived plasmablasts are a type of ASC that are responsible for generating lowaffinity IgM antibodies early in the immune response to help with infections, before highaffinity antibodies are generated later in the GC. Whereas short-lived plasmablasts
contribute to the early immune response, memory B cells contribute to long-term
immunity. Memory B cells cease proliferation and become quiescent once differentiated
and instead acquire a naïve-like phenotype and rejoin the circulating B cell pool (99,
100). If there is a second challenge with the same Ag, memory B cells can be stimulated
to participate in secondary responses by quickly differentiating into plasma cells or GC B
cells, accelerating the development of secondary GCs and quickly reinforcing antibody
titers (100) (Figure 1.1F). The differentiation of GC B cells marks the end of the pre-GC
phase as upon differentiation they migrate into the B cell follicle, along with TFH cells,
and are responsible for seeding the GC (78, 101, 102). (Figure 1.1D).

1.3.3 The germinal center
The GC is an organized collection of cells, predominantly GC B cells, TFH cells,
FDCs, and other minor populations of cells which form at the center of B cell follicles.
From the GC, several B cell subsets are generated: GC-derived memory B cell subsets,
plasma cells, and long-lived plasma cells (58). The GC is an environment optimized for
inducing SHM and CSR within GC B cells for the purposes of driving GC B cells to
acquire high-affinity class-switched BCRs (53, 103). Thus, a GC B cell’s affinity for Ag
and their BCR isotype is not fixed in a GC.
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However, inducing CSR and SHM can generate non-functional BCRs or BCRs
that recognize their Ag with a lower-affinity (104, 105). Thus, CSR and SHM in GC B
cells needs to be complemented by selective pressure to expand functional high-affinity B
cell clones and eliminate low-affinity or non-functional B cell clones. This is the role
played by the TFH cell. Much like the pre-GC time point, it is physical interactions
between GC B cells and TFH cells within the GC that are responsible for selecting GC B
cells to continue in the GC and for directing B cell fate choices. Unlike pre-GC B and T
cell interactions however, GC interactions are much shorter in nature but are nonetheless
essential for GC maintenance (78, 106). These interactions are ultimately what controls
the GC response as a whole and in the following sections I will describe how T cells
influence the fate choices B cells make during GC responses. Furthermore, I will discuss
the properties of GC B cells, ASCs, memory B cells, and TFH cells in more detail.

1.4

Germinal center B cells
GC B cells are distinguished from naive B cells or memory B cells based upon

their expression of the following markers in mice: GC B cells are Bcl6+, CD38low,
CD95high, GL-7+, and IgD- (107). Properties associated with GC B cells include relatively
high levels of apoptosis, high levels of proliferation, and active SHM. Below, I will
describe in more detail how GC B cells are maintained in immune responses and factors
influencing their differentiation.

1.4.1 The light and dark zones of the germinal center
GC B cells exist in two major phases, a light zone (LZ) phase and a dark zone
(DZ) phase (Figure 1.2A). These structures are essential and unique as the disruption of
either of these structures impacts GC maintenance, SHM, and the production of B cell
subsets (108). The LZ of the GC is where FDCs are found and TFH cells concentrate
(109). In this zone, GC B cells are referred to as centrocytes and compete with each other
for the limiting resource in the GC, Ag, which is concentrated on FDCs (110). The ability
of a particular centrocyte to obtain Ag is determined by their affinity for Ag. The
acquisition of Ag leads to centrocytes internalizing and processing Ag for presentation on
MHC class II molecules (17). The amount of Ag presented by centrocytes is directly
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proportional to the interaction time they secure with TFH cells and by extension the
amount of costimulatory signaling they receive from TFH cells (111-113). Receiving TFH
cell signals are important for influencing the differentiation of GC B cells (this will be
further discussed in subsequent sections), but also because TFH cell signals are
responsible for selecting centrocytes to enter the DZ of the GC. To enter the DZ, GC B
cells upregulate the chemokine receptor CXCR4 that binds the chemokine CXCL12
secreted by follicular reticular cells in the DZ (108, 114). The presence of CXCL12 in the
DZ attracts CXCR4+ GC B cells, which are now referred to as centroblasts. Once in the
DZ, centroblasts downregulate surface BCRs and costimulatory molecules before
undergoing SHM and CSR (58).
As centroblasts are mutating their BCRs, they are also undergoing extensive
proliferation (115, 116). The number of rounds of proliferation and the length of time that
a centroblast stays in the DZ are thought to be influenced by their interactions with TFH
cells that occurred in the LZ (115, 117). As the length of time in the DZ is directly
proportional to the amount of SHM a centroblast will undergo (115), the retention in the
DZ of the GC is advantageous for acquiring a high-affinity BCR. Additionally, as
centroblasts proliferate, they are also under pressure to undergo apoptosis (118), a
process that is thought to be inhibited through signals acquired from the TFH cell (111).
Class-switch recombination also occurs in the DZ of the GC and, although CSR does not
affect the Ag-affinity of a BCR, switching to other BCR isotypes can modify intracellular
signaling in B cells and can affect the fate choices and competitiveness of B cells in the
GC (56, 119, 120). Thus, a combination of SHM and CSR can influence the
competitiveness of individual B cell clones.
After a period of time, the centroblast will complete its proliferation and will
begin expressing its newly mutated BCR and costimulatory molecules, while
downregulating CXCR4 allowing it to enter the LZ of the GC where it will again
compete for Ag. This process of continuously cycling between the LZ and DZ of the GC
is generally known as the cyclic re-entry model of the GC. Overall, the combination of
selection pressures to enter the DZ, apoptosis, and proliferation serve to expand the
population of high-affinity B cell clones over continuous rounds of LZ-DZ transitions
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ultimately resulting in a slow progression in the GC towards higher-affinity B cells (79)
(Figure 1.2B). Indeed, the starting affinity of B cells entering the GC can increase by a
million fold by the end of the GC (121, 122) where these high-affinity B cell clones
typically become the primary B cell clone in the GC when they emerge (123). As GC B
cells are the precursor to all other GC-derived B cell subsets, and GCs can potentially
continue for months (124, 125), retention and expansion of a particular B cell clone
within the GC will lead to that particular B cell clones progeny dominating the products
of a GC as it continues. This is further complicated as certain subsets of B cells emerge
from the GC at different times. Memory B cells emerge from the GC first, with optimal
memory B cell production typically lasting ~22 days post-immunization; thereafter
plasma cell differentiation tends to be favored (126). Consequently, retention in the GC
not only affects the continued production of a particular B cell clone, but also the
differentiation of that clone into particular B cell subsets that are favored in the later
portions of the GC response.
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Figure 1.2. B cell differentiation and selection in the light and dark zones of the germinal
center.
(A) GC B cells in the LZ of the GC are in constant competition with one another to
acquire Ag sequestered on FDCs (110). Germinal center B cells that do not acquire Ag do
not secure interactions with TFH cells and persist in the LZ promoting memory
differentiation (127). B cells that successfully compete for Ag and interact with TFH cells
will be selected to transition into the DZ of the GC (111) or alternatively may begin
plasmablast/plasma cell differentiation if they receive strong BCR signaling (128). GC B
cells that transition into the DZ upregulate CXCR4 and downregulate surface receptors
associated with B and T cell interactions (58, 108). Once in the DZ, B cells begin to
proliferate at an increased rate (115) and may also undergo apoptosis depending on their
resistance to apoptosis determined by T cell help acquired in the LZ (118). As this is
occurring, GC B cells that survive mutate their BCR through SHM and CSR in an
attempt to generate a new higher-affinity and class-switched BCR before transitioning
back to the LZ (58). The transition back to the LZ is associated with the downregulation
of CXCR4, upregulation of costimulatory molecules and their newly mutated BCR. (B)
The fates of low, medium, and high-affinity GC B cells in the GC are summarized based
upon the model provided above.
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1.4.2 Germinal center B cell differentiation
The GC status of B cells is a temporary and unstable state that is maintained by
the expression of the master transcription factor, Bcl6 (129). As GC B cells are an
intermediate, the eventual fate of a GC B cell is death or differentiation that is determined
by the expression of transcription factors. The expression of Bcl6 suppresses Blimp-1
expression, where Blimp-1 is the master transcription factor directing plasma cell
differentiation, and thus secures the GC B cell identity (130, 131). GC B cell
differentiation is not thought to be directly antagonistic with memory B cell
differentiation as the expression of Bach2, a transcription factor that has recently
emerged as an important driver in memory differentiation, is not directly antagonistic
with Bcl6 (127).

1.5

Memory B cells
The study of memory B cells in mice is complicated by the lack of a universal

marker to differentiate memory B cells from naïve B cells (132). This is further
complicated by a paucity of knowledge on B cell subsets as all non-plasma cell, non-GC
B cell, and non-naïve B cells are grouped together as memory B cells. This is in part due
to the definition of memory B cells typically used in studies: a B cell that has participated
in a B cell response that has since acquired a quiescent, naïve-like phenotype. True
memory B cells, however, should also show evidence of: (1st), persistence over time;
(2nd), attaining a quiescent state; (3rd), specificity for a known Ag; and lastly, the ability
to respond in secondary immune responses (100). Thus, without a universal marker to
identify all memory B cells in mice, demonstration of memory requires satisfying the
above criteria.

1.5.1 Memory B cell subsets
Historically, memory B cells have been defined as class-switched naïve-like B
cells as class-switching only occurs after B cells have participated in an immune
response, but also because it was easy to identify class-switched B cells. More recently it
was discovered that many memory B cells are IgM+ (133) and indeed not all memory B
cells require the GC as many differentiate before GC formation (126, 134). Studies
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looking at the functionality of IgM+ vs IgG+ memory B cell subsets identified several
differences between the two subsets (Table 1.1) and lead to the idea that memory B cell
responses were controlled by their BCR isotype. However, recent studies grouping
memory B cells based upon the expression of CD80 and PD-L2, have provided better
predictive power than the usage of class-switching alone (135) (Table 1.1). Thus,
although class-switching can be useful for predicting how conventional memory B cells
will differentiate in secondary immune responses, new markers are providing a more
refined view.
Relatively recently a subset of CD27+/- CD21- B cells, also known as
Atypical/age/exhausted/autoimmune associated B cell (ABCs), have been identified in a
variety of different chronic diseases such as rheumatoid arthritis (136), malaria (137),
human immunodeficiency virus (138), cytomegalovirus (139), hepatitis C virus infections
(140), and MS (141). Based on these papers, ABCs appear to be Ag experienced as they
class-switched and are clonally related to standard memory B cells produced in GCs
(137). Furthermore, ABCs tend to be polyreactive often recognizing self-Ags or are
specific for Ags associated with the infectious agent or autoimmune disease (136, 138,
140, 142). This subset is only beginning to be defined (Table 1.1) but appears to be a GCderived subset that can contribute to immune responses.
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Table 1.1. Summary of memory B cell subsets and their functions.
Subset

Function and properties

Naïve-like Primarily enter the GC in secondary immune responses (143) unless their
IgM+

activation is suppressed by circulating IgG (102). Typically these cells are
low affinity for Ag and have not undergone extensive SHM (129). A large
portion of these cells are generated prior to GC formation (126).

Class-

Primarily contribute to the GC and secondary plasma cell responses (143).

switched,

Recruited into secondary immune responses preferentially over IgM+

IgD- IgM-

memory B cells (144, 145). Typically these cells are higher affinity for

IgG+

their Ag have some SHM (129). Primarily GC derived (126).

CD80-

These cells primarily enter the GC in secondary immune responses

PD-L2-

regardless of isotype (135). These cells are mostly low-affinity and not
class-switched. They are typically made early in the GC response (126).

CD80+

These cells primarily differentiate into plasma cells in secondary immune

PD-L2+

responses regardless of isotype (135). Most of these cells are higher
affinity and class-switched memory B cells. They are typically generated
late in the GC response (126).

CD80+/-

These cells express either CD80 or PD-L2, but not both. They have a

PD-L2+/-

phenotype intermediate between double positive and double negative
memory B cells (135).

ABC

Commonly express Tbet, CD11b, CD11c, and downregulate CD21 and
CD23 (146, 147). Some cells with this phenotype can act as potent Agspecific APCs and are poorly responsive in secondary responses (136138, 148). Nonetheless, others have found that they can be serial
transferred to give rise to new GCs and have stem like properties (149).
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1.5.2 Memory B cell differentiation
Although the transcription factors responsible for programming the memory B
cell identity are not well characterized, there is one notable transcription factor associated
with memory B cells. Memory B cell differentiation tends to be favored by high
expression of Bach2 in the GC (127, 150) where Bach2 is antagonistic to the expression
of the master regulator of plasma cell differentiation, Blimp-1 (127). Nonetheless, both
naïve B cells and memory B cells express Bach2. Thus Bach2 alone cannot be
responsible for the memory B cell identity. Another possibility is that memory B cell
differentiation may not be controlled entirely by transcription factors but also through
epigenetics, an aspect still being characterized (151). B cells destined to differentiate into
memory B cells in the GC tend to accumulate in the LZ of the GC as these B cells
typically are not selected by TFH cells to transition into the DZ (108, 152). Indeed, low
BCR Ag-affinity and, thus, a low capacity to compete for TFH cell help, favors memory B
cell differentiation (127). Consistent with this, expression of Bach2 in GC B cells is
inversely proportional to BCR Ag-affinity (127). Thus, a relative lack of T cell help tends
to favor memory B cell differentiation.

1.6

Plasmablasts and plasma cells
Classically, the primary function of plasmablasts/plasma cells, collectively

referred to as ASCs, is to produce antibodies that neutralize, opsonize, or lyse their
targets. Antibodies can differ in isotype where particular isotypes are specialized to
interface with different immune effector mechanisms. Through the production of
antibodies, ASCs can be responsible for completely abolishing infections, the prevention
of infectious diseases, and autoimmunity (153, 154). Thus, ASCs represent an important
subset of effector cells produced from the B cell response.
ASCs are identified using the CD138 marker (155) and can be broadly split into
plasmablasts and plasma cells. Plasmablasts are an actively proliferating precursor to
terminally differentiated plasma cells (156). While both plasmablasts and plasma cells
make antibodies, plasma cells are more polarized towards effector functions as a result of
expanding their endoplasmic reticulum to accommodate increased protein expression
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(157). Unlike plasma cells, plasmablasts maintain expression of MHC class II, the BCR,
and co-stimulatory molecules and retain the capacity to interact with T cells for
proliferative and anti-apoptotic signals (156, 158, 159). Altogether, B cells initially
differentiate into highly proliferative plasmablasts that can eventually terminally
differentiate into non-proliferative plasma cells that are highly specialized toward their
effector functions.

1.6.1 Differentiation of plasmablasts and plasma cells
The fate decision to become a plasma cell originates in the B cell, decided by its
BCR affinity, and is completed by the T cell, by influencing the proliferation vs cell
death of plasmablasts (128, 160). In particular, differentiation of B cells into ASCs is
favored by having a relatively high-affinity for Ag as this primes B cells to begin ASC
differentiation but also leads to B cells securing additional T cell help through the
presentation of additional Ag on MHC class II (112, 128). Indeed, when two populations
of equal-affinity B cells are in competition, targeting Ag to one of the populations will
cause the targeted population to secure more T cell help and increased representation in
the ASC population as result of increased proliferation (128, 160, 161). B cells destined
to become ASCs typically leave the LZ of the GC to undergo a brief period of
proliferation in the DZ before these cells leave the GC altogether to become a part of the
plasma cell pool (128). Differentiation into ASCs is induced by Blimp-1 (162-164) and
by suppressing Bcl6 expression (165). Overall, the size of the plasma cell response is
influenced by a combination of B cells choosing to differentiate into plasma cells based
upon BCR-affinity, but also expansion based upon T cell signals.

1.6.2 Subsets of plasmablasts and plasma cells
ASCs are generated from two major sources in the GC response: an initial burst
prior to GC formation and throughout the ongoing GC (78, 156). Pre-GC ASC
differentiation typically consists of low-affinity, primarily IgM plasmablasts that localize
to the medullary cords of the LN via CXCR4 expression where they continue to produce
antibodies until they apoptose or leave the tissue (99, 159, 166, 167). This population has
typically been described as short-lived. However, a portion of these Pre-GC ASC give
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rise to long-lived IgM+ plasma cells that localize to the spleen and bone marrow (101).
From these locations, long-lived plasma cells can produce antibodies continuously over a
long period of time and contribute to long-term immunity.
ASCs produced from the GC can be separated into plasma cells and long-lived
plasma cells. Plasma cells derived from the GC localize to the medullary cords of the LN
similarly to pre-GC-derived ASCs (167). Germinal center-derived long-lived plasma cells
localize to the bone marrow where they are maintained as a niche (101). Long-lived
plasma cells do not live indefinitely. Their niche in the bone marrow has a maximum
capacity and as a result, some vaccinations require booster immunization to maintain
long-lived plasma cell numbers (168). Germinal center-derived ASCs are important as
both short and long-lived ASCs are more likely to be class-switched, have undergone
substantial SHM, and recognize their Ag with high-affinity relative to pre-GC plasma
cells (101). Overall, pre-GC and GC-derived ASCs have similar but not necessarily
overlapping functions in the immune response.

1.7

T follicular helper cells
T follicular helper cells were originally identified as a cell that accumulates in B

cell follicles in autoimmune mice and was associated with excessive GC formation (169).
Indeed, it is now clear that the maintenance of the GC response is critically dependent on
TFH cells (170). TFH cells localize to the B cell follicle and concentrate in the LZ of the
GC where they interact with GC B cells and direct their selection (171). TFH cells are
typically identified through the expression of several different markers on CD4+ T cells:
CXCR5+, PD-1+, ICOS+, GL-7+, Bcl6+ and low CD62L expression (172).

1.7.1 Pre-T follicular helper cells
The differentiation of TFH cells is initiated through interactions between DCs and
CD4+ T cells at the initiation of the immune response. T cells that begin to express Bcl6
based on these interactions are known as pre-TFH cells. These cells have acquired most of
the features of a TFH cell but they do not localize to the GC. Instead pre-TFH cells go
towards the B cell follicle-T cell zone boundary where they form interactions with B cells
(78, 172). These interactions are essential for GC formation, but, they are also required
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for pre-TFH cells to finish their differentiation into mature TFH cells (78, 173). In addition
to pre-TFH cell differentiation, memory TFH cells are also generated from early DC-T cell
interactions. Memory TFH cell differentiation does not require B cell interactions as they
enter the circulation shortly after interacting with DCs (94). As memory TFH cells
circulate through secondary lymphoid organs, they can participate in secondary immune
responses if their Ag is present (174).

1.7.2 T follicular helper cells and their associated subsets
T follicular helper cells promote the GC response using cytokines such as IL-4,
IL-9, IL-10, IL-21, and surface receptors to modify B cell differentiation (106, 150, 175177) (discussed in more detail in section 1.8). However, expression of these molecules
can differ between individual TFH cells and thus, can differ in their capacity to provide T
cell help. In particular, TFH cells found in the B cell follicle have a less polarized
phenotype characterized by: lower expression of Bcl6, co-stimulatory molecules, and
cytokine expression but normal PD-1 expression (178, 179). Indeed, if TFH cells are
forced to localize to the B cell follicle, using mice deficient in CXCR5 and S1PR2, they
are less capable of maintaining GC’s (178). Both follicular and GC TFH cells require
interactions with B cells to maintain their phenotype as inadequate interaction with B
cells causes T cells to lose their PD-1 high phenotype required for them to persist in the
immune response (78, 170, 180).
Recently another population of T cells called T follicular regulatory (TFR) cells
has also been defined. These cells express many of the same receptors and transcription
factors as conventional TFH cells do. However, they also express FoxP3, the transcription
factor driving regulatory cell identity (181). T follicular regulatory cells can originate
from Tregs generated during T cell development (182) or naïve T cells can be induced to
differentiate into TFR cells through immunization (183, 184). The differentiation of these
cells is thought to be similar to TFH cell generation including the requirement for B-T
interactions for their maintenance (94). T follicular regulatory cells have been described
to inhibit GC responses by inhibiting both TFH cells (185) and GC B cells (186). Indeed,
the ratio of TFH cells to TFR cells can affect GC progression where the maintenance of the
TFH cell population is of critical importance (187). Of note, both the TFH cell and TFR cell
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populations are dynamic and thus, the ratio of these cells can change over the course of
the GC response (182, 183). Nonetheless, the role of the TFR cell in the GC is
complicated as these cells are also responsible for producing IL-10 (175), a cytokine that
promotes GC B cell survival (188), and thus may in some scenarios promote GCs (189).
Overall, the TFR cell population plays an important role in suppressing autoimmunity
(190) while in some scenarios, TFR cells can promote GC responses.

1.8

B and T cell interactions
Throughout the GC the physical interaction between B and T cells is essential for

the maintenance of the GC and the differentiation of B cells into the various B cell
subsets. In these interactions, B and T cells exchange signals via secreted cytokines and
ligation of surface receptors. The sum of these signals induce intracellular signaling
cascades that ultimately influence B and T cell biology and will be discussed in detail
here.

1.8.1 Cellular identity and signal integration
The identity of cells, such as B or T cells, is determined by a set of core
transcription factors that program their identity (191). Typically, these transcription
factors are constitutively expressed in the nucleus and are responsible for continuously
inducing the production of proteins associated with a cell’s particular identity. The
identity of a cell can change if the expression of the core set of transcription factors
changes. Changes in the expression of these transcription factors can occur by several
mechanisms: (1st), signaling can drive the inactivation or degradation of core
transcription factors (192); (2nd), induced expression of another core transcription factor
may repress the expression of others (193); (3rd), and signaling may drive transcription
factors normally based in the cytoplasm to enter and accumulate in the nucleus thereby
changing the nuclear content of core transcription factors (130). Amongst these
mechanisms, the controlled activation of cytoplasmic-based transcription factors to
translocate in the nucleus is particularly important as they can act as hubs of signal
integration. Indeed, by controlling their nuclear localization, positive and negative
signaling from multiple different pathways can be summed together into one decision
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(194, 195). Altogether, core transcription factors are responsible for programming
cellular identity where the expression of core transcription factors can be modified
through cellular signaling.
Two commonly used pathways in the immune system are the nuclear factor kappa
B (NFκB) and nuclear factor of activated T cells (NFAT) pathways. The NFκB pathway
is activated through either a canonical pathway or a non-canonical pathway that
converges upon the activation of the IκB kinase complex. The IκB complex is responsible
for directing the degradation of IκB proteins which normally retain NFκB proteins in the
cytoplasm preventing them from being active (195). The NFAT pathway is activated by
anything that raises intracellular Ca2+ levels to a sufficiently high level to activate
calmodulin (196, 197). Upon binding Ca2+, calmodulin interacts with calcineurin, a
phosphatase that removes phosphate groups from the regulatory domain of NFAT
proteins, thereby exposing their nuclear localization sequence resulting in their
localization to the nucleus. As these activating events are quite common across several
immune signaling pathways (see Table 1.2), the activation of these transcription factors
commonly coincides with B and T cell interactions. In addition to these pathways, the
immune system uses other transcription factors such as the AP-1 complex, STAT
proteins, or other factors to contribute to immune cell decisions; however, these will not
be discussed in detail in this thesis.

1.8.2 Receptors and cytokines influencing B cell differentiation
B and T cells use a number of surface receptors and cytokines to communicate
with one another to influence the others differentiation and survival. These receptors and
cytokines have been studied in great detail including the study of: the regulation of their
expression over the course of the immune response, how signaling through these
receptors and cytokines is transduced and integrated into common signaling pathways,
and how they influence the GC response and the production of B cell subsets. Below, I
have outlined the expression patterns and effects of receptors and cytokines known to
affect the GC response (Table 1.2).
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Table 1.2. Summary of the expression and functions of key signaling molecules affecting
the germinal center response.
T cell

B cell

Major

Effect on the GC

Pathway(s)
FasL

CD95

Caspase-3, 7

Mediates the selection of high-

(activated T

(activated and

and 8 (200))

affinity GC B cells and suppresses

cells (198))

GC B cells

autoimmunity through the induction

(198, 199))

of apoptosis (201-203).

CD40L

CD40 (all B

(activated T

cells (204))

NFκB (205)

Required for GC maintenance.
Promotes B cell proliferation and

cells (204))

resistance to cell death (111, 206,
207).

CD28 (all T

CD80 CD86

NFAT,

cells (208))

(activated and

NFκB, PI3K,

GC B cells

AP-1 (210)

(209))
CTLA4 (TFH

CD80 CD86

CD86 is required to initiate GC
responses and CD80/CD86 maintain
the GC and promote plasma cell
differentiation (198, 211, 212).

Inhibits

Suppresses the expansion of TFH cells

and TFR cells

NFAT,

and GC B cells (186, 215, 216).

(186, 213))

NFκB, AP-1
(214)

ICOS

ICOSL (all B

NFAT,

(activated T

cells (217))

NFκB, PI3K,

maintenance and contributes to the

AP-1 (208)

selection of high affinity B cells in

cells (190,
208))

ICOS is required for TFH cell

the GC (218, 219).

PD-1 (TFH

PD-L1 (Naïve

Inhibits

Inhibits TFR cells (222), promotes

and TFR cells

and GC B

NFAT,

plasma cell differentiation and GC B

(220, 221))

cells (180))

cell maintenance (223), and prevents
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PD-L2 (GC B

NFκB, PI3K,

cells (222))

AP-1 (220)

IL-4 (pre-TFH

IL-4R

STAT6 (225)

and TFH cells

(activated and

differentiation, GC B cell survival,

(224))

GC B cells

and SHM and CSR (224, 226-228).

excessive accumulation of TFH cells
in the GC (180).
Promotes memory B cell

(224))
IL-9 (TFH

IL-9R (GC B

STAT1/3/5

cells (150))

cells (150))

(229)

IL-10 (TFH

IL-10R (GC

STAT3 (230)

and TFR cells

B cells (175))

Promotes memory B cell
differentiation (150).
Inhibits GC B cell apoptosis and
promotes GC B cell proliferation

(175))

(175, 188, 231).

IL-21 (pre-

IL-21R

STAT1/3

TFH and TFH

(activated and

(232)

cells (224))

GC B cells

Promotes GC B cell proliferation and
plasma cell differentiation at the
expense of memory B cells (233,

(224))

234).

SLAM (pre-

SLAM

Integrins,

Promotes IL-4 production in TFH cells

TFH and TFH

(Activated

NFκB (236)

and plasma cell differentiation (237).

cells (235))

and GC B
cells (235))

CD84 (pre-

CD84

Integrins

TFH and TFH

(Activated

(238)

cells (235))

and GC B

Needed for optimal GC formation,
optimal antibody responses, and TFH
cell maintenance (235).

cells (235))
Ly108 (pre-

Ly108

Integrins

Inhibits GC induction and

TFH and TFH

(Activated

(238)

cells (235))

and GC B

interactions until this receptor is

cells (235))

engaged (239).

maintenance by promoting short B-T
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1.9

Thesis overview
This thesis characterizes the progression of autoreactive GCs directed against

MOG protein and establishes rules controlling its progression. This was accomplished by
developing a new MOG expression system that can be easily manipulated to change the
properties of the immunizing Ag. The primary goal of this thesis was to characterize the
basic rules that control B cell differentiation in GC responses and to apply these rules to
an autoimmune GC model that has a pathogenic B cell component. I hypothesized that B
cells participating in GCs directed against an autoAg would make different fate choices
relative to a standard model Ag and that T cells would control these fate choices.

1.9.1 Chapter 2: Simple and Efficient Production and Purification of Mouse
Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune
Encephalomyelitis Studies
Herein, I describe the process of production and purification of the model autoAg
I use throughout this thesis, mMOGtag protein. I show that mMOGtag protein obtains the
correct 3-D conformation and can be recognized by MOG-specific B and T cells. I also
show that mMOGtag protein is amenable to modification for experimental purposes by
creating a new MOG protein that manipulates T cell Ag-affinity, called haMOGtag. Both
mMOGtag and haMOGtag induce EAE through protein immunization including the
incorporation of pathogenic B and T cells confirming that both induce adaptive immune
responses that contribute to CNS demyelination. Overall, the mMOGtag expression
system has proven to be an effective system for purifying large amounts of MOG protein
making it possible to characterize how autoreactive B cell responses are initiated and how
they contribute to EAE.

1.9.2 Chapter 3: Autoreactive T cells preferentially drive differentiation of
short-lived memory B cells at the expense of germinal center
maintenance.
In this chapter, the tools developed in the previous chapter are used to determine
whether B cell responses directed against an autoAg are different from those of a model
foreign-Ag. I show that GCs directed against mMOGtag protein collapse early and instead
form large numbers of memory B cells. While robust immune memory was generated in
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the foreign-Ag driven GC response, in the form of memory B cells and long-lived plasma
cells, MOG-specific memory B cells are short lived and few long-lived plasma cells are
generated through mMOGtag immunization. Collapse of the autoreactive GC was largely
under the control of the autoreactive T cells. However, GC collapse could be partially
corrected when T cells were stimulated with a high-affinity T cell Ag. Despite clear
evidence for T cell control of the GC response, autoreactive and foreign-Ag specific T
cells did not differ in phenotype but rather, differed only by the absolute number of T
cells controlling in the GC response. Altogether, this chapter characterizes the
development of the anti-MOG GC response and shows that T cells are capable of
influencing some aspects of the GC response, but not others.

1.9.3 Chapter 4: Reporters for in vivo and in vitro monitoring of NFκB and
NFAT signaling
For the final chapter, I describe the generation of fluorescent reporters capable of
monitoring intracellular signaling in real-time for the purposes of understanding how
signals are exchanged between interacting cognate pairs of B and T cells. I show that by
combining a fluorescent marker of the nuclei of cells with fluorescently labelled NFκB or
NFAT proteins, I can monitor intracellular signaling in living cells. Using the Clustered
regularly interspaced short palindromic repeats (CRISPR)/Cas9 genomic editing tool, I
show that I can edit mouse genomes to express my reporters but generation of a reporter
mouse was unsuccessful. This issue was addressed by constructing a new reporter for
NFAT activity that is compatible with conventional gene knock-in methods and will be
used to generate a reporter mouse. Overall, this project demonstrates the potential of a
reporter capable of determining the timing and kinetics of signal exchange between B and
T cells during their interactions.
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Chapter 2

2

Simple and Efficient Production and Purification of Mouse
Myelin Oligodendrocyte Glycoprotein for Experimental
Autoimmune Encephalomyelitis Studies
Multiple sclerosis is a chronic inflammatory disease of the CNS, thought to occur

as a result of autoimmune responses targeting myelin. Experimental autoimmune
encephalomyelitis is the most common animal model of CNS autoimmune disease and is
typically induced via immunization with short peptides representing immunodominant
CD4+ T cell epitopes of myelin proteins. However, B cells recognize unprocessed protein
directly, and immunization with short peptide does not activate B cells that recognize the
native protein (240). As recent clinical trials of B cell-depleting therapies in MS have
suggested a role for B cells in driving disease in humans, there is an urgent need for
animal models that incorporate B cell-recognition of autoAg. To this end, I have
generated a new fusion protein containing the extracellular domain of the mouse version
of MOG as well as N-terminal fusions of a His-tag for purification purposes and the
thioredoxin protein to improve solubility (mMOGtag). A tobacco etch virus (TEV)
protease cleavage site was incorporated to allow, if desired, the removal of all tag
sequences, leaving only the enriched MOG1-125 extracellular domain. Here, I describe a
simple protocol using only standard laboratory equipment to produce large quantities of
enriched mMOGtag or MOG1-125. This protocol consistently generates over 200 mg of
mMOGtag protein. Additionally, the same purification protocol successfully purified a
family of modified mMOGtag proteins, one of which is described in detail here, highaffinity MOG (haMOGtag), which incorporates a high-affinity T cell epitope and is
capable of stimulating potent MOG-specific T cell responses. Immunization with either
mMOGtag, MOG1-125, or haMOGtag generates an autoimmune response that includes
pathogenic B and T cells that recognize the native mouse MOG Ag. Furthermore, it was
found that haMOGtag immunization potentiated EAE development. Together, this protein
expression system has proven to be reliable and amenable to modification permitting the
study of how B cells contribute to EAE and how manipulating B and T cells affects EAE
development.
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2.1

Introduction
MS is a human disease characterized by chronic inflammation and

neurodegeneration of the CNS which is thought to be driven by an autoimmune response
directed towards myelin. The loss of myelin and axons over time result in the gradual
decline of cognitive and motor function (241). "Experimental Autoimmune
Encephalomyelitis" is an umbrella term for animal models of autoimmune disease
directed towards CNS myelin. Like human MS, EAE is typically characterized by
immune cell infiltration of the CNS and, in some cases, demyelination (38). However, the
degree to which any given EAE model resembles human MS in part depends on the
species or strain used and on the complexity of the underlying anti-myelin autoimmune
response.
Anti-myelin autoimmunity can be experimentally induced in several ways, but the
most common method used today is to immunize mice with a short peptide of amino
acids mimicking the immunodominant CD4+ T cell epitope of a myelin protein. This
represents the minimum requirement to induce a pathogenic immune response. Perhaps
the most common of these is a 21 amino acid peptide derived from myelin
oligodendrocyte glycoprotein (MOG35-55), which is used to induce EAE in C57Bl/6 mice
(242). However, for some experimental purposes it is desirable or even necessary to
immunize with larger protein Ags and indeed there are several advantages to this over
immunization with short peptides. First, due to MHC restriction, short peptides are
usually only effective in a very limited number of animal strains, while larger protein Ags
representing either the whole protein or a specific domain can be processed normally for
presentation in multiple inbred mouse strains or even in different species (243). Second, a
larger protein Ag is capable of inducing a more complex immune response by
incorporating additional types of lymphocytes through Ag recognition of a broader array
of epitopes, rather than limiting Ag recognition to a small population of CD4+ T cells
responding to a single peptide. For example, B cells via their BCR interact directly with
whole protein rather than processed peptides. We and others have shown that B cells
activated by MOG35-55 immunization do not recognize whole MOG protein (240). Since
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B cells were recently demonstrated to play a pathogenic role in human MS (244), EAE
models that incorporate B cells in autoimmune pathology are increasingly important.
Despite the advantages of using larger protein Ags to induce EAE, there remain
few commercially available sources for such proteins. Indeed, while short peptides like
MOG35-55 can be synthesized very quickly and at a relatively low cost, the commercial
options for MOG protein are limited and cost substantially more to purchase. Currently,
there are several expression vectors available that research groups can use to generate
MOG extracellular domain (MOG1-125). However, all of the expression systems that I
have identified in the literature are based on older technologies that have since been
replaced with more efficient expression systems (245). Further, most are based on rat or
human MOG (246). For some investigations of autoimmunity in mice, an Ag based on
the mouse MOG (mMOG) autoAg is preferable. In addition to the problems highlighted
above, a new expression system would ideally be modular as this would allow for the
manipulation of variables associated with the Ag. Indeed, several studies have made use
of specific point mutations in Ags to manipulate B cell Ag-affinity (247, 248) as well as
T cell Ag-affinity (249-251). Thus, a modular MOG expression system would permit an
in depth characterization of how B and T cell Ag-affinity contributes to the progression
and maintenance of the EAE autoimmune response. Finally, all expression vectors of
MOG-based proteins that I have identified are fusion proteins containing additional
amino acids to the MOG1-125 base (245, 252). These include a tag for purification and
usually other sequences as well, many of which with a function I was unable to identify,
which in some cases may need to be removed for experimental purposes.
To address these limitations, I generated a family of proteins based on the mouse
MOG extracellular domain fused to a tag containing thioredoxin to combat the known
insolubility of MOG protein (240). The tag sequence also contains a 6xHis sequence for
purification and a TEV protease cleavage site that allows for the complete removal of all
tag sequences, if desired. This is the only method that I am aware of that efficiently
generates enriched MOG1-125 protein. To facilitate production of large amounts of
protein, the MOG1-125 sequence was codon-optimized for bacterial expression and the
mMOGtag fusion protein was inserted into the pET-32 expression system. Additionally,
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the mMOGtag-pET-32a vector contains several restriction enzyme sites and is easily
polymerase chain reaction (PCR) amplified permitting manipulation through cloning
techniques. An example of this is given here through the production of ‘high-affinity’
mMOGtag (haMOGtag) Ag, which incorporates a high-affinity T cell epitope recognized
by MOG-specific CD4+ T cells, allowing for the experimental manipulation of the CD4+
T cell response. Here, I show that I can produce and purify large quantities of mMOGtag
protein, enriched MOG1-125, and haMOGtag using non-specialized equipment available to
most immunology laboratories. I then show that these proteins are capable of inducing
MOG-specific B and T cell responses in the context of EAE and that the haMOGtag Ag
can manipulate MOG-specific T cell responses.

2.2

Results

2.2.1 A protocol for expressing mMOGtag protein
To develop a system with which I could produce large amounts of mMOG
protein, I took advantage of the pET-32a protein expression system in BL21 E.coli. This
was accomplished by inserting bacterial codon optimized mMOG extracellular domain
(amino acids 1-125) sequence (based upon GenBank NM_010814.2) into the pET-32a
vector along with an N-terminal TEV protease cleavage site. The mMOG1-125 and TEV
protease sequences are expressed in frame with the proceeding sequences in the pET-32a
vector including E.coli thioredoxin protein, an S-Tag, and a 6xHis tag to make the
mMOGtag protein (Figure 2.1).
To make the mMOGtag protein, BL21 bacteria transformed with the pET-32a
mMOGtag vector are induced to express mMOGtag with Isopropyl β-D-1thiogalactopyranoside (IPTG) overnight. This resulted in a substantial increase in
mMOGtag expression as seen by the appearance of a 31.86 kilodalton (kDa) band on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) after induction
(TO/N) relative to pre-induction (T0) (Figure 2.2A and 2.2B). The BL21 bacteria are then
lysed and pelleted to collect inclusion bodies primarily containing the mMOGtag protein
(253). Inclusion bodies are then solubilized with guanidine, a chaototopic agent that
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disrupts protein folding (254), to produce a crude solution of mMOGtag prior to
purification (Figure 2.2B). The protein is then purified through four rounds of incubation
with nickel resin, that can be used to purify His-tag labelled proteins (255), followed by
elution to collect our 6xHis tag labelled mMOGtag protein. As guanidine prevents the
mMOGtag protein from folding, dialysis is used to slowly remove guanidine from the
purified protein allowing the protein to slowly fold into the correct 3-D protein
conformation. Once folded, the protein is concentrated to 5 mg/ml using PEG3350 and
PEG8000 to generate enriched and concentrated mMOGtag protein. Purity of mMOGtag
protein was confirmed by SDS-PAGE (Figure 2.2B).
To determine whether the mMOGtag protein produced had acquired the correct 3D conformation, I took advantage of a mouse strain called the IgHMOG mouse, which
expresses a heavy chain BCR that confers MOG specificity to B cells in this mouse
(256). I hypothesized that if mMOGtag had acquired the correct conformation, it should
preferentially bind to IgHMOG B cells over wild type C57Bl/6 B cells. Lymph node cells
from either IgHMOG or C57Bl/6 mice were incubated with mMOGtag Ag, to label MOGspecific B cells, then labelled with a secondary anti-His antibody and a tertiary anti-IgG1
antibody. Binding of mMOGtag to B cells was then assessed by flow cytometry. As
shown in Figure 2.2C, mMOGtag-specific B cells could be detected in both WT C57Bl/6
mice and IgHMOG mice however mMOGtag preferentially bound to IgHMOG cells, often
labelling between 20-30% of the B cells in these mice well above the background level
seen in the fluorescence minus one (FMO) control.
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Figure 2.1. mMOGtag protein.
Linear structure, and amino acid and DNA sequences of the mMOGtag fusion protein. The
DNA sequence for the extracellular domain of mouse MOG (MOG1-125, lower sequence
in blue) was codon-optimized for expression in bacteria (black). This sequence was
synthesized and inserted into a vector to create an N-terminal fusion to a tag containing
E.coli thioredoxin and an S-Tag to counteract the known insolubility of the MOG protein
(253, 257), as well as a 6x His Tag for purification (258). A TEV protease cleavage site
separates the MOG1-125 from the tag sequences. TEV-mediated cleavage between
glutamine-164 and glycine-165 using an alternative consensus TEV cleavage site (258)
results in removal of all non-MOG amino acids.
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Figure 2.2. Purification of mMOGtag.
(A) To generate mMOGtag protein, bacteria expressing the mMOGtag protein are grown to
high densities then induced to express mMOGtag using IPTG. After an overnight culture,
the bacteria are lysed and through a series of pelleting steps the protein fraction
containing inclusion bodies, which contains mMOGtag, is extracted. mMOGtag is then
purified from the crude protein fraction through four cycles of absorption onto charged
nickel resin and elution of the mMOGtag protein. A portion of the pooled eluate is then
taken for a Bradford assay to determine the yield of mMOGtag protein and the rest of the
eluate is dialyzed into acetate buffer over the course of several days. Lastly, the protein is
concentrated using PEG3350 and PEG8000 to a final concentration of 5 mg/ml based
upon the yield of mMOGtag determined in the Bradford assay. (B) Shown are protein
samples that were collected from various points across the protein purification procedure
and analyzed by SDS-PAGE gel. T0= BL21 bacteria prior to protein induction, TO/N=
BL21 bacteria post-induction of protein expression, Crude mMOGtag= Solubilized
mMOGtag protein prior to protein purification, Enriched mMOGtag= mMOGtag protein
after purification. (C) Binding of the mMOGtag protein to CD19+ CD4- naive B cells from
lymph nodes from either wild type C57Bl/6 mice or IgHMOG mice that express an
immunoglobulin heavy chain specific for MOG protein (245, 256) was assessed using
flow cytometry. mMOGtag-specific B cells were identified by staining LN cells with
mMOGtag followed by a secondary anti-His tag antibody and a fluorescent tertiary antiIgG1 antibody. Staining of cells from C57Bl/6 or IgHMOG mice is shown along with a
mMOGtag FMO control stain of IgHMOG cells. The proportion of IgHMOG B cells binding
mMOGtag protein is written above the gating displaying mMOGtag binding.
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2.2.2 TEV protease can remove the tag sequence to generate enriched
MOG1-125 that can be purified
As the tag sequence is derived from foreign-Ags, some experiments or protocols
may have need of enriched MOG1-125 Ag. To accomplish this, I developed a protocol to
remove all of the exogenous sequence associated with the mMOGtag Ag to make enriched
MOG1-125 (summarized in Figure 2.3A). In this protocol, purified mMOGtag protein is
dialyzied into TEV protease cleavage buffer then TEV protease is mixed with the
mMOGtag protein to remove the tag sequence. After cleavage, the buffer is changed and
the volume is reduced by dialysis. Then nickel resin is used to remove impurities from
MOG1-125, namely the tag sequence, uncut mMOGtag, and the TEV protease. After four
rounds of absorption onto nickel resin, the protein left in the original solution is then
folded similarly to mMOGtag and concentrated to 2.24 mg/ml to be equimolar with
mMOGtag at 5 mg/ml. As shown in Figure 2.3B, this protocol can be used to generate
enriched MOG1-125 as seen by the prominent band at 14.28 kDa on an SDS-PAGE gel.
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Figure 2.3. Generation of MOG1-125.
(A) After collecting the mMOGtag eluate from the mMOGtag purification described in
Figure 2.2A, the mMOGtag protein is dialyzed into TEV protease cleavage buffer. Once
the dialysis is complete, TEV protease is added to the mMOGtag solution resulting in the
cleavage of mMOGtag into the MOG1-125 protein and the associated tag sequence. The
volume of the cleavage solution is then reduced and dialyzed into buffer B prior to
protein purification. Impurities from the cleavage solution are removed by four
successive rounds of absorption onto charged nickel resin and elution of the impurities
ultimately resulting in a solution of enriched MOG1-125. The concentration of the MOG1125

protein is determined through a Bradford assay and the protein is folded over the

course of several days through dialysis. Once dialysis is complete, the MOG1-125 protein
is concentrated to 2.24 mg/ml using PEG3350 and PEG8000. (B) Shown are protein
samples run on a SDS-PAGE gel demonstrating purification of MOG1-125. Enriched
mMOGtag = mMOGtag protein prior to TEV cleavage, mMOGtag w/ TEV = Protein
fraction that was collected after 72 hr of incubation of mMOGtag with TEV protease,
Elution = Protein fraction that remained bound to the nickel resin during the MOG1-125
purification protocol, Enriched MOG1-125 = MOG1-125 protein after purification.
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2.2.3 Generation of haMOGtag, a variation of mMOGtag that alters T cell
antigen affinity
In addition to studying the immune response induced against mMOG protein, the
mMOGtag expression system provides a general platform to easily produce manipulated
versions of the protein to investigate how properties of the immunizing Ag affect
developing immune responses. For example, T cell affinity for Ag is a central component
of T cell activation (19) but is not well characterized in the context of GCs. To this end, I
have generated several variations of the mMOGtag Ag: a version based on the rat MOG
protein (rMOGtag), a humanized version of mMOG that I call B cell dependent MOG
(bMOGtag), and lastly a version that manipulates Ag-affinity called haMOGtag. Although
the bMOGtag and rMOGtag Ags have been purified and validated, I will only focus on
haMOGtag in this thesis.
The haMOGtag protein is based upon manipulating the mMOGtag Ag to
incorporate a high-affinity T cell epitope, thereby altering the affinity of T cell
recognition, by taking advantage of a common feature of TCRs known as polyreactivity
(259) that is especially prevalent in autoreactive T cells (260). Polyreactivity is feature of
TCRs where a single TCR molecule can recognize more than one Ag with different Agaffinities. Autoreactive TCRs, including TCRs that recognize the MOG35-55 peptide such
as the 2D2 TCR, tend to bind peptide:MHC with relatively low affinity (261). However,
analysis of the MOG35-55-specific 2D2 TCR revealed that it also recognizes a second
peptide derived from amino acids 18-30 from the Neurofilament-M protein (NF-M18-30)
(262), and in fact binds NF-M18-30 with higher affinity than it does MOG35-55 (261). Of
note, this property is not just an artifact of the 2D2 TCR, as cross reactivity between
MOG35-55 and NF-M18-30 is common in C57Bl/6 mice (263). The usage of polyreactivity
to assess how T cell Ag-affinity affects immune responses is highly desirable because it
involves stimulating the same T cell to different degrees. Other models that use different
T cell clones to look at affinity will always have the confounding factor that the two T
cells could simply be generally different beyond their affinity.
I took advantage of the polyreactivity of the 2D2 TCR to generate a modified
mMOGtag Ag that incorporates amino acids 13-35 from NF-M, containing the NF-M18-30
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epitope, in between the N-terminal tag and the TEV protease cleavage site in the original
mMOGtag Ag (Figure 2.4A – referred to as haMOGtag). Incorporation of the haMOGtag
pET-32a vector into BL21 bacteria and purification of the haMOGtag protein were both
successful using our protocol as seen by the prominent 34.36 kDa band on an SDS-PAGE
gel (Figure 2.4B). Enriched haMOGtag protein was further confirmed to have acquired the
correct 3-D conformation as haMOGtag, much like mMOGtag, bound IgHMOG B cells
(between 20-25% of the IgHMOG B cells depending on the experiment) to a greater degree
than wild type C57Bl/6 B cells (Figure 2.4C).
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Figure 2.4. Structure and purification of the haMOGtag protein.
(A) Schematic of the haMOGtag protein. The haMOGtag protein is structurally similar to
the mMOGtag protein however amino acids 13-35 derived from NF-M were inserted
inbetween the TEV protease site and the S-tag in the original mMOGtag protein. Below
the amino acid sequence of NF-M13-35 and MOG38-50 are shown where the sequences
highlighted in grey represent the minimal amino acid sequence required to induce 2D2 T
cell responses (262) and amino acids highlighted in red represent amino acids that change
between NF-M18-30 and MOG38-50. (B) Shown are protein samples that were collected
from various points across the protein purification procedure and run on a SDS-PAGE
gel. T0= BL21 bacteria prior to protein induction, TO/N= BL21 bacteria post-induction of
protein expression, Crude haMOGtag= Solubilized haMOGtag protein prior to protein
purification, Enriched haMOGtag= haMOGtag protein after purification. (C) Binding of the
haMOGtag protein to CD19+ CD4- naive B cells from LN’s from either wild type C57Bl/6
mice or IgHMOG mice was assessed using flow cytometry. haMOGtag-specific B cells
were identified by staining LN cells with haMOGtag followed by a secondary anti-his tag
antibody and a fluorescent tertiary anti-IgG1 antibody. Staining of cells from C57Bl/6 or
IgHMOG mice is shown along with a haMOGtag FMO control stain of IgHMOG cells. The
proportion of IgHMOG B cells binding haMOGtag protein is written above the gating
displaying haMOGtag binding.
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2.2.4 haMOGtag induces greater MOG-specific T cell responses relative to
mMOGtag in vitro and in vivo
Having confirmed that I could produce both mMOGtag and haMOGtag, I sought to
determine whether these proteins could induce different myelin-specific T cell responses.
I hypothesized that haMOGtag would induce larger T cell responses based on higheraffinity engagement of the TCR. To accomplish this, I set up an in vitro T cell stimulation
assay where splenocytes from wild type C57Bl/6 mice were loaded with either mMOGtag
or haMOGtag. Unloaded splenocytes were used as a negative control and splenocytes
loaded with the model foreign-Ag nitrophenyl conjugated ovalbumin (NPOVA) were
used as a positive control. Splenocytes were then incubated with Carboxyfluorescein
succinimidyl ester (CFSE) labelled T cells from 2D2 (MOG specific T cells (264)) or
OTII (OVA specific T cells (265)) mice. After three days of incubation, T cell
proliferation was assessed by flow cytometry looking for CFSE dilution. All Ags induced
proliferation of T cells relative to the no Ag control confirming that each Ag was capable
of being properly presented (Figure 5A - left). Of the three Ags, NPOVA induced the
greatest degree of proliferation with a large percentage of OTII T cells having undergone
2, 3, and 4 cell divisions relative to 2D2 T cells incubated with either MOG-based Ag
(Figure 2.5A). Proliferation induced with haMOGtag Ag was intermediate between that of
NPOVA and mMOGtag where a greater proportion of T cells had undergone proliferation
relative to mMOGtag (Figure 2.5A). Thus, in vitro haMOGtag was capable of inducing a
larger 2D2 T cell response relative to mMOGtag.
To determine whether this was true in vivo, a similar assay was set up where
CFSE labelled red fluorescent protein (RFP) positive 2D2 T cells were transferred into
wild type C57Bl/6 mice. Mice were then immunized by flank injections with either
mMOGtag or haMOGtag and T cell proliferation and differentiation in the draining
inguinal LNs was assessed d2 and d3 post-immunization. Proliferation of 2D2 T cells as
seen by CFSE dilution was greater at the d2 time point in haMOGtag immunized mice
relative to mMOGtag however by the d3 time point these two populations were no longer
different (Figure 2.5B and 2.5C). Thus, proliferation of MOG-specific T cells towards
mMOGtag was not compromised but rather delayed.
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Figure 2.5. haMOGtag induces greater MOG-specific T cell proliferation than mMOGtag
(A) In vitro proliferation assay assessing T cell proliferation to NPOVA, mMOGtag, and
haMOGtag. Splenocytes loaded with either NPOVA, mMOGtag, or haMOGtag were
incubated with CFSE labelled OTII T cells (NPOVA) or 2D2 T cells (mMOGtag and
haMOGtag) for three days. On the third day, CFSE dilution was assessed by flow
cytometry. A representative FACS plot is shown on the left and the quantification of
proliferation is shown on the right. Data is representative of three independent
experiments with three technical replicates, error bars represent standard deviation. (B
and C) CFSE labelled RFP+ 2D2 T cells were transferred into non-fluorescent C57Bl/6
recipients then immunized in the flanks with mMOGtag or haMOGtag and CFSE dilution
in RFP+ CD4+ CD8- CD19- T cells in the draining inguinal LN was assessed by flow
cytometry on d2 (B) or d3 (C) post-immunization. (B and C) Data is based on one
experiment. Error bars represent standard deviation for panels B (n=4 mMOGtag, n=3
haMOGtag) and C (n=5 mMOGtag, n=4 haMOGtag). Comparisons between multiple
groups were done using a one-way ANOVA with a Bonferroni correction and
comparisons between single groups were done using a Student’s T-test, *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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2.2.5 mMOGtag and haMOGtag can both induce EAE incorporating antimyelin B and T cells
MOG proteins are commonly used for the induction of EAE where there is
considerable interest in understanding how B cell responses contribute to EAE
progression. To determine whether the mMOGtag and haMOGtag proteins can induce EAE
with associated myelin-specific B and T cell responses, I transferred green fluorescent
protein (GFP) positive IgHMOG B cells and RFP+ 2D2 T cells into non-fluorescent
C57Bl/6 recipients then immunized the recipients with mMOGtag or haMOGtag via flank
injections. On d0 and d2, pertussis toxin (PTX) was administered to promote EAE
induction (266) and mice were scored daily based on disease severity. Mice immunized
with either Ag were capable of developing EAE where haMOGtag immunized mice
developed EAE with greater incidence (Figure 2.6A). Spinal cords taken from these mice
demonstrated inflammation and demyelination within the CNS (Figure 2.6B).
Furthermore, histological analysis of draining inguinal LNs of these mice showed that
MOG-specific GFP+ B and RFP+ T cells could be seen within GCs confirming that these
cells were activated through immunization and were actively participating in anti-myelin
autoimmunity (Figure 2.6C).
To determine if haMOGtag immunization impacts the B cell antibody response,
serum from the above mice were analyzed for circulating IgM and IgG anti-MOG1-125
specific antibodies using an enzyme-linked immunosorbent assay (ELISA). No difference
in either IgM or IgG anti-MOG antibodies were observed (Figure 2.6D). This finding was
confirmed in a separate experiment where wild type C57Bl/6 mice were immunized with
mMOGtag or haMOGtag to induce EAE. Then, the number of anti-MOG1-125 specific
plasma cells in the draining inguinal LNs and bone marrow was assessed using an
enzyme linked immuno-spot (ELISpot) assay. Equivalent numbers of IgM+ and IgG+
plasma cells were confirmed to be present in the draining inguinal LNs and bone marrow
of mMOGtag and haMOGtag immunized mice (Figure 2.6E).
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Figure 2.6. mMOGtag and haMOGtag both induce EAE incorporating myelin-specific B
and T cells.
(A-D) RFP+ 2D2 T cells and GFP+ IgHMOG B cells were transferred into non-fluorescent
C57Bl/6 recipients then immunized with either mMOGtag or haMOGtag. Mice were
injected with intraperitoneal (i.p.) PTX on d0 and d2 post-immunization and were scored
daily to assess their physical disability. Then, d14 post-immunization the draining
inguinal LNs and spinal cords were taken for histology and blood was taken to analyze
the serum for anti-MOG1-125 antibodies. (A) Disease curves of mMOGtag and haMOGtag
immunized mice are shown, the disease incidence for each group is shown on the legend
(n=6 per group). Errors bars represent standard error of the mean (SEM). (B) Shown are
representative histological sections of spinal cords from mMOGtag and haMOGtag
immunized mice stained with the antibodies shown on the left and FluoroMyelin to stain
myelin. (C) Shown are representative images of inguinal LNs from mMOGtag and
haMOGtag immunized mice, LN sections were stained with IgD to outline the B cell
follicle. (B and C) Scale bars represent 100 µm. (D) Serum from mMOGtag and
haMOGtag immunized mice were analyzed for IgM and IgG anti-MOG1-125 antibodies.
(E) C57Bl/6 mice were immunized with either mMOGtag or haMOGtag and injected with
PTX i.p. d0 and d2 post-immunization. Day 18 post-immunization draining inguinal LNs
and bone marrow were extracted and assessed for MOG1-125 specific IgM+ or IgG+
plasma cells using an ELISpot assay. Data is representative of 1-3 independent
experiments. A Student’s T-test was used for single comparisons.
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2.3

Discussion
Here, I have described a protocol for the production of mMOGtag protein and how

to generate enriched MOG1-125 from mMOGtag. This protocol is based both on standard
His-tag based protein purification methods, as well as a previously described protocol for
the generation of an older MOG-based protein (245). Previously we demonstrated that
immunization with mMOGtag or MOG1-125 not only induces EAE with greater spinal cord
inflammation and demyelination compared to the standard MOG35-55 peptide, but also
that pathogenic IgHMOG B cells that recognize MOG protein are activated to produce a
germinal center in response to mMOGtag or MOG1-125, but not to MOG35-55 (240). Thus,
our mMOGtag protein successfully incorporates MOG-specific B cells into an immune
response directed against the brain and spinal cord allowing us to study how autoreactive
B cells differentiate and contribute to EAE.
One major difference between the mMOGtag protein described here and
previously published forms of recombinant MOG protein is that these studies use the
extracellular domain of human MOG protein (246, 247, 267). This is significant because
mMOG and human MOG have different properties and induce different forms of EAE. In
particular, human MOG induces a B cell dependent form of EAE (49) whereas rodent
versions of MOG induce T-cell dependent EAE that is complemented by Ag-specific B
cells (41, 240, 268). The change from T cell-dependent to B cell-dependent EAE can be
attributed to a single amino acid change, a S42P mutation in the human MOG protein
(268, 269). This mutation resides within the immunodominant MOG35-55 epitope (243)
and induces delayed proliferation of MOG-specific T cells relative to MOG35-55 (data not
shown). As T cell priming is less efficient in human MOG immunized mice, it is unclear
whether studies using human MOG are inducing a potent enough T cell response for
them to make a major contribution to EAE progression. Thus, one major advantage of the
mMOGtag protein over the human MOG version is that T cells are unambiguously being
primed with the endogenous autoAg, which leads to potent T cell responses that can drive
inflammation.
The other form of MOG commonly used in EAE models is the extracellular
domain of rat MOG protein. The rat MOG and mMOG proteins share the same MOG35-55
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immunodominant epitope and both induce T cell-dependent EAE (41, 270). Although rat
MOG and mMOG induce similar effector T cell responses, they do differ in Treg
activation (271). In particular, rat MOG differs from mMOG at 6 amino acids that reside
in subdominant T cell epitopes recognized by Treg cells, ultimately impacting their
ability to respond to rat MOG. As a result of inefficient Treg activation, rat MOG induces
more severe EAE than mMOG (271). Ideally, EAE models should not exclude regulatory
processes that would normally be present in MS patients (272, 273), as overcoming these
regulatory processes would be expected to be a part of the development of autoimmune
disease. As a result, EAE induced with mMOG protein better recapitulates regulatory
processes expected to be a part of MS. Nonetheless, rat MOG can still be useful
experimentally to manipulate regulatory T cell responses.
In addition to manipulating Treg responses, I have also shown here that I could
generate a version of the mMOGtag protein that manipulates Ag-affinity, haMOGtag, to
promote MOG-specific T cell responses using a high-affinity T cell epitope recognized
by MOG-specific T cells. In the EAE experiment described here, haMOGtag induced EAE
with greater incidence relative to mMOGtag immunized mice, a finding that has been
repeated several times. This may be related to my finding that 2D2 T cells proliferate
faster in response to haMOGtag relative to mMOGtag consistent with previously published
work showing faster signaling kinetics in 2D2 T cells stimulated with NF-M18-30 relative
to MOG35-55 (261). It is therefore possible that stronger T cell responses are better at
priming T cells to induce EAE where I may expect that inducing a weaker T cell response
would reduce disease incidence. Indeed, we have previously shown that a version of our
mMOGtag protein containing the S42P mutation described above, bMOGtag, that induces
even slower kinetics of T cell activation relative to mMOGtag, cannot induce EAE
through T cell stimulation alone whereas mMOGtag and haMOGtag can (268). This shows
how our modular mMOGtag platform can be manipulated for experimental needs to
answer basic questions about immunology and EAE induction. Indeed, in Chapter 3 of
this thesis I will use the tools produced here to determine factors that limit the initiation
and progression of GC responses directed against the MOG protein.
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In addition to the ability to manipulate the autoimmune B and T cell responses,
the mMOGtag system is valuable as a system to identify and study MOG-specific B cells.
The first way that this can be done is using the MOG1-125 Ag as a reagent for an ELISpot
to identify MOG-specific plasma cells in a tissue. Indeed, here I was able to show that
MOG1-125-specific plasma cells are found in draining LNs and bone marrow postimmunization with mMOGtag. The mMOGtag Ag can also be used as a flow cytometry
reagent to identify MOG-specific B cells. In the experiments shown in this chapter,
MOG-specific B cells were identified by staining them with mMOGtag followed by a
secondary anti-his antibody and a tertiary anti-mouse IgG1 antibody. This method has the
flaw that it identifies IgG1+ B cells in addition to identifying mMOGtag-specific B cells.
This can be addressed through direct conjugation of the mMOGtag protein to a
fluorophore, thereby removing the need for the tertiary anti-IgG1 antibody, a method that
we have validated previously (240) and will use in Chapter 3 of this thesis. Similar
methods have been used to study GC responses induced with nitrophenyl (NP)
haptenated proteins but, the NP system has one major advantage over our MOG based
system, the ability to study antibody/BCR-affinity by manipulating the conjugation ratio
of NP to protein to increase or decrease Ag-avidity (274). Thus, although mMOGtag is a
useful tool for studying MOG-specific B cells and plasma cells, it does not have the same
utility as previously established methods for studying GC responses to other Ags.
In summary, here I have described a simple protocol for producing and purifying
large quantities of mMOGtag protein. Furthermore, the addition of a TEV protease
cleavage site to our mMOGtag protein provides the opportunity to generate enriched
MOG1-125 that can be used to identify MOG-specific antibodies in serum or detect MOGspecific plasma cells. I have also shown that our expression system is modular by
producing haMOGtag, an Ag that successfully manipulated the induction of EAE and the
underlying T cell response by stimulating autoreactive T cells with a high-affinity T cell
epitope. Furthermore, as both mMOGtag and haMOGtag are recognized and bound by antimyelin autoimmune B cells, EAE induced with these proteins incorporates myelinspecific B cell-mediated contributions into their pathology. Therefore, this protein
expression system allows us to not only begin to study how B cells contribute to EAE,
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but also how manipulations of B cells or T cells modify how the underlying autoimmune
response develops and by extension how EAE progresses.

2.4

Materials and Methods

2.4.1 Mice
C57Bl/6, 2D2 TCR-transgenic (264), SMARTA TCR-transgenic
(4694;Tg(TcrLCMV)327Sdz/JDvsJ), and OTII TCR-transgenic mice
(4194;Tg(TcraTcrb)425Cbn/J) were purchased from Jackson Laboratories, Bar Harbor,
Maine. IgHMOG MOG-specific BCR knock-in mice (256) were received as a gift from Dr.
H Wekerle. Mice expressing fluorescent proteins within all nucleated cells, either dsRed
(RFP; 6051; Tg(CAG-DsRedpMST)1Nagy/J) under control of the β-Actin promoter or
eGFP via the ubiquitin promoter (4353; Tg(UBCGFP)30Scha/J) were obtained from the
Jackson Laboratory. Mice were housed in a specific pathogen-free barrier at the
University of Western Ontario’s West Valley Barrier Facility (London, Ontario). All
animal protocols (2011-047 and 2015-090) were approved by the Western University
Animal Use Subcommittee.

2.4.2 Antibodies used for flow cytometry or histology
The following antibodies were purchased from BD Biosciences (Franklin Lakes,
New Jersey): anti-CD4-V450 and A647 (RM4-5), anti-CD19-BV711 (1D3), and antiIgG1-APC (A85-1). The following antibody was purchased from BioLegend (San Diego,
California): anti-His Tag-purified (J099B12). The following antibodies were purchased
from Thermo Fisher Scientific (Waltham, Massachusetts): anti-IgD-eF450 (11–26), antiCD3-FITC (145-SC11), and anti-CD4-PE-Cy5 (RM4-5). FluoroMyelin Red for myelin
staining was purchased from Invitrogen (Carlsbad, California).

2.4.3 Recombinant mMOGtag and haMOGtag vector design and purification
The mMOGtag insert was designed using SnapGene software (Chicago, Illinois) to
include the following: a TEV cleavage sequence site (ENLYFQ/G), the extracellular
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immunoglobulin domain of mouse MOG (residues 1–125), a TAA stop codon and BglII
and EcoRI restriction sites added to the 5' and 3' ends, respectively. The mMOGtag insert
sequence was codon optimized for bacterial protein expression in E. coli then synthesized
in the pQE-12 vector (Celtek Genes, Franklin, Tennessee). The insert was then cloned
into the pET-32a(+) vector containing the gene for thioredoxin (Novagen, Madison,
Wisconsin) and then transformed into BL21 E. coli using standard transformation
procedures(275).
A protocol for purification of mMOGtag protein was adapted from previous
systems (245) and is described in more detail in a Jain et al. 2016 (276). pET-32a(+)
mMOGtag BL21 E. coli were cultured in LB medium at 37 °C to an O.D. of 0.6, when
protein expression was induced overnight with 1 mM IPTG. Bacterial cells were pelleted
and suspended in lysis buffer (0.1 mg/mL hen egg lysozyme, 0.1% Triton-X (v/v) in
PBS) then lysed to collect inclusion bodies. The inclusion body pellet was suspended in
500 mM NaCl, 20 mM Tris–HCl, 5 mM imidazole, pH 7.9 (Buffer A) and incubated at 4
°C, then denatured with the addition of 6 M guanidine (Buffer B). The protein suspension
was centrifuged at 4 °C to collect the supernatant containing the solubilized proteins.
Before protein absorption, His-Bind nickel resin (Novagen, Madison, Wisconsin) was
prepared according to the manufacturer's instructions. Briefly, the nickel resin was
washed and treated with distilled water and 100 mM NiSO4, then equilibrated with Buffer
B. The solubilized proteins containing mMOGtag was incubated with the charged nickel
resin in a standard 50 mL centrifuge tube at 4 °C. Following centrifugation, the
supernatant was kept for further rounds of purification and mMOGtag was eluted from the
pelleted resin with 500 mM imidazole, 500 mM NaCl, 6 M guanidine and 20 mM Tris–
HCl pH 7.9. Elutions were pooled and exchanged by overnight dialysis at 4 °C into the
storage buffer containing 0.115% glacial acetic acid, 3 mM sodium acetate and
concentrated with PEG3350 and PEG8000 to 5 mg/mL before storage at -80 °C. Unless
otherwise stated, reagents were purchases from Bioshop (Burlington, Ontario). Protein
expression and quantification were confirmed using standard SDS-PAGE and Bradford
assay kits (Bio-Rad, Hercules, California) according to manufacturer’s instructions.
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To generate haMOGtag, the pET-32 mMOGtag vector was mutated by PCR using
the following primers: 5'TCTTCTTTTTCTCGCGTTTCTGGTTCTCCGTCTTCTGGTTTTGAAAACTTGTATT
TCCAAGGACAGTTTCGCG 3' and the reverse primer 5'GCGAGAAAAAGAAGAACGGGTTTCGGTAACACGACGATATGCACCGGAGCC
ACCACCGGTAC 3'. The resulting vector was sequenced to confirm the insertion of the
13-35 NF-M sequence (based on NCBI Reference Sequence: NP_032717.2) and
transformed into BL21 bacteria for expression. Expression of the haMOGtag protein is
similar to what was listed above for mMOGtag. However, haMOGtag was concentrated to
5.394 mg/mL to be equimolar with mMOGtag.

2.4.4 TEV protease cleavage of mMOGtag protein
Purified mMOGtag was dialyzed into 50 mM Tris–HCl, 0.5 mM EDTA and 5 mM
2-Mercaptoethanol pH 8. Then, AcTEV protease (Thermo Fisher Scientific, Waltham,
Massachusetts) was added to mMOGtag protein at a 1:20 ratio and incubated at room
temperature for 72 hrs. The protein was then dialysed into pure water then concentrated
with PEG8000 to a final volume of 35 mL. The protein was then dialyzed into buffer B
and the tag, AcTEV protease, and uncut mMOGtag impurities were removed through
incubation with charged nickel resin as described above. After four rounds of incubation
with nickel, the original volume was then dialyzed into 0.115% glacial acetic acid and
concentrated using PEG3350 and PEG8000 to 2.24 mg/ml before storage at -80 °C.
Unless otherwise stated, reagents were purchases from Bioshop (Burlington, Ontario).
Protein expression and quantification were confirmed using standard SDS-PAGE and
Bradford assay kits (Bio-Rad, Hercules, California) according to manufacturer’s
instructions.

2.4.5 Adoptive transfer of B and T cells and immunization
Naïve Ag-specific T cells were isolated from RFP+ 2D2 mice and naïve Agspecific B cells were isolated from GFP+ IgHMOG mice as previously described (78).
Briefly, LNs and spleens of RFP+ T cell and GFP+ B cell mice were dissociated and B
and T cells were isolated using EasySep Negative selection Mouse B and T cell
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Enrichment Kits (StemCell Technologies, Vancouver, Canada). Five million GFP+
IgHMOG B cells and 5 x 105 2D2 T cells were transferred i.v into C57Bl/6 or SMARTA
recipients 2 days prior to immunization. Mice were immunized in each flank with
equimolar amounts of the given Ag (250 μg mMOGtag and 270 μg haMOGtag) in
complete freund’s adjuvant (CFA) and injected with 250 ng PTX on days 0 and 2 postimmunization. Draining inguinal LNs were harvested at the indicated time points for
analysis.

2.4.6 Flow cytometry
Draining popliteal LNs were harvested from mice for flow cytometric analysis as
previously described (78). Briefly, LN cell suspensions were blocked with an anti-Fcγ
receptor, CD16/32 2.4G2 (BD biosciences, Franklin Lakes, New Jersey), in PBS
containing 2% FBS before further incubation with the indicated antibodies. Dead cells
were excluded by staining with either the Fixable Viability Dye eFluor506 or propidium
iodide (Thermo Fisher Scientific, Waltham, Massachusetts). Flow cytometry was
performed on a BD Immunocytometry Systems LSRII cytometer and analyzed with
FlowJo software (Tree Star, Ashland, Oregon).

2.4.7 Induction of EAE
Six to 8 week old mice were immunized s.c. on d0 at two sites on the hind flanks
with a total of either 0.5 mg of mMOGtag or 0.54 mg of haMOGtag mixed 1:1 with 4
mg/mL desiccated M. tuberculosis (H37 Ra) in incomplete freund’s adjuvant (SigmaAldrich, St. Louis, Missouri). At the same time mice were also administered 250 ng of
pertussis toxin (List Biological Laboratories, Campbell, California) i.p. and again on d2.
Clinical disease was monitored daily and was scored according to standard conventions
(277) as follows: 0, no clinical signs; 1, tail paralysis; 2, tail paralysis and hind limb
weakness; 3, hind limb paralysis; and 4, complete hind limb paralysis and front limb
weakness. Half points were given for intermediate scores.
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2.4.8 Immunofluorescence histology
At the end of the experiment, spinal cords and inguinal LNs were extracted from
mice and prepared as previously described (78). Briefly, spinal cords and LNs were
extracted and incubated overnight in 1% paraformaldehyde (PFA), 95 mM L-Lysine, 10
mM sodium periodate, pH 7.2 (Bioshop, Burlington, Ontario). Tissues were then
incubated in solutions of increasingly concentrated sucrose until a final concentration of
30% sucrose (Bioshop, Burlington, Ontario). Then, 5–9 evenly spaced spinal cord tissues
spanning the lumbar to cervical regions were cut and frozen in OCT (Tissue-Tek, St.
Torrance, California) media or directly frozen in OCT media for inguinal LNs. Serial
cryostat sections (7 μm) were blocked in PBS containing 1% Bovine Serum Albumin,
0.1% Tween-20 and 10% rat serum before proceeding with staining. Sections were
mounted with ProLong Gold Antifade Reagent (Invitrogen, Carlsbad, California) and
stored at −20 °C. Tiled images of whole spinal cord sections or inguinal LNs (20×) were
imaged using DM5500B fluorescence microscope (Leica microsystems, Concord, ON,
Canada).

2.4.9 In vitro and in vivo T cell proliferation assays
RFP+ OTII or 2D2 CD4+ T cells were enriched through negative selection as
described above. Splenocytes of wild type C57Bl/6 mice were depleted of red blood cells
using ACK lysis buffer (Thermo Fisher Scientific, Waltham, Massachusetts). The cells
were then transferred into 10% FBS RPMI with L-glutamine (Thermo Fisher Scientific,
Waltham, Massachusetts) supplemented with 1x penicillin/streptomycin (WISENT,
Saint-Bruno, Quebec, Canada). One million splenocytes were then added to individual
wells of a sterile 48-well plate and were incubated with either 35 μg NP-OVA, 25 μg
mMOGtag, or 27 μg haMOGtag for one hour at 37 °C 5% CO2. OTII or 2D2 T cells were
CFSE (Thermo Fisher Scientific, Waltham, Massachusetts) labelled as described in (278)
and 4 x105 T cells were added to the Ag loaded splenocytes. After three days of coculture, CFSE labeling of Ag-specific T cells was analyzed by flow cytometry. For the in
vivo assays, T cells were CFSE labelled as listed above and transferred into mice, also
listed above.

62

2.4.10 ELISpots and ELISA
96-well plates were coated overnight at 4°C with 0.5 μg MOG1-125. Wells were
blocked with 1% (wt/vol) BSA in PBS, then incubated with serial diluted bone marrow or
LN cells at 37°C in 5% CO2. Spots were detected using a goat alkaline phosphataseconjugated anti-mouse IgM or IgG antibody (MABTECH, Nacka Strand, Sweden) and 5bromo-4-chloro-3-indolyl-phosphate substrate (Sigma-Aldrich, St. Louis, Missouri) and
counted under a Leica M80 dissection microscope. To detect circulating antibodies
against MOG1-125, 96-well plates were incubated with MOG1-125 and blocked with BSA
as written above. Blood was extracted from mice using a cardiac puncture into preloaded
syringes with 0.5 M EDTA and spun at 4500 x g for 15 minutes. Plasma was extracted
and incubated with the 96-well plate for one hour at room temperature. Plates were
incubated with anti-IgM or IgG antibodies and then the alkaline phosphatase yellow
(pNPP; Sigma-Aldrich, St. Louis, Missouri) substrate. OD405 was measured using an
Eon microplate spectrophotometer (BioTek, Winooski, Vermont).

2.4.11 Statistical analyses
PRISM software (GraphPad Software, La Jolla, California) was used to analyze
flow cytometry and histology data. For statistical comparisons, a Student’s T-test was
used for single comparisons and a one-way ANOVA followed by a T test with
Bonferroni correction was used for multiple comparisons.
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Chapter 3

3

Autoreactive T cells preferentially drive differentiation of
short-lived memory B cells at the expense of germinal center
maintenance.
B cell fate decisions within a GC are critical to determining the outcome of the

immune response to a given Ag. Here, I characterize GC kinetics and B cell fate choices
in response to the autoAg MOG, and compare them to the response to a standard model
of foreign Ag (NP-haptenated ovalbumin, NPOVA). Both Ags generated productive
primary responses, as evidenced by GC development, circulating Ag-specific antibodies,
and differentiation of memory B cells. However, in the MOG response the status of the
cognate T cell partner drove preferential B cell differentiation to a memory phenotype at
the expense of GC maintenance, resulting in a small ongoing GC. Indeed, placing the
same NP-specific B cells under the control of either OVA or MOG-specific T cells, I
identified that preferential memory B cell differentiation over GC maintenance was
instructed by the MOG-specific T cell. Furthermore, the MOG-specific T cell could not
efficiently expand the early low-affinity plasmablast response although plasma cell
differentiation occurred similarly within the GC under the control of either T cell. The
collapse of MOG-driven GCs, but not plasmablast expansion, could be partially reversed
by hyperactivating MOG-specific T cells with a high-affinity Ag suggesting low T cell
Ag-affinity limits the MOG-driven GC response. Despite this, TFH cells exhibited no
observed differences in the expression of cytokines or surface receptors previously
identified as controlling memory B cell differentiation in the different model systems.
Interestingly, memory B cells formed in the MOG GC were short-lived leading to the
failure of secondary challenges with Ag to induce GC responses. The short-lived nature
of memory B cells was not programmed by the autoreactive T cell. Overall these results
highlight properties of B and T cells that contribute to B cell fate choices in GC responses
and how these are relevant to an autoimmune response.
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3.1

Introduction
Tailoring the immune response to a given Ag is a crucial function of the immune

system, as the quality and nature of the response impacts the success of pathogen
clearance as well as subsequent long-lived immunity. This is further complicated in cases
where the response directly targets or cross reacts with an autoAg. Nearly all naturally
occurring immune responses incorporate both B and T cell recognition of the Ag, and
collaboration between B and T cells specific for said Ag produces a GC response (94,
279, 280). Throughout the GC response, B cell survival, proliferation, and differentiation
to either antibody-producing plasma cells or memory B cells is dependent upon, and
informed by, direct interactions with T cells specific for the same Ag (cognate
interactions) (58). However, the signals that drive differential fate choices made by B
cells responding to different Ags and how they are influenced by features of the Ag itself
are not well understood.
Interactions with cognate T cells are critical during two distinct phases of the
developing B cell response. The first phase occurs shortly after exposure to a new Ag, but
prior to GC formation. During this phase, cognate B-T interactions are essential to the
initiation of Ag-stimulated B cell proliferation and also to driving B cell differentiation
along three distinct pathways: 1st, short-lived plasmablasts that produce low-affinity
largely IgM antibodies; 2nd, early (mostly) IgM memory B cells; and 3rd, GC B cells
that reenter the follicle to initiate a new GC (281). The second phase of B-T cell
interactions occurs within the mature GC itself. GC B cells undergo clonal expansion and
SHM largely within the DZ, before migrating to the LZ to compete for survival signals
supplied through interactions with specialized cognate TFH cells (58). Evidence also
suggests that TFH cells provide signals that, in addition to maintaining the GC by
selecting GC B cells for survival and additional rounds of proliferation and mutation in
the DZ, further influence GC B cell differentiation into memory B cells or plasma cells.
GC-derived plasma cells and long-lived plasma cells produce the high-affinity, classswitched antibodies critical to pathogen clearance and long-term immunity; while
different subpopulations of GC-derived memory B cells are able to rapidly differentiate
into plasma cells or re-initiate the GC upon re-exposure to Ag.
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Several TFH-derived signals have been identified that can, through genetic
deletion or antibody blockade, influence B cell differentiation. These include the
cytokines IL-4 and IL-21 (177, 233) and receptors PD-1 and ICOS (218, 223). It is
possible that differential expression of these factors is the mechanism by which the
immune system tailors the B cell response to different Ags, but this has not been
explored. B cell receptor affinity for Ag is known to influence B cell fate choice, with
higher-affinity being linked to preferential plasma cell differentiation (248), but how or if
an Ag can influence the cognate T cell partner or the signal it provides to B cells is not
known.
Recent advances in understanding GC development and the cognate B-T
interactions that drive them have benefited from model Ag systems in which B and T
cells specific for the Ag can be identified and their activation and differentiation tracked
over the course of the response. For example, we and others have transferred fluorescent
protein-marked ovalbumin (OVA)-specific T cells isolated from OTII mice and
nitrophenyl hapten (NP)-specific B cells from B1-8 mice to non-fluorescent proteinmarked mice to track both cell types in the developing GC following immunization with
NPOVA (78, 106). Similar models based on other (mostly) foreign-Ags produce GCs
with similar kinetics and patterns of B cell differentiation. A model system based on an
autoAg may provide a tool with which to dissect the mechanisms by which the immune
system itself controls differential outcomes, without relying on external blockade or
deletion of candidate factors. Yet comparable models that examine the development of
the autoimmune GC remain under explored.
MOG is a well characterized autoAg associated with anti-myelin autoimmunity of
the CNS, both in human MS and the well-characterized animal model EAE. In MS, antimyelin B cells and antibodies show evidence of SHM, indicating that they are GCderived (72, 282). Currently, the most common way to induce MOG autoimmunity in
C57Bl/6 mice is to immunize with the MOG35-55 peptide that corresponds to the CD4+ T
cell epitope, a method that excludes B cell targeting of the MOG protein (240). However,
as I have showed earlier (Chapter 2), immunization with a larger peptide corresponding
with the MOG-extracellular domain does indeed result in GC development incorporating
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anti-MOG B cells (240, 283). Therefore, using the tools assembled and developed in
Chapter 2, we can use our MOG-based model Ag system in an analogous manner to the
NPOVA system described above for investigation of differential B cell fate choice under
the control of notably different Ags.
Here, I demonstrate that the GC develops very differently in response to MOG
compared to the well characterized NPOVA system. In comparison to the NPOVA
response, B cell fate choice in the MOG GC response was heavily biased against plasma
cells. Further, while the initial stages of the MOG GC developed normally, it was not
sustained and instead collapsed early, producing a large number of memory-phenotype B
cells. By manipulating the T cell controlling the same B cell response, I determined that,
while plasma cell differentiation was largely independent of T cell influence,
immunoglobulin class-switching, GC maintenance, and B cell differentiation into a
memory-phenotype were largely under the control of the T cell partner. By manipulating
the Ag itself, I, for the first time, found the T cell affinity for Ag impacts B cell fate
choice. Finally, we determined that memory-phenotype B cells derived from the MOG
GC are not long-lived, resulting in a failed memory response to secondary-challenge.
Finally, the short-lived nature of MOG-specific memory B cells is not due to education
by the autoimmune T cell.

3.2

Results

3.2.1 Immunization with MOG autoAg results in an atypical, unsustained
GC response
In order to identify and track responding B and T cells throughout an immune
response to two different Ags, GFP+ B cells (either NP-specific B1-8+ Jκ-/- (284, 285) or
MOG-specific IgHMOG (256)) and RFP+ T cells (either OVA-specific OTII (265) or
MOG-specific 2D2 (264)) were isolated from transgenic mice and transferred into wild
type C57Bl/6, non-fluorescent protein-marked recipients (Figure 3.1A). Two days posttransfer, mice were immunized in the footpad with the appropriate Ag (NPOVA for
recipients of B1-8 B cells and OTII T cells, or mMOGtag for recipients of IgHMOG B cells

67

and 2D2 T cells) in CFA. Lymph nodes were harvested for histological analysis 5d postimmunization, representing the outcomes of early, pre-GC cognate interactions between
responding B and T cells, or 10d post-immunization, representing a mature GC time
point.
While virtually no transferred fluorescent cells could be observed in LNs from
unimmunized mice (data not shown), large numbers of fluorescent B and T cells derived
from the original transferred populations were readily evident at the 5d time point in both
Ag systems (Figure 3.1B, top and 3.1C). Consistent with previous observations (78), PD1+ RFP+ TFH cells were distributed throughout the follicle and GC in both model systems,
although the density of RFP+ T cells was significantly lower in mMOGtag-immunized
mice (Figure 3.1B, 3.1C, 3.1E).
Very large numbers of GFP+ CD138+ cells, representing the early short-lived
plasmablast response, were evident outside of the follicles and within medullary cords of
NPOVA- but not mMOGtag-immunized mice (Figure 3.1D). By 10d post immunization
fewer, but equivalent numbers of plasma cells were within medullary cords in both model
systems.
Within B cell follicles, dense clusters of GFP+ cells (Figure 3.1B and 3.1C) that
were also IgDlo, Ki67+, and Bcl-6+ (Figure 3.1A and 3.1E) were evident in both systems
5d post-immunization, indicating that early pre-GC B-T interactions were sufficient to
drive GC B cell differentiation and establishment of a new GC. However, by 10d postimmunization, the GC in the MOG Ag system had largely disappeared, while this time
point corresponded with the full development of a mature and organized GC in the
NPOVA system (Figure 3.1B, bottom and 3.1C). Small clusters of Ki67+ and Bcl-6+ cells
could still be observed in follicles of mMOGtag-immunized mice, however these were
much smaller and less dense than those observed in NPOVA mice (Figure 3.1E). Instead,
greater numbers of individual GFP+ cells were scattered throughout the follicle (Figure
3.1B and 3.1C). Very few individual GFP+ cells were evident in the follicle in the
NPOVA system, and virtually all remained confined in the GC.
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Figure 3.1. Differential GC development in the NPOVA and MOG model Ag systems.
(A) Fluorescent protein-marked B and CD4+ T cells specific for NPOVA or MOG were
isolated and transferred into wild type, non-fluorescent protein-marked recipients. Two
days post-transfer, mice were immunized with either NPOVA or mMOGtag in CFA in the
footpad. Draining popliteal LNs were harvested for histology d5 and d10 postimmunization, representing the early and mature GCs. (B) Immunofluorescence of LNs
from NPOVA and mMOGtag immunized mice to visualize RFP+ T cells and GFP+ B cells
derived from transferred Ag-specific cells. Sections were also stained for IgD to outline B
cell follicles. Scale bars represent 100 µm. (C) The density of GFP+ or RFP+ cells in the
GC or follicle was quantified. Each data point represents the average value across one
histological section for a single mouse. * p<0.05, **p<0.01, ***p<0.001. A Student’s Ttest was used for single comparisons. (D) Higher magnification of the regions of interest
outlined by the dashed lines in panel B showing CD138 staining for plasma cells. (E)
Higher magnification of the regions of interest outlined by the solid white line in panel B
were further examined for Ki67, Bcl6, and PD-1 expression. Data is representative of 1
of 2 experiments.

69

70

3.2.2 Preferential differentiation of B cells with a memory phenotype in
response to MOG autoAg
The developing GC response was analyzed by flow cytometry in a separate,
identical experiment. Consistent with our histological observations, the early CD19int
CD138+ plasma cell response was nearly absent in mMOGtag-immunized mice compared
to a very large response in the NPOVA system (Figure 3.2A-3.2C). This was true of both
the GFP+ response derived from transferred, Ag-specific B cells and the endogenous
GFP- response (Figure 3.2C bottom), confirming that this is a feature of the anti-MOG
response.
While Ag-specific GFP+ CD95hi CD38lo GC B cells were evident in both the
NPOVA and MOG systems at the d5 time point, they made up a significantly smaller
proportion of the total GFP+ B cell population in the MOG system (Figure 3.2A-3.2C),
and most dramatically at the d10 time point, consistent with the collapse of the GC
response observed by histology. A similar collapse of the endogenous, GFP- GC was also
observed in mMOGtag immunized mice (Figure 3.2C bottom). The proportional loss of
GFP+ Ag-specific GC B cells and plasma cells in the MOG response was offset by a large
increase in the proportion of CD95lo CD38hi cells, a phenotype shared by naïve and
memory B cells (Figure 3.2C, top right).
Evaluation of immunoglobulin class-switching in the GC B cell population 8d
post immunization, prior to complete collapse of the MOG GC, revealed that the ratio of
IgG1 to IgM-expressing GC B cells was significantly higher in NPOVA-immunized mice
(Figure 3.2E). Nevertheless, and despite the bias against plasma cell development (Figure
3.2A and 3.2C), mMOGtag-immunized mice were still capable of mounting an Agspecific antibody response, albeit smaller than observed to NPOVA. Indeed, by ELISpot
the number of anti-MOG IgM and IgG producing cells was significantly lower in LN’s
14d post immunization compared to anti-NP producing cells (Figure 3.2D, middle).
Similar analysis of bone marrow revealed a reduction in anti-MOG IgM, but not IgGproducing cells (Figure 3.2D, right). This was reflected by reduced levels of circulating
anti-MOG compared to anti-NP IgM but not IgG, as measured by ELISA of serum from
the same mice (Figure 3.2D, left).
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As the anti-MOG GC response is an autoimmune response, it was possible that
regulatory processes, such as the induction of Bregs (44), Tregs (286), or TFR cells (187),
could have contributed to the collapse of the MOG GC response. In a separate
experiment, there was no difference between the MOG and NPOVA systems in IL-10
production by GFP+ or GFP- B cells, a measure of Breg cells, or by T cells (Figure 3.2F).
Neither were there any differences in the proportion of Treg or TFR cells. Therefore, an
enhanced regulatory response was not responsible for the failed GC in the MOG system.
It has also been suggested that administration of PTX, which is often used in conjunction
with MOG-immunization to induce EAE, could modify regulatory responses and by
extension, potentially affect the GC (287). However, I found that PTX administration did
not rescue the MOG GC (Figure 3.3A) and had no effect on circulating antibody titers
(Figure 3.3B).
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Figure 3.2. Early collapse of the MOG GC to a memory B cell phenotype.
(A-C and F) Fluorescent protein-marked B and CD4+ T cells specific for NPOVA or
MOG were transferred into non-fluorescent protein-marked C57Bl/6 mice that were then
immunized with NPOVA or mMOGtag. Draining LNs were harvested for analysis by
flow cytometry d5 and d10 post-immunization. (A) Representative gating of GFP+ cells
for plasma cells (PC), GC B cells, and memory/naive B cells (M/N). (B) Shown is the
absolute number of GFP+ cells per LN. (C) Quantification from panel A showing size of
each cell subset (as defined in panel A, gating shown above each plot) derived from the
transferred GFP+ B cells (top row) or from endogenous GFP- cells (bottom row). Data is
expressed as the percentage of all GFP+ cells for Plasma cells, or percentage of all GFP+
B cells (CD19+ CD138-) for GC and Memory/Naïve B cells. One representative of two
separate experiments is shown. Of note, the difference between GFP- plasma cells at d5
was not seen using a non-parametric test. (D) C57Bl/6 mice were immunized with either
NPOVA or mMOGtag in CFA. Day 14 post-immunization, draining popliteal LNs and
bone marrow were taken for ELISpot analysis of NP- or MOG-specific IgM or IgG.
Blood serum from the same mice was assayed by ELISA for circulating anti-NP or MOG IgM or IgG antibodies. Data is representative of 1 of 2 experiments. Of note, no
statistically significant difference is seen in the number of IgM plasma cells in the bone
marrow when using a non-parametric test. (E) The ratio of IgG1 expressing cells over
IgM expressing GC B cells d8 post-immunization is shown. Data is representative of 1 of
2 experiments. (of note, there was no statistically significant difference between the
groups when using a non-parametric test). (F) The percentage of all T cells expressing
IL-10 (top) or FoxP3 (top middle), the percentage of Bcl6+ PD-1high expressing FoxP3
(middle), and the percentage of B cells expressing IL-10 for GFP+ cells (bottom middle)
and GFP- cells (bottom) are shown d10 post-immunization. Data is based on one
experiment. In all graphs, each data point represents an individual mouse. * p<0.05,
**p<0.01, ***p<0.001. A Student’s T-test was used for single comparisons.
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Figure 3.3. Administration of pertussis toxin does not save the MOG-induced GC from
collapse
(A and B) Fluorescent protein-marked MOG-specific B and CD4+ T cells were
transferred into non-fluorescent protein-marked C57Bl/6 mice that were then immunized
with mMOGtag. On days 0 and 2, mice were injected i.p. with either PBS or PTX.
Draining LNs were harvested for analysis by flow cytometry d10 post-immunization. (A)
Shown is the absolute number of GFP+ cells per LN (left) and each cell subset derived
from the transferred GFP+ B cells is expressed as the percentage of all GFP+ cells for
Plasma cells, or percentage of all GFP+ B cells (CD19+ CD138-) for GC and
Memory/Naïve B cells. (B) Blood serum from the same mice was assayed by ELISA for
circulating anti-mMOGtag IgM or IgG antibodies. Data is based on one experiment. In all
graphs, each data point represents an individual mouse. A Student’s T-test was used for
single comparisons.
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3.2.3 Ag-specific GFP+ CD95lo CD38hi B cells are Ag experienced
To confirm that the GFP+ CD95lo CD38hi B cells observed above derive from
previously activated and proliferating cells, bromodeoxyuridine (BrdU) was injected d4,
d5, and d6 post-immunization to label proliferating cells. On d10 post-immunization,
LNs were harvested for flow cytometry analysis. In this way, only cells that were actively
proliferating during the labeling period (note that only a proportion of actively
proliferating cells would be labeled, due to the short half-life of free BrdU in mice), but
had then become quiescent would retain BrdU labeling (126). Indeed, neither nonproliferating endogenous GFP- CD95lo CD38hi follicular B cells (Figure 3.4A), nor
proliferative GFP+ CD95hi CD38lo GC B cells (data not shown) stained with BrdU. In
contrast, a proportion of GFP+ CD95lo CD38hi memory/naïve B cells were BrdU+ in both
model systems, confirming that some of them derived from previously activated cells.
Nonetheless, a relatively smaller portion of MOG-specific memory-phenotype B cells
had labelled with BrdU, making it unclear how many of these cell had actually expanded
due to mMOGtag-immunization.
To more precisely establish whether GFP+ CD95lo CD38hi B cells in the MOG
system had indeed derived from previously activated cells, GFP+ IgHMOG B cells were
isolated and labeled with Cell Tracker Yellow (CTY) prior to transfer along with either
OVA or MOG-specific T cells. The CTY dye was used to monitor proliferation as the
fluorescent signal from this dye halves whenever cells proliferate. Furthermore, this dye
was used in combination with fluorescently labelled mMOGtag protein to identify
mMOGtag-specific B cells. Recipients expressing an irrelevant transgenic TCR
(SMARTA) were used as recipients to limit the endogenous T cell response. Control
mice were left unimmunized or, to measure Ag-non-specific expansion, recipients of
OVA-specific T cells were immunized with OVA to generate a GC response to an
irrelevant Ag. Compared to unimmunized mice at the same time point, immunization
with OVA protein resulted in a small, non-significant increase in GFP+ cells in draining
LNs d10 post-immunization and, as expected, they did not participate in the GC response
(Figure 3.4B, top). Immunization of mice with mMOGtag that received MOG-specific T
cells however, resulted in an increase in GFP+ cells. Consistent with above (Figure 3.2C),
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the majority had a CD95lo CD38hi naïve/memory B cell phenotype, but some CD95hi
CD38lo GC B cells were still evident. Approximately 90% of these GFP+ GC B cells
bound fluorescently-labelled mMOGtag antigen (Figure 3.4B, bottom), and all had fully
diluted out the CTY dye (data not shown). Among the GFP+ CD95lo CD38hi
naïve/memory B cell population, ~50% bound mMOGtag Ag (Figure 3.4B, bottom).
Further, a proportion of these cells had at least partly diluted CTY, indicating that they
derived from proliferating cells (Figure 3.4C, left). While some non-specific expansion
and CTY dilution was observed in the OVA-immunized mice, compared to expanded
GFP+ memory B cells in MOG-immunized mice, they had a higher mean fluorescence
intensity (MFI) for CTY, indicating that immunization with OVA did not induce the
same extent of proliferation (Figure 3.4C, middle). Furthermore, CTY dilution was
concentrated in the mMOGtag-binding population in MOG-immunized but not OVAimmunized mice, indicating that expansion of the CD95lo CD38hi had been driven by Ag
(Figure 3.4C, right).
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Figure 3.4. Memory-phenotype B cells generated in response to MOG are Agexperienced
(A) Fluorescent protein-marked OVA or MOG-specific B and T cells were transferred
into non-fluorescent protein-marked SMARTA recipient mice and immunized with
NPOVA or mMOGtag, respectively. Mice were injected i.p. with BrdU d4, d5, and d6
post-immunization and BrdU incorporation in the GFP+ or GFP- memory/naïve B cell
populations was assessed by flow cytometry d10 post-immunization. Each graph
represents a separate experiment and the data points in the mMOG graph were pooled
from two separate experiments. (B and C) IgHMOG GFP+ B cells were labelled with CTY
then transferred into SMARTA recipient mice along 2D2 or OTII T cells. Mice were then
immunized with either mMOGtag, OVA (for those that received OTII T cells), or given no
immunization and the GC response was assessed by flow cytometry d10 postimmunization. (B) Data is expressed as the absolute number of GFP+ cells, as the
percentage of all GFP+ B cells (CD19+ CD138-) for GC and Memory/Naïve B cells (top
panels), or as the percentage of all GFP+ GC or Memory/Naïve B cell that are mMOGtag+
(bottom panels). Of note, the difference in the percentage of GFP+ B cells as GC B cells
between the OVA and MOG groups was not seen in a non-parametric ANOVA. (C) Data
is expressed as the percentage of GFP+ Memory/Naïve B cells that are CTYlow/neg (left)
(of note, one data point in the ‘none’ group was identified as an outlier; furthermore, a
statistically significant difference is seen between the ‘none’ group and MOG group
when using a non-parametric ANOVA), the MFI CTY of CTYlow/neg Memory/Naïve B
cells (middle), or the percentage of CTYlow/neg Memory/Naïve B cells that are MOGtag+
(right). Data is based on one experiment. In all graphs, each data point represents an
individual mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for
single comparisons and a one-way ANOVA was used for multiple comparisons.
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3.2.4 T cells partially control the outcome of the germinal center response
to MOG
To begin to decipher the role for the cognate T cell partner in instructing
differential B cell fate choice and the failure of GC maintenance in the MOG vs NPOVA
systems, we took advantage of the modular nature of the hapten Ag system to place NPspecific B1-8+ Jκ-/- B cells under control of either OVA-specific OTII T cells (NPOVA)
or MOG-specific 2D2 T cells (NPMOG). Fluorescent protein-marked NP-specific B cells
were transferred to non-fluorescent protein-marked SMARTA recipients and either OVA
or MOG-specific T cells were transferred at the same time. Recipients were immunized
2d later with NPOVA for mice that received OTII T cells or NPMOG for those that
received 2D2 T cells and LNs were harvested d5 or d10 post-immunization for analysis
by flow cytometry or, in a separate experiment, histology.
Five days post-immunization, there was no significant difference in the number of
GFP+ cells, but short-lived plasmablasts made up a smaller proportion of the NP-specific
GFP+ response under control of MOG-specific T cells compared to OVA specific T cells
(Figure 3.5A). However, similar results were not seen at the d10 time point suggesting
plasma cell numbers had fully recovered by d10. A large population of GC B cells was
evident d5 post-immunization by flow cytometry (Figure 3.5A) and large GCs were seen
by histology (Figure 3.5B and 3.5C) in both systems, indicating that OVA and MOGspecific T cells are capable of supporting the early formation of a GC. However, by d10
post-immunization there was evidence that the NPMOG GC had begun to collapse, as
reflected by the significant drop in numbers of GFP+ cells and that GC B cells made up a
smaller proportion of the total Ag-specific population compared to the NPOVA response
(Figure 3.5A), and GCs were less dense (Figure 3.5B and 3.5C). This was balanced by a
significant increase in the proportion of Ag-specific B cells with a memory/naïve CD38hi
CD95lo phenotype (Figure 3.5A). Furthermore, the immunoglobulin class-switching on
GC B cells was also significantly reduced under the control of MOG-specific T cells
(Figure 3.5D). Therefore, ongoing maintenance rather than initiation of the GC, as well
as the immunoglobulin class-switching, are in part controlled by the T cell partner of the
cognate B-T pairing.
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Figure 3.5. MOG-specific T cells induce early GC collapse to a memory B cell
phenotype.
Fluorescent protein-marked NP-specific B cells and either OVA or MOG-specific CD4+
T cells were transferred into non-fluorescent protein-marked SMARTA recipients that
were then immunized with either NPOVA or NPMOG. Draining popliteal LNs were
harvested for analysis by flow cytometry or, in a separate experiment, histology at d5 and
d10 post-immunization. (A) The absolute numbers of GFP+ cells and size of the given
cell subset is shown as a percentage of all GFP+ cells (Plasma cells) or all GFP+ B cells
(GC B cells and Memory/Naïve B cells). The d5 and d10 time points were assessed in
separate experiments, data shown is representative of 2 to 3 individual experiments. Of
note, no statistically significant difference is seen in the proportion of GFP+ plasma cells
between groups at the d5 time point when using a non-parametric test. Furthermore one
of the data points at the d10 time point in the NPOVA group was identified as an outlier.
(B) Representative histological sections from NPOVA or NPMOG-immunized mice to
visualize NP-specific GFP+ B cells and either RFP+ OVA-specific or MOG-specific T
cells, respectively. Sections were stained for IgD to outline B cell follicles. Data is
representative of one experiment. Scale bars represent 100 µm. (C) The density of GFP+
or RFP+ cells in the GC was quantified from histological images. (D) The ratio of IgG1over IgM-expressing GC B cells d5 and d10 post-immunization is shown. Of note,
differences in class-switching were not seen when using a non-parametric test. Each data
point represents an individual mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test
was used for single comparisons.
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3.2.5 Low T cell Ag-affinity limits the MOG GC response
A common feature of autoimmune TCRs, including TCRs that recognize the
MOG35-55 peptide, is that they tend to bind peptide:MHC with relatively low-affinity
(288, 289). Additionally, many are also polyreactive including the MOG35-55-specific
2D2 TCR that also recognizes the NF-M18-30 peptide with higher-affinity than it does
MOG35-55 (261, 262). I took advantage of polyreactivity of the 2D2 TCR to determine if
TCR affinity for Ag influences B cell fate choice and maintenance of the GC response by
using our modified haMOGtag Ag that incorporates the NF-M18-30 epitope.
Fluorescent protein-marked MOG-specific B and T cells were transferred to
SMARTA recipients which were then immunized with either mMOGtag or haMOGtag.
Lymph nodes were harvested d5 or d10 post-immunization for analysis by flow
cytometry. No differences in plasma cell differentiation were observed at either time
point (Figure 3.6A). However, consistent with the hypothesis that the TCR affinity of the
T cell partner in the cognate pair influences GC maintenance vs B cell differentiation,
partial recovery of the GC with a corresponding decrease in the proportion of memoryphenotype B cells was observed 10d post-immunization with haMOGtag. In contrast to
our observations where NP-specific B cells were placed under control of two different T
cells (Figure 3.5), T cells responding to haMOGtag did not affect immunoglobulin classswitching in the GC (Figure 3.6B), suggesting that these outcomes are controlled
separately or that they represent a gradient of potential outcomes influenced by different
levels of T cell activation and signal production.
In the cyclic re-entry model of the GC response (280), GC B cells undergo
repeated rounds of proliferation and SHM, largely in the DZ, followed by migration to
the LZ to receive survival and differentiation signals, primarily from TFH cells. We
hypothesized that the collapse of the MOG GC was due to the inability of TFH cells to
drive LZ B cells to maintain GC status and reenter the DZ, instead resulting in
differentiation to a memory phenotype. To test this, proliferation of GC B cells was
analyzed by BrdU uptake, along with the expression of CXCR4 as a marker of DZ GC B
cells. Consistent with our hypothesis, BrdU labeling of GC B cells was significantly
higher in mice immunized with NPOVA and haMOGtag compared to mMOGtag, and more
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GC B cells were of the CXCR4+ DZ phenotype in mice immunized with NPOVA, while
haMOGtag-induced GCs were intermediate (Figure 3.6C).
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Figure 3.6. Increasing T cell Ag-affinity partly rescues the MOG GC from early collapse.
(A and B) Fluorescent protein-marked MOG-specific B and T cells were transferred into
non-fluorescent protein-marked SMARTA recipients that were then immunized with
mMOGtag or haMOGtag. Draining popliteal LNs were harvested for analysis by flow
cytometry at d5 and d10 post-immunization. The d5 and d10 time points were assessed in
separate experiments, data shown is the combination of two separate experiments. (A)
The absolute numbers of GFP+ cells and size of the given cell subset at both d5 and d10
post-immunization is shown as a percentage of all GFP+ cells (Plasma cells) or all GFP+
B cells (GC B cells and Memory/Naïve B cells). Of note, no statistically significant
difference is seen in the number of GFP+ cells per LN at the d5 time point when using a
non-parametric test. Additionally, one data point in the d10 MOG group comparing the
percentage GC B cells amongst GFP+ B cells was identified as an outlier. (B) The ratio of
IgG1- over IgM-expressing cells was determined for GC B cells. (C) Fluorescent proteinmarked Ag-specific B and T cells were transferred into non-fluorescent protein-marked
SMARTA recipients that were then immunized with NPOVA, mMOGtag, or haMOGtag.
Mice were injected i.p. with BrdU 7d post-immunization, and draining popliteal and
inguinal LNs were harvested for analysis by flow cytometry 12hrs later. The percentage
of GFP+ GC B cells that are BrdU+ (left) or CXCR4+ (right) is shown. Of note, no
statistically significant differences between the haMOG and MOG groups when using a
non-parametric test. Data is based on one experiment. Each data point represents an
individual mouse. * p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for
single comparisons and a one-way ANOVA was used for multiple comparisons.
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3.2.6 Levels of T cell activation do not explain the differential B cell
response between the different model systems
In an attempt to understand the underlying mechanism behind the differential
outcome of the GC response in the different model Ag systems, Ag-specific TFH cells
(CXCR5+ PD-1hi RFP+) were isolated by FACS from LNs of mice 10d postimmunization with NPOVA, mMOGtag, or haMOGtag (Figure 3.7A and 3.7B). Messenger
RNA was isolated for quantitative digital droplet PCR analysis of the expression of genes
with a known role in providing T cell help and differentiation signals to GC B cells.
Surprisingly, little difference was observed in mRNA expression levels of the canonical
TFH cytokines IL-4 and IL-21 (Figure 3.7C – note that the small difference in IL-4
expression was not consistent across experiments). Again, there was no difference in the
expression of IL-10 (Figure 3.7C, top). Neither were there differences in the mRNA
expression of the surface receptors CD40L, ICOS, PD-1, CD28 and CTLA-4 (Figure
3.7C, middle). Equivalent surface expression of ICOS and PD-1 by Ag-specific TFH cells
was confirmed in a separate experiment by flow cytometry (Figure 3.7D). Interestingly,
the master regulator of regulatory T cells, FoxP3, mRNA was expressed at significantly
higher levels by TFH cells from haMOGtag-immunized mice (Figure 3.7C bottom), a
finding confirmed by flow cytometry (Figure 3.7D). The significance of this observation
is not clear, as an increased ratio of TFR cells would seem to counter the larger GC
response in haMOGtag vs mMOGtag-immunized mice. Nevertheless, this finding was
consistent across three separate ddPCR and flow cytometry experiments. Thus,
differences in gene expression by TFH cells cannot explain why B cells in the NPOVA,
mMOGtag, and haMOGtag induced GCs make different fate decisions.
I consistently observed that the absolute number of TFH cells was greater in the
NPOVA vs MOG systems (Figure 3.7B, and also reflected in Figure 3.1C) and that
haMOGtag immunization produced intermediate numbers of TFH cells (Figure 3.7B). This
resulted in an identical GC B cell:TFH cell ratio across model Ag systems (one example
presented in Figure 3.7E). To determine if the size of the GC response was simply linked
to the size of the T cell response to a given Ag, different numbers of 2D2 T cells were
transferred along with equal numbers of MOG-specific B cells into SMARTA recipient
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mice. While immunization with mMOGtag resulted in a significantly larger Ag-specific T
cell response in mice that received more cells, there was no similar increase in the
number of TFH cells, nor was there an alteration in the GC response (Figure 3.7F).
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Figure 3.7. TFH cell phenotype is not altered by Ag.
(A-C) RFP+ OVA or MOG-specific T cells were transferred along with non-fluorescent
protein-marked NP or MOG-specific B cells into non-fluorescent protein-marked
SMARTA recipient mice that were then immunized with NPOVA, mMOGtag, or
haMOGtag in CFA. Draining popliteal and inguinal LNs were harvested 10d later and TFH
cells (CD4+ CD19- RFP+ CXCR5+ PD-1hi) were sorted by FACS sorted for subsequent
analysis of gene expression by digital droplet PCR. One representative of two
independent experiments is shown. (A) An example of gating for CXCR5+ PD-1hi TFH
cells is shown. (B) The absolute number of TFH cells per LN is shown (left panel), along
with size of the TFH population as a percentage of total RFP+ T cells (right panel). Of
note, no statistically significant differences are seen between the NPOVA and haMOG
groups in the left graph or between any groups on the right graph when using a nonparametric test. (C) Digital droplet PCR analysis of mRNA levels (copies per cell) for the
listed gene. Of note, between the NPOVA and MOG groups, no statistically significant
difference is seen in IL-4 copies and a statistically significant difference is seen in CD28
copies when using a non-parametric test. (D-E) Fluorescent protein-marked Ag-specific
B and T cells were transferred into non-fluorescent protein-marked SMARTA recipients
that were then immunized with NPOVA, mMOGtag, or haMOGtag. Draining popliteal and
inguinal LNs were harvested d8 post-immunization for analysis by FACS. (D) MFI for
ICOS and PD-1 on RFP+ CXCR5+ PD-1hi TFH cells (top two panels) and the percent of
TFH cells (Bcl6+ PD-1hi) that were FoxP3+ (bottom panel) are shown. Data is based on
one experiment. (E) Ratio of GC B cells to TFH cells in the different Ag systems. (F)
Fluorescent protein-marked MOG-specific B cells and different numbers of MOGspecific T cells (0.5, 2, or 8 x 106 2D2 T cells) were transferred into non-fluorescent
protein-marked SMARTA recipients that were then immunized with mMOGtag. Draining
popliteal LNs were harvested 10d post immunization for FACS analysis. The absolute
number of RFP+ T cells per LN (top left panel) and RFP+ TFH cells per LN is shown
(bottom left panel). The percentage of the GFP+ B cells with a GC B cell (top right panel)
or memory B cell (bottom right panel) phenotype is shown. Data is based on one
experiment. Each data point represents an individual mouse. * p<0.05, **p<0.01. A oneway ANOVA was used for multiple comparisons.
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3.2.7 The MOG-induced GC does not generate effective B cell memory
The primary function of memory B cells is to respond to secondary immune
challenge (100). To determine if CD38hi CD95lo memory phenotype B cells generated
from the MOG GC are responsive to Ag challenge, we performed an experiment that
isolates the primary and secondary responses within the same mouse (Figure 3.8A). B
and T cells specific for NPOVA protein were transferred into groups of SMARTA
recipients and MOG-specific cells were transferred into a third group of SMARTA mice.
Recipients were then immunized in the left footpad only with NPOVA or mMOGtag
depending on the cells transferred into them. Then 34 days later, mice were immunized in
the right footpad with NPOVA or PBS if they had originally been immunized with
NPOVA, or again immunized with mMOGtag. Left and right draining LNs were analyzed
separately by flow cytometry 5d post-secondary challenge. Control mice immunized with
NPOVA in CFA in the left footpad but “challenged” with PBS alone showed an ongoing
primary (but small in absolute terms - Figure 3.8B, top) GFP+ GC response in the left but
not right draining LNs (Figure 3.8B, middle bottom). This confirmed that the lymphatics
on the left and right sides of the animal were indeed separate allowing for separate
analysis of the primary and secondary immune responses within the same animal. As
expected, memory phenotype B cells made up the vast majority of GFP+ cells on the right
side, confirming that memory B cells generated in the primary GC properly circulate and
home to lymphatic tissues (Figure 3.8B, bottom). As expected, secondary-challenge with
NPOVA resulted in generation of plasmablasts (Figure 3.8B, middle top) and initiation of
a GC response on the right side. This contrasted starkly with the secondary challenge
response in mMOGtag-immunized mice. Consistent with previous observations, the
primary GC response on the left side in mMOGtag-immunized mice had disappeared,
along with evidence of plasma cells at the d39 time point, leaving GFP+ cells with
exclusively a CD38hi CD95lo phenotype. Despite the clear presence of memoryphenotype GFP+ cells in the right LN, secondary-challenge with mMOGtag Ag did not
produce a new GC response or plasma cells.
Recently, subsets of memory B cells have been identified based on differential
expression of PD-L2 and CD80 (290). Double negative memory cells are associated with
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the establishment of a new GC (135). Nevertheless, CD38hi CD95lo GFP+ B cells in
mMOGtag-immunized mice were almost entirely double negative, while a significant
proportion of memory cells in NPOVA immunized mice expressed PD-L2 and/or CD80
(Figure 3.10A). Immunoglobulin class-switching remained reduced on GFP+ memory
cells in the MOG system compared to the NPOVA system (Figure 3.10B), and
significantly fewer IgG-producing long-lived plasma cells were recovered from the bone
marrow (Figure 3.10C).
In the above experiment, it is possible that the B cell memory response in MOGimmunized mice failed due to the lack of T cells capable of responding to secondary
challenge. Therefore, we performed a separate experiment where new naïve MOGspecific T cells were transferred 2d prior to secondary-challenge with mMOGtag (groups
iv and v, Figure 3.8C). Transfer of new naïve T cells did not result in an appreciable
secondary GC response suggesting the secondary GC response was not limited by a lack
of T cell help (Figure 3.8D). Nevertheless, the large majority of the very-rare GC B cells
induced by secondary immunization bound mMOGtag, as expected (Figure 3.9A, top).
Interestingly, only ~12% of memory-phenotype B cells in either LN were MOG-specific
at this late time point (Figure 3.9A, bottom), which is a considerable reduction from the
~50% observed d10 post-immunization (Figure 3.4B). This raised the possibility that the
memory B cell response in the MOG system fails due to the selective loss of MOGspecific memory B cells over time. Therefore, we repeated the experiment using the
NPOVA and mMOGtag systems, but performed secondary-challenge d19 postimmunization (Figure 3.9B). At this intermediate time point, the GC response to
secondary-challenge in LNs on the right side were equivalent between the NPOVA and
MOG systems (groups vi and vii, respectively. Figure 3.9C) although, as with the
primary response (Figure 3.2C), the plasma cell response was significantly lower with
mMOGtag challenge (Figure 3.9C). As expected, the large majority of GC B cells bound
appropriate Ag (NP and MOG, respectively) in the secondary-response (Figure 3.9D).
Importantly, ~60% of memory-phenotype B cells in either LN in the MOG-system bound
mMOGtag, which is similar to the proportion of MOG-specific memory B cells d10 postimmunization (Figure 3.4B), and considerably greater than observed d39 post-primary
immunization (Figure 3.9A). While this percentage of Ag-binding cells was lower than
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observed in the NPOVA system (Figure 3.9D), it suggests that a threshold number of Agbinding cells are required to respond to Ag and that, over time, MOG-binding cells are
lost and B cell memory fails.
To test whether MOG-specific memory B cells could respond in small numbers,
GFP+ Ag-specific CD38hi CD95lo memory phenotype cells were sorted by FACS from
mMOGtag or NPOVA immunized mice. Ten days post-immunization, a small number of
naïve/memory-phenotype B cells, 7.5 x 103, were transferred to new SMARTA recipients
along with naive T cells specific for the relevant Ag. Following secondary-challenge,
small numbers of GFP+ NP-specific cells were recovered, the majority of which were
plasma cells or GC B cells (Figure 3.10D). In contrast, MOG-specific cells were either
completely undetectable or exclusively of the CD38hi CD95lo phenotype, indicating that
they had not responded to secondary-challenge. This suggests that NP-specific memoryphenotype B cells could respond in small numbers; however, MOG-specific memoryphenotype B cells could not.
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Figure 3.8. Memory B cells produced by the MOG-induced GC response are
unresponsive during secondary immune responses.
(A and B) Fluorescent protein-marked Ag-specific B and T cells were transferred into
non-fluorescent protein-marked SMARTA recipients that were then immunized in their
left footpad with either NPOVA or mMOGtag in CFA. Thirty-four days postimmunization, mice were immunized in their right footpad with NPOVA, PBS, or
mMOGtag in CFA in the right footpad, as shown. (B and D) The primary response in the
left draining popliteal and inguinal LNs and secondary response in the right LNs were
analyzed separately by flow cytometry 5d post-secondary challenge. The absolute
numbers of GFP+ cells and size of the given Ag-specific subsets as a percentage of the
total GFP+ cells (Plasma cells) or GFP+ B cells (GC and Memory/Naïve B cells) is shown
for the left and right sides separately. (B) No statistically significant differences are seen
between the NPOVA-NPOVA and MOG-MOG groups on the left f.p. for the GC B cells
and memory B cell subsets using a non-parametric test. Furthermore, on the right f.p.
there were no differences between the NPOVA-NPOVA and MOG-MOG groups by
absolute numbers, and between the NPOVA-NPOVA and NPOVA-PBS groups for GC B
cells, plasma cells, or memory B cells when using a non-parametric test. (C and D)
Fluorescent protein-marked MOG-specific B and T cells were transferred into nonfluorescent protein-marked SMARTA recipients that were then immunized in their left
footpad with mMOGtag in CFA. Thirty-two days post-immunization 5 x 105 naïve 2D2 T
cells were transferred then d34 post-immunization, mice were immunized in their right
footpad with PBS or mMOGtag in CFA, as shown. Of note, a statistically significant
difference between the MOG-PBS and MOG-MOG groups in the proportion of GFP+ B
cells as GC B cells is seen when using a non-parametric test. Data shown is based on one
experiment. Each data point represents an individual mouse. * p<0.05, **p<0.01,
***p<0.001. A Student’s T-test was used for single comparisons and a one-way ANOVA
was used for multiple comparisons.
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Figure 3.9. MOG-specific memory B cells are responsive but they are short-lived.
(A) Is from the experiment described in Figure 3.8C. (A and D) The proportion of GFP+
B cells (GC and Memory/Naïve B cells) that are Ag-specific is shown for the left and
right sides separately. (B-D) Fluorescent protein-marked Ag-specific B and T cells were
transferred into non-fluorescent protein-marked SMARTA recipients that were then
immunized with either NPOVA or mMOGtag in CFA in their left footpad. Seventeen days
post-immunization 5 x 105 naïve Ag-specific T cells were transferred then d19 postimmunization, mice were immunized in their right footpad with NPOVA or mMOGtag in
CFA, as shown. (C) The primary response in the left draining popliteal and inguinal LNs
and secondary response in the right LNs were analyzed separately by flow cytometry 5d
post-secondary challenge. The absolute numbers of GFP+ cells and size of the given Agspecific subsets as a percentage of the total GFP+ cells (Plasma cells) or GFP+ B cells
(GC and Memory/Naïve B cells) is shown for the left and right sides separately. Of note,
no statistically significant difference is seen between the NPOVA-NPOVA and MOGMOG groups in the left f.p. for absolute numbers of GFP+ cells when using a nonparametric test. Data shown is based on one experiment. Each data point represents an
individual mouse. * p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for
single comparisons and a one-way ANOVA was used for multiple comparisons.
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Figure 3.10. Characterization of MOG-specific memory B cells and their functionality.
(A) Fluorescent protein-marked NPOVA or MOG-specific B and T cells were transferred
into non-fluorescent protein-marked SMARTA recipients that were then immunized in
their left footpad with either NPOVA or mMOGtag in CFA, respectively. Thirty-four days
post-immunization, mice were immunized in their right footpad with NPOVA, PBS, or
mMOGtag in CFA in the right footpad, as shown in Figure 3.7A. Representative staining
and quantification for CD80 and PD-L2 on NPOVA and MOG GFP+ memory/naïve B
cell subsets. Groups shown are for the NPOVA-NPOVA and MOG-MOG groups. (B)
The ratio of IgG1 B expressing cells over IgM expressing B cells amongst GFP+
memory/naïve B cells is shown. (C) At the same time, bone marrow was harvested for
ELISpot quantification of NP- or MOG-specific IgG producing plasma cells. (D)
Fluorescent protein-marked NPOVA or MOG-specific B and T cells were transferred
into non-fluorescent protein-marked SMARTA recipients that were then immunized with
NPOVA or mMOGtag in CFA, respectively. Draining popliteal and inguinal LNs were
harvested d10 post-immunization and CD19+ CD4- CD138- CD38hi CD95lo GFP+
memory/naïve B cells were sorted. Seventy five hundred NP or MOG-specific B cells
were transferred along with 5 x 105 naïve OVA or MOG specific T cells into new nonfluorescent protein-marked SMARTA recipient mice. These were immunized with
NPOVA or mMOGtag and 5d later draining popliteal and inguinal LNs were analyzed by
flow cytometry. The absolute numbers of GFP+ cells per LN (shown on the left) and size
of the given Ag-specific subsets as a percentage of the total GFP+ cells (Plasma cells) or
GFP+ B cells (GC and Memory/Naïve B cells) is shown on the right. Of note, no
difference is seen between the NPOVA and MOG groups when using a non-parametric
test. Data shown is based on one experiment. Each data point represents an individual
mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for single
comparisons.
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3.2.8 Memory B cell responsiveness is not programmed by the MOGspecific T cell
To determine if the failure of MOG-specific B cell memory was due to education
from MOG-specific T cells, an experiment was performed to determine if MOG-specific
T cells could instruct short-lived memory into NP-specific memory B cells. Nitrophenylspecific B cells were transferred along with either OVA or MOG-specific T cells into
SMARTA recipient mice. Mice were then immunized with NPOVA, if they receive
OVA-specific T cells, or NPMOG, if they received MOG-specific T cells, in the left
footpad only. Thirty-two days later, naive T cells specific for the opposite Ag (mice that
originally received OVA-specific T cells had a new transfer of MOG-specific T cells or
vice versa) were transferred; then mice were challenged with Ag in the right footpad 2d
later such that the NP-conjugated protein matched with the cells of the secondary transfer
(Figure 3.11A). This was done to eliminate any potential confounding factors associated
with differences in the generation of T cell memory or regulatory cells from the primary
immune response. Left and right draining LNs were analyzed separately by flow
cytometry d5 post-secondary challenge. Analysis of the primary response in the left LN
revealed that, as at d10 (Figure 3.5), the NP-specific B cell response under control of
MOG-specific T cells was heavily biased to memory-phenotype cells at the expense of
GC B cells (Figure 3.11B). The presence of IgG-producing long-lived plasma cells in the
bone marrow was also reduced (Figure 3.11C). In contrast, and as opposed to the MOGspecific B cells in the previous experiment (Figure 3.10A), there was no difference in the
proportion of CD80 PDL2 double negative memory NP-specific B cells under the control
of either T cell (Figure 3.11D), nor was there a defect in immunoglobulin class-switching
of memory cells (Figure 3.11E). Also, analysis of the right LN clearly demonstrated that
NP-specific B cells educated by MOG-specific T cells in the primary response were able
to respond to secondary-challenge (Figure 3.11B). Overall, this confirmed that the failure
of MOG-specific memory B cells was not due to T cell education, but, rather was
something intrinsic to the B cell or its environment.
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Figure 3.11. Autoimmune T cells do not induce short-lived memory in MOG-specific B
cells during the GC response.
(A) Fluorescent protein-marked NP-specific B cells and OVA or MOG-specific T cells
were transferred into non-fluorescent protein-marked SMARTA recipients that were then
immunized in their left footpad with either NPOVA or NPMOG. Thirty-two days postimmunization, naïve T cells of the reciprocal specificity were transferred to these
recipient mice, as shown, followed two days later by immunization with that Ag in the
right footpad. (B) The primary response in the left draining popliteal and inguinal LNs
and secondary response in the right LNs were analyzed separately by flow cytometry d5
post-challenge. The absolute numbers of GFP+ cells and size of the given Ag-specific
subsets as a percentage of the total GFP+ cells (Plasma cells) or GFP+ B cells (GC and
Memory/Naïve B cells) is shown for the left and right sides separately. Of note, a
statistically significant difference is seen between the groups in the left f.p. when using a
non-parametric test. (C-E) Groups shown are based upon what they were immunized with
for the primary immunization. (C) At the same time, bone marrow was harvested for
ELISpot quantification of NP-specific IgM or IgG producing plasma cells (the Ag used to
coat plates was based on the primary immunogen). (D) Memory/naïve phenotype GFP+ B
cells were analyzed for expression of CD80 and PD-L2. Of note, no statistically
significant differences between groups are seen when using a non-parametric test. (E)
The ratio of IgG1 over IgM expressing B cells amongst GFP+ memory/naïve B cells is
shown. Data shown is based on one experiment. Each data point represents an individual
mouse. *p<0.05, **p<0.01, ***p<0.001. A Student’s T-test was used for single
comparisons.
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3.3

Discussion
Here, I manipulated Ag model systems as a novel approach to investigate how the

immune system controls B cell fate choice and differentiation to produce different GC
outcomes tailored to the specific Ag in an autoimmune setting. The response to NPOVA
and other NP-haptenated proteins is well characterized (126, 291), and in many ways is
considered to represent the default response to a foreign-Ag. Myself and others have
shown that the anti-NP GC consistently forms 4-5d after exposure to Ag, peaks ~2 wks
post exposure, and remains active for several weeks after that (78, 135). I show here that,
while the GC response to MOG develops with similar kinetics, it is not sustained and
instead dissipates early. This should not be interpreted as a failed GC response, however,
as it still produces measurable levels of circulating, class switched anti-MOG antibody.
Further, subcutaneous immunization with MOG protein is a well-established method to
induce the anti-myelin autoimmune model EAE. In my hands, mice immunized with
mMOGtag develop a robust disease with evidence that GC-derived anti-MOG B cells
contribute to both disease severity and chronic disease course (240, 283). Therefore,
although short-lived, the MOG GC is productive.
The GC response is sustained by interactions between GC B cells and TFH cells,
predominantly in the LZ of the GC. The outcome of these interactions can select B cells
to maintain their GC status and cycle back into the DZ for additional rounds of cell
division, mutation, and return to the LZ for selection (58). Alternatively, GC B cells can
be driven to memory or plasma cells fates (292). The first major finding of this study is
that, in the MOG GC response, early failure of the GC is associated with preferential
differentiation to a memory phenotype at the expense of maintaining the GC. Indeed,
within the small GC B cell population in the collapsing MOG response there is a clear
bias to a LZ phenotype, suggesting that B cells are not being selected to return to the DZ
for proliferation. A similar bias to memory cell differentiation is seen for B cells
defective in CXCR4, which is required for proper DZ B cell homing (108). By histology,
this manifests as a small, less-organized GC with a large number of individual GFP+ cells
distributed throughout the follicle. In the GC response to a foreign-Ag, memory B cell
differentiation has been shown to occur predominantly in the early stages, shortly after
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GC formation, with plasma cell differentiation preferentially occurring later in the
response (126). Therefore, it is possible that the early dissolution of the MOG GC to
generate memory B cells represents an extreme acceleration of this same process.
It is clear from my observations that the status of the cognate T cell partner
strongly influences the dichotomy between GC maintenance and memory B cell
differentiation, along with immunoglobulin class-switching. Indeed, MOG-reactive T
cells induced a similar GC outcome when paired with NP-specific B cells and enhanced
T cell activation via high-affinity Ag partly rescued the MOG GC from collapse and
reduced memory B cell differentiation. In this case, immunoglobulin class-switching was
not impacted, suggesting that there is a gradient to the GC parameters that are influenced
by T cell status. Interestingly, while BCR affinity has previously been linked to plasma
cell differentiation (128, 248) (see below), this is the first report that I am aware of that
demonstrates that TCR affinity for Ag can impact B cell fate choice.
It is not clear what signals the cognate T cell partners use to drive differential GC
maintenance vs memory B cell differentiation in the two model systems. Previously
identified T cell signals that influence GC formation and memory differentiation include
ICOS and PD-1 (218, 223). TFH-produced cytokines, IL-21, IL4, and IL-10 have also
been shown to be required for proper GC development (175, 177, 233). Nevertheless, I
did not find evidence that these are differentially expressed by TFH cells in the NPOVA
and MOG systems. Therefore, the immune system may employ other signals to modulate
GC outcome in response to different Ags. The size of the TFH cell pool itself may be one
of these “signals”, as we consistently observed a direct correlation between the number of
TFH and GC B cells in our different model systems. An attempt to modulate this by
increasing the total T cell response was not successful, suggesting that other factors limit
the size of the TFH cell niche in an Ag-dependent way. Indeed, maintenance of the PD-1hi
phenotype on TFH cells is dependent on their ongoing cognate interactions with B cells
(78, 293). Therefore, it is difficult to separate cause and effect with regards to the GC B
cell:TFH cell ratio.
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While the balance between GC maintenance and memory B cell differentiation,
along with immunoglobulin class-switching, were heavily influenced by the status of the
cognate T cell partner, plasma cell differentiation and memory B cell unresponsiveness
were not. Plasma cell differentiation has been linked to BCR affinity (128, 248). Further,
plasma cells preferentially differentiate later in the GC response compared to memory
cells (126). It is possible that the MOG GC doesn’t last long enough to produce BCRs
with sufficiently high-affinity to promote plasma cell differentiation. The accumulation
of somatic mutations in anti-MOG B cells and BCR affinity for Ag will need to be
explored in future studies. However, this would not explain the almost complete absence
of early, short lived plasmablasts that typically derive from pre-GC interactions. The
starting affinity for Ag in the Ig-heavy chain knockin (IgHMOG) B cells is clearly
sufficient to allow for B cell activation to proliferate and initiate the GC. Additional
investigation will be required to determine if (potentially) low BCR affinity accounts for
reduced plasma cell formation, or if the few (but productive) plasma cells that do form in
the MOG GC response represent clones that attained a threshold affinity that allowed for
their differentiation.
Finally, it is clear from our studies that, despite the preference for differentiation
to memory phenotype B cells in the MOG system, this differentiation may not be
complete as the cells are not long-lived, resulting in a failure to respond to secondarychallenge. Our Ag-binding studies demonstrate that the primary GC response is indeed
driven by specific Ag, as virtually all GC B cells bind mMOGtag. Among naïve/memory
phenotype cells, the proportion that bound specific Ag was lower in the MOG compared
to NPOVA systems, which may be in part explained by the properties of the IgHMOG
mouse. The heavy chain knock-in for the IgHMOG mouse combines with endogenous light
chains resulting in ~30% of cells being specific for MOG, while the B1.8 heavy chain
paired exclusively with the lambda light chain in a kappa chain-deficient mice results in
~90% of cells binding NP (294). Nevertheless, the large majority of proliferated memoryphenotype B cells bound to MOG Ag at the d10 time point, confirming that they derived
from the Ag-response. However, over time there was a selective loss of these MOGbinding cells. Intriguingly, capacity to bind MOG Ag also appeared to be lost among the
rare remnants of the MOG GC at later time points (compare Figure 3.3B to 3.7H) and
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therefore, there may be an active selection against MOG-binding not observed in the
NPOVA system. Further study will be required to determine if this is the case.
In conclusion, I showed here that different Ags can drive GC responses with very
different outcomes. Further, I identify GC maintenance vs memory B cell differentiation
as a fate decision dichotomy that is regulated independently from plasma cell
differentiation, and that the status of the cognate T cell partner heavily influences the
former, but not the latter. Finally, I show that, despite a preference for memory B cell
formation in the MOG system, differentiation may not be complete as the Ag-specific
cells are not long-lived. My findings have implications both for our fundamental
understanding of how B cell fate choice is regulated in the GC response, and for our
understanding of how autoimmune B cells participate in autoimmune responses, and antimyelin responses in particular.

3.4

Materials and Methods

3.4.1 Mice
C57Bl/6, 2D2 TCR-transgenic (264), SMARTA TCR-transgenic (4694;
Tg(TcrLCMV)327Sdz/JDvsJ), and OTII TCR-transgenic mice (4194;
Tg(TcraTcrb)425Cbn/J) were purchased from Jackson Laboratories, Bar Harbor, Maine.
B1-8 mice (285) with a homozygous deletion of the Jκ locus (284) were a generous gift
from Dr. Ann Haberman. IgHMOG MOG-specific BCR knock-in mice (256) were
received as a gift from Dr. H Wekerle. Mice expressing fluorescent proteins within all
nucleated cells, either dsRed (RFP; 6051; Tg(CAG-DsRedpMST)1Nagy/J) under control
of the β-Actin promoter or eGFP via the ubiquitin promoter (4353;
Tg(UBCGFP)30Scha/J) were obtained from the Jackson Laboratory. Mice were housed
in a specific pathogen-free barrier at West Valley Barrier. All animal protocols (2011047) were approved by the Western University Animal Use Subcommittee.
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3.4.2 Antibodies for histology/flow cytometry
The following antibodies were purchased from BD Biosciences, Franklin Lakes,
New Jersey: anti-Bcl6 A647 or v450 (K112-91), anti-CD138 BV421 or biotin (281-2),
anti-CXCR5 APC (2G8), anti-CD19 BV711 (1D3), anti-CD4 v450 (RM4-5), anti-CD62L
A700 (Mel14), anti-CD95 PE-Cy7 (Jo2), anti-IgG1 APC (A85-1), anti-B220 PE-Cy7
(RA3-6B2), Streptavidin v450 or APC-Cy7, and anti-CD80 PE (16-10A1). The following
antibodies were purchased from Thermo Fisher Scientific, Waltham, Massachusetts: antiBrdU A647 (MoBU-1), anti-IgM A568 (polyclonal), anti-CXCR4 PE (2B11),
Streptavidin A568, anti-Ki67 unconjugated. The following antibodies were purchased
from eBioscience, Waltham, Massachusetts: anti-PD-1 biotin (RMP1-30), anti-CD38 PE
or PE-Cy5 (90), anti-CD4 PE-Cy5 (RM4-5), anti-FoxP3 eF660 (FJK-16s), anti-IgD
eF450 (11-26c), anti-IgG1 PerCP-eF710 (M1-14D12), Streptavidin APC, anti-ICOS
biotin (C398.4A), and anti-PD-L2 biotin (TY25). The following antibodies were
purchased from BioLegend, San Diego, California: anti-His Tag purified (J099B12), antiPD-1 PE-Cy7 (RMP1-30), anti-rabbit IgG Dylight 649 (polyclonal), anti-IL10 A647
(JES5-16E3), anti-CD4 A647 (RM4-5), and anti-CD4 A700 (RM4-5).

3.4.3 MOG production and purification
mMOGtag and haMOGtag proteins were produced and purified as described in
Chapter 2. The final equimolar concentrations were 5 mg/mL for mMOGtag and 5.394
mg/mL for haMOGtag with no detectable impurities as determined by SDS-PAGE.

3.4.4 Adoptive transfer of B and T cells and immunization
Naïve Ag-specific T cells were isolated from RFP+ 2D2 and OTII mice and naïve
Ag-specific B cells were isolated from GFP+ IgHMOG and B1-8 Jκ-/- mice as previously
described (78). Briefly, LNs and spleens of RFP+ Ag-specific T cell and GFP+ Agspecific B cell mice were dissociated and B and T cells were isolated using EasySep
Negative selection Mouse B and T cell Enrichment Kits (StemCell Technologies,
Vancouver, Canada). Unless otherwise stated, 5 × 105 RFP+ T cells and either 1 x106
GFP+ B1-8 Jκ-/- or 5 × 106 GFP+ IgHMOG B cells (to account for the fact that only 20% are
MOG-specific (240)) were transferred i.v into C57Bl/6 or SMARTA recipients 2d prior
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to immunization. In experiments using CellTrace Yellow (ThermoFisher), 5x106 B cells
were labelled according to the manufacturer’s protocol prior to transfer. Mice were
immunized in the footpad with equimolar amounts of the given Ag (125 μg mMOGtag,
175 μg NPOVA, 125 μg NPMOGtag (both at a 1:25 protein:NP ratio), 135 μg haMOGtag)
in CFA (of note, unless otherwise stated mice were not injected with PTX, in the scenario
where PTX is used, 250 ng were injected on days 0 and 2 post-immunization). Unless
otherwise stated, draining popliteal LNs were harvested at the indicated time points for
analysis. In experiments using BrdU, 1.5 mg of BrdU was injected i.p at the specified
time points.

3.4.5 Flow cytometry
Draining popliteal LNs were harvested from mice for flow cytometry analysis as
previously described (240). Briefly, LN cell suspensions were stained with A647
conjugated mMOGtag (conjugated using Alexa Fluor 647 antibody labelling kit,
ThermoFisher) or NP30PE (Biosearch Technologies) then blocked with an anti-Fcγ
receptor, CD16/32 2.4G2 (BD biosciences), in PBS containing 2% FBS before further
incubation with the indicated antibodies. Dead cells were excluded by staining with either
the Fixable Viability Dye eFluor506 (eBioscience), propidium iodide (Thermoscientific),
or 7-AAD (Biolegend). Flow cytometry was performed on a BD Immunocytometry
Systems LSRII cytometer and analyzed with FlowJo software (Tree Star, Ashland,
Oregon). For cytokine staining, 2 x 106 freshly isolated cells were stimulated with cell
activation cocktail with brefeldin A (Biolegend) for 4 hrs at 37°C then stained as listed
above. For intracellular stains of IL-10, FoxP3 or Bcl6, cells were fixed and
permeabilized with Cytofix / Cytoperm solution (BD Bioscience) after cell surface
staining. Fixed cells were then intracellularly stained for IL-10, FoxP3, and Bcl6 at 4°C
overnight. For BrdU staining, cells were fixed in 2% PFA then permeabilized in 0.1%
Tween 20 for two nights at 4°C. The DNA within the fixed cells was degraded using
DNase I (Sigma-Aldrich, St. Louis, Missouri) then stained with anti-BrdU antibody. Cell
sorting was performed using a BD FACS ARIAIII where cells were sorted into 100%
FBS.
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3.4.6 Immunofluorescent histology
Tissues were prepared for histology as previously described (240). Briefly, whole
popliteal LNs were fixed in periodate–lysine–paraformaldehyde (PLP), subsequently
passed through sucrose gradients to protect from freezing artifacts and then frozen in
OCT (TissueTek, Torrance, California) media. Serial cryostat sections (7 μm) were
blocked in PBS containing 1% Bovine Serum Albumin, 0.1% Tween-20 and 10% rat
serum before proceeding with staining. Sections were mounted with ProLong Gold
Antifade Reagent (Invitrogen, Carlsbad, California). Tiled images of whole LN sections
(20×) were imaged using DM5500B fluorescence microscope (Leica, Wetzlar, Germany).

3.4.7 Digital Droplet PCR (ddPCR)
T follicular helper and naïve T cells were sorted by flow and RNA was extracted
from cells using a RNeasy Plus Micro Kit (QIAGEN, Hilden, Germany) and immediately
converted into cDNA using a Superscript VILO cDNA Synthesis Kit (Invitrogen).
ddPCR reactions were set up using ddPCR EvaGreen 2x Supermix (Bio-Rad, Hercules,
California) and the following primers: IL-4 Sense – 5'
AGATGGATGTGCCAAACGTCCTCA 3', IL-4 Antisense – 5'
AATATGCGAAGCACCTTGGAAGCC 3', IL-10 Sense – 5'
GGTTGCCAAGCCTTATCGGA 3', IL-10 Antisense – 5'
ACCTGCTCCACTGCCTTGCT 3', IL-21 Sense – 5'
TGAAAGCCTGTGGAAGTGCAAACC 3', IL-21 Antisense – 5'
AGCAGATTCATCACAGGACACCCA 3', CD40L Sense – 5'
GTGAGGAGATGAGAAGGCAA 3', CD40L Antisense – 5'
CACTGTAGAACGGATGCTGC 3', ICOS Sense – 5' TGACCCACCTCCTTTTCAAG
3', ICOS Antisense – 5' TTAGGGTCATGCACACTGGA 3', PD-1 Sense – 5'
CGTCCCTCAGTCAAGAGGAG 3', PD-1 Antisense – 5'
GTCCCTAGAAGTGCCCAACA 3', CD28 Sense – 5' TGACACTCAGGCTGCTGTTC
3', CD28 Antisense – 5' TTCCTTTGCGAGAAGGTTGT 3', CTLA4 Sense – 5'
GCTTCCTAGATTACCCCTTCTGC 3', CTLA4 Antisense – 5'
CGGGCATGGTTCTGGATCA 3', FoxP3 Sense – 5'
CCCAGGAAAGACAGCAACCTT 3', FoxP3 Antisense – 5'
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TTCTCACAACCAGGCCACTTG 3'. ddPCR reactions were run on a QX200 Droplet
Digital PCR System (Bio-Rad) and analyzed using Quantasoft software (Bio-Rad). Gene
expression was normalized to the number of sorted cells and expressed as mRNA copies
per cell.

3.4.8 ELISpots and ELISA
96-well plates were coated overnight at 4°C with 0.5 μg NPOVA, NPMOGtag, or
mMOGtag. Wells were blocked with 1% (wt/vol) BSA in PBS, then incubated with serial
diluted bone marrow or lymph node cells at 37°C in 5% CO2. Spots were detected using a
goat alkaline phosphatase-conjugated anti-mouse IgM or IgG antibody (MABTECH,
Nacka Strand, Sweden) and 5-bromo-4-chloro-3-indolyl-phosphate substrate (SigmaAldrich) and counted under a Leica M80 dissection microscope. To detect circulating
antibodies using an ELISA, 96-well plates were incubated with Ag and blocked with
BSA as written above. Blood was extracted from mice using a cardiac puncture and spun
at 4500 x g for 15 minutes. Serum plasma was extracted and incubated with the 96-well
plate for one hour at room temperature. Plates were incubated with anti-IgM or IgG
antibodies and then the alkaline phosphatase yellow (pNPP; Sigma-Aldrich) substrate.
OD405 was measured using an Eon microplate spectrophotometer (BioTek, Winooski,
Vermont).

3.4.9 Image and statistical analyses
Histology images were analyzed using ImageJ software to quantify the density of
B and T cells in germinal centers (Bcl6+ IgD-) and B cell follicles (IgD+ cells excluding
five cells deep worth of the outermost perimeter of the B cell follicle near the capsule).
PRISM software (GraphPad Software, La Jolla, California) was used to analyze flow
cytometry and histology data. For statistical comparisons, a Student’s T-test was used for
single comparisons and a one-way ANOVA followed by a T test with Bonferroni
correction was used for multiple comparisons. Additionally, data sets were also analyzed
using non-parametric a Mann-Whitney test for single comparisons and a Kruskal-Wallis
test with a Dunn’s correction for multiple comparisons. Unless otherwise stated, the
results were the same with each test. Outliers were identified using ROUT method.
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Chapter 4

4

Reporters for in vivo and in vitro monitoring of NFκB and
NFAT signaling
The development of a high-affinity class-switched B cell response is absolutely

dependent on cognate interactions between B and T cells. Signals are exchanged between
B and T cells during these interactions that inform B cell fate choices however, the
precise timing of signal exchange has never been established. This is important as
cognate interactions can differ substantially in duration over the course of the immune
response and between individual B-T pairings making it difficult to establish how long
and short B-T interactions may uniquely contribute to the immune response. Studying the
relationship between intracellular signaling and interaction duration is complicated by the
lack of tools available for visualizing intracellular signaling in individual cells in living
tissue. To address this issue, I sought to generate reporters that were capable of
visualizing signaling by monitoring the activity of two key transcription factors: p65
(NFκB) and NFAT1. These proteins integrate signaling through multiple different
receptors involved with B and T cell activation. To monitor p65 and NFAT1 activity, two
fluorescent reporters were constructed using a histone 2 B-GFP fusion protein, which will
label the nuclei of cells, coupled to the expression of the mCherry fluorescent protein
linked to the N-terminus of the p65 or NFAT1 proteins. In vitro stimulation of
macrophage cell lines transfected with these reporters revealed that mCherry labelled p65
or NFAT1 were excluded from the nucleus in the steady state but could be induced to
translocate into the nucleus when stimulated. Using the CRISPR/Cas9 genomic editing
system, these reporters were adapted for insertion of the mCherry labelled p65 or NFAT1
constructs into the NFAT1 or p65 loci to allow expression from their endogenous loci.
Although I was not successful in editing the p65 locus, initial experiments editing the
NFAT1 locus in vitro were successful. However, this was not successfully translated into
making reporter mice carrying the reporter. I am now adapting the reporter to be inserted
into the Rosa26 locus and single cell zygote injections will be used to generate a reporter
mouse controlled by Cre recombinase expression.
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4.1

Introduction
Communication between immune cells is essential in shaping an immune

response and can determine if a pathogen infection persists or if it is successfully cleared.
A critical component of immunity is the B cell response that is coordinated by
communication between B and T cells specific for the same Ag through direct physical
interactions that occur at the pre-GC phase and throughout the GC response (78, 206).
Interactions between B and T cells are coordinated through cytokines and the engagement
of multiple cell surface receptors that initiate intracellular signaling (295). The induction
of cellular signaling is responsible for informing cells to become activated, differentiate,
or undergo cell death and, thus, determines the output of the immune response. As a
result, B and T cell interactions are essential for the duration of a GC response. Yet, the
duration of interactions formed between B and T cells varies considerably over the course
of the immune response, where pre-GC interactions are longer than those that occur in
the GC, and between individual B-T pairings at each time point (78, 106). Indeed, in our
lab we have seen at the pre-GC phase, B-T interactions occurring in MOG immunized
mice are significantly shorter than those that occur in NPOVA immunized mice (Parham
KA et al. in progress). Thus, B-T cell interaction length may contribute to the different
fate choices seen in these two systems. However, it is difficult to address this hypothesis
because we still do not understand the basics of how signaling kinetics and interaction
kinetics are related to one another. Additionally, as GC B-T interactions are shorter than
pre-GC interactions, it is not clear whether the kinetics of signal exchange change over
the course of the response.
Traditional methods of monitoring intracellular signaling, such as western blots,
rely on pooling millions of cells and analyzing in bulk and are therefore inappropriate for
analyzing individual events amongst a variable pool of cells. Furthermore, fate decisions
are made at the single cell level and thus can only be studied by analyzing individual cells
(296). Direct imaging of cells during their interactions using two-photon intravital
microscopy solves this problem, however this technology requires fluorescent reporters
(297). This is problematic as most fluorescent activation reporters currently rely on de
novo expression of a fluorescent protein driven by a promoter which requires time to
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transcribe, translate, and fold the fluorescent protein (298, 299). This results in a delay
between the time of signal initiation and the time of visible reporter activity making it
impossible to determine the kinetics of activation using transcription-based reporters
(298, 299). Commercially available fluorescent Ca2+ signaling reporters, that fluoresce
when binding to intracellular Ca2+ (300), allow real-time visualization of signaling and
could address this issue (301). However, these reporters are not retained in cells over long
periods of time and can be diluted out of cells as they proliferate making their use
impractical in rapidly expanding immune responses (302). Ideally, an activation reporter
should continuously provide instantaneous information about cellular signaling.
Designing a reporter that provides real-time signaling information is possible by
taking advantage of how immune signaling becomes integrated: through the activation of
transcription factors. Signaling cascades initiated at the cell membrane rely on a wide
variety of adaptor proteins and signaling enzymes to initiate intracellular signaling. These
signaling pathways tend to converge on a much more limited number of common
transcription factors. In this way, the signals from various surface receptors can be
integrated to refine the signal that is transmitted to the nucleus to alter the expression of
specific genes. Nuclear factor of activated T cells and NFκB are two key transcription
factors that are downstream of receptors involved in both B and T cell activation (195,
303). Both are maintained in the cytosol and upon activation translocate into the nucleus
where they can initiate gene transcription (196, 304). Thus, by monitoring the cellular
location of NFκB and NFAT, we can obtain real-time evidence of ongoing signaling that
is relevant to cellular immune activation.
The NFAT family consists of 5 related proteins where NFAT1, NFAT2, and
NFAT4 are expressed in B and T cells (305). Of these, NFAT1 and NFAT2 have
considerable overlap in function where deletion of either gene alone leads to subtle
changes in B and T cell responses (306-308) and double deletion leads to accelerated
differentiation of B cells and the inability of T cells to function (309). As both of NFAT
proteins are expressed in and affect B and T cells across an immune response, either
could act as a potential reporter of B and T cell activation. Of these two proteins, I
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focused on NFAT1 as fusion proteins using NFAT1 have been described previously
(310).
The NFκB family includes 5 proteins: p65, Rel-B, c-Rel, p105/p50, and p100/52
that form homo- or heterodimers in order to be transcriptionally active (304). Only the
p65, RelB, and c-Rel proteins have C-terminal transactivation domains that promote
transcription whereas the p50 and p52 proteins do not directly promote transcription but
rather competitively inhibit NFκB binding sites and are not associated cellular activation
(304). Amongst the NFκB proteins that have transactivation potential and could act as
reporters for activation, the Rel-B gene is only expressed transiently in B cells during the
GC response and thus would not act as good reporter of B cell activity (311). In contrast,
c-Rel and p65 are both expressed in mature B cells and the GC (312). Thus, either could
act as a reporter of activation. However, fusion proteins of p65 have already been
described making p65 a more appealing target (313).
Here, I describe the generation of fluorescent reporters based on the NFAT1 and
p65 proteins. This was accomplished by making fusion proteins of the NFAT1 and p65
proteins where the N-terminus of each is fused to the mCherry fluorescent protein. The
fluorescently tagged reporters were then combined with a nuclear marker, Histone 2 BGFP (H2B-GFP), for accurate quantification of nuclear versus cytoplasmic localization.
These reporters proved to be functional and useful for quantifying intracellular signaling.
However, when attempting to generate reporter mice using the CRISPR/Cas9 system by
inserting my reporter constructs into the endogenous p65 or NFAT1 loci, I was unable to
generate any founder mice. Therefore, I have generated a new version of the reporter that
has been adapted for insertion into the Rosa26 locus and will be used to generate an
NFAT1 reporter mouse whose expression of the reporter will be under the control of Cre
recombinase. Overall, this reporter mouse will extend what is currently possible with
intravital two-photon microcopy by allowing us to see signaling in real-time within
immune cells in vivo.
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4.2

Results

4.2.1 Fusion of p65 or NFAT1 to fluorescent proteins generates functional
reporters capable of monitoring their nuclear and cytoplasmic
localization
To construct the p65 and NFAT1 reporters, cDNA sequences for mouse p65 or
NFAT1 were cloned into the pEGFP-N1 vector along with the DNA sequence encoding
the mCherry fluorescent protein. The mCherry gene was inserted upstream of the p65 or
NFAT1 sequences creating N-terminal fusions. To unambiguously determine whether p65
or NFAT1 are in the nucleus, the mCherry fusion proteins were combined with a nuclear
marker, histone 2 B (H2B) fused to the N-terminus of GFP (H2B-GFP). By using a
nuclear marker, the nucleus can be identified with GFP and the ratio of nuclear vs
cytosolic mCherry can be calculated with certainty. As only 1 protein can be expressed
from a single mRNA transcript, and the H2B-GFP and mCherry fusion proteins must be
expressed as separate proteins, a T2A site was incorporated between into the fusion
proteins allowing both proteins to be expressed separately from a single mRNA transcript
at a 1:1 ratio (314). Altogether, the reporters were constructed such that the H2B-GFP
gene was followed by a T2A site allowing for expression of a second mCherry-p65
fusion protein (H2B-GFP-T2A-mCh-p65) or a mCherry-NFAT1 fusion protein (H2BGFP-T2A-mCh-NFAT1) as shown in Figure 4.1A.
To determine whether the T2A site separates the two fusion proteins into
functional reporters, RAW267.4 macrophages were transfected with either the H2B-GFPT2A-mCh-p65 or the H2B-GFP-T2A-mCh-NFAT1 vectors. Cells were stimulated with
lipopolysaccharide (LPS) (known to induce p65 signaling (315)) or phorbol 12-myristate
13-acetate (PMA) + ionomycin (known to induce NFAT signaling (316)), respectively.
Cells were then fixed at 0, 10, 20, 40, or 60 min time intervals and imaged by fluorescent
microscopy. For both the p65 and NFAT1 reporters, the T2A site effectively split the
H2B-GFP fusion protein from the mCherry fusion proteins as seen by the separation of
green and red fluorescence in unstimulated cells (Figure 4.1C and 4.1E). In addition to
the H2B-GFP protein properly localizing to the nucleus, the H2B-GFP protein was seen
to effectively monitor proliferation through the visualization of chromosomes condensing
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during mitosis, a feature and advantage of H2B-GFP over other nuclear markers (317)
further confirming that this protein was functional (Figure 4.1B). The p65 and NFAT1
fusion proteins were also seen to be functional as the stimulation of RAW267.4
macrophages resulted in p65 and NFAT1 translocating from the cytoplasm to nucleus as
seen by GFP and mCherry co-localization (Figure 4.1C and 4.1E) and a shift in the ratio
of mCherry in the cytoplasm to mCherry in the nucleus (Figure 4.1D and 4.1F). Together,
these results confirm that the p65 and NFAT1 reporters are functional and capable of
providing quantitative information on cytoplasmic to nuclear translocations.
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Figure 4.1. Reporters capable of monitoring the cytoplasmic and nuclear localization of
the p65 and NFAT1 proteins.
(A) Schematics of the H2B-GFP-T2A-mCh-p65 or NFAT1 constructs that were inserted
into the pEGFP-N1 vector using the indicated restriction sites. (B-F) RAW macrophage
were transfected with H2B-GFP-T2A-mCherry-p65 then stimulated with 1 µg/ml LPS
(B-D) or transfected with H2B-GFP-T2A-mCherry-NFAT1 then stimulated with 1 µg/ml
ionomycin and 0.25 µg/ml PMA (E and F) for the indicated periods of time. Cells were
then fixed and imaged in bright field, GFP, and mCherry channels. (B) Shown are two
images of RAW macrophage undergoing proliferation as seen by the condensation of
chromosomes visualized by H2B-GFP. (C and E) Representative images of unstimulated
and stimulated RAW macrophage are shown. (D and F) Quantification of average
mCherry MFI in the nucleus (defined by GFP fluorescence) over the average mCherry
MFI in the cytoplasm where each data point represents a single cell. Data shown is
representative of three individual experiments. For panel D: n=31 for time 0, n=38 for
time 10, n=30 for time 20, n=22 for time 40, n=28 for time 60. For panel F: n=71 for time
0, n=66 for time 10, n=97 for time 20, n=55 for time 40, n=57 for time 60. **p<0.01,
****p<0.0001. A one-way ANOVA comparing time 0 to the other time points was used
for multiple comparisons.
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4.2.2 Using the CRISPR/Cas9 system to generate a reporter knock-in at the
p65 locus in vitro
The purpose for constructing these reporters is to visually monitor signaling
within primary B and T cells during immune responses. However, the forms described
above are based upon overexpression of the p65 and NFAT1 proteins. This is problematic
as the overexpression of p65 protein is known to affect the biology of cells (318, 319). To
avoid problems associated with overexpression, the p65 reporter was adapted to insert the
H2B-GFP-T2A-mCh construct into the genome of mouse cells ahead of the p65 gene in
the p65 locus to be expressed off of the endogenous promoter. To insert DNA into the
genome in a site directed fashion, arms of homology that consist of DNA segments that
are homologous to the DNA in either direction of the insertion site direct the homologous
recombination pathway to insert the DNA contained between the arms of homology into
the genome (320). Based on this, a DNA donor vector containing two ~1 kbp arms of
homology corresponding to the DNA sequence of the p65 locus upstream and
downstream of the ATG start codon was constructed. In between the two arms of
homology, the H2B-GFP-T2A-mCh reporter was inserted upstream of the p65 gene
resulting in a fusion of the fluorescent reporters to the N-terminus of the p65 protein
(Figure 4.2A).
As DNA donor vectors do not incorporate into DNA in a site directed fashion
unless the homologous recombination DNA repair pathway is induced, the CRISPR/Cas9
system was used to create targeted DNA damage at the p65 locus to enhance
incorporation efficiency. The Cas9 enzyme is a RNA guided DNA endonuclease that can
be used to induce double stranded DNA breaks at any site in the genome that has been
targeted by a RNA guide (321). As homologous recombination is one of the pathways
used to repair double stranded DNA damage (322), the CRISPR/Cas9 system can be used
to promote recombination of a DNA donor vector into the genome. To target the p65
locus using the CRISPR/Cas9 system, a guide RNA was designed based on available
tools (323) (Figure 4.2B) and incorporated into the pX330 vector that expresses the Cas9
enzyme as well as the associated guide RNA.
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To test the efficacy of the CRISPR/Cas9 system to facilitate incorporation of the
p65 DNA donor vector into the genome of cells, J774 macrophages were transfected with
the p65 DNA donor vector along with its associated pX330 vector. Two days posttransfection, cells were either fixed for fluorescent microscopy or their genomic DNA
was isolated for genotyping. Insertion of the p65 reporter in the p65 locus was not
detected in wild type J774 macrophage however, insertion of the reporter was detected in
transfected cells although this was not consistent across repeat experiments (no band was
observed in 2 of 4 experiments) (Figure 4.2C).
By microscopy, a small proportion of observed cells were fluorescent, indication
that they had incorporated the p65 donor vector (Figure 4.2D). Due to the low
incorporation rate, further characterization of the functionality of the p65 reporter was not
possible. Although not shown here, several guide RNAs were tested. However, none of
these guide RNAs proved to be efficient in facilitating insertion into the p65 locus. Thus,
although the p65 reporter can insert into the p65 locus, it does not occur efficiently.
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Figure 4.2. CRISPR/Cas9-mediated editing of the p65 locus.
(A) Targeting strategy for inserting the H2B-GFP-T2A-mCherry construct into exon 1 of
the p65 locus. Shown is the DNA donor vector consisting of two ~1 kbp arms of
homology, corresponding to the sequence around the ATG start codon in the p65 locus,
surrounding the H2B-GFP-T2A-mCherry DNA construct. Upon recombination with the
p65 locus, transcription begins at a new start codon at the start of the H2B gene and
continues through to the p65 gene. (B) Diagram showing the CRISPR/Cas9 cut site. The
guide RNA is shown in orange including the nucleotide sequence used to target the p65
locus, the location of the double stranded break is shown in red, the site of translation
initiation is shown in yellow, and in black is the protospacer associated motif that is
required CRISPR mediated cutting (324). (C and D) J774 macrophage were transfected
with the p65 DNA donor vector and a pX330 vector containing the Cas9 gene and
sequence encoding the guide RNA specific for the p65 locus. Two days post-transfection,
DNA was isolated to detect incorporation of the p65 vector into the p65 locus by PCR
(C), or cells were fixed and imaged in the GFP and mCherry channels (D). (C) To detect
site-specific incorporation into the p65 locus two primers were used, one specific for the
p65 locus and the other specific for the mCherry gene. The negative control is pure p65
donor vector DNA, the positive control is pure p65 donor vector DNA with ~2 kbp arms
of homology, WT is untransfected J774 macrophage, and p65 is J774 macrophage
transfected with the p65 donor vector and pX330 vector (Representative of 2 of 4
experiments).
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4.2.3 The CRISPR/Cas9 system can be used to generate a reporter knock-in
at the NFAT1 locus in vitro
Similar to the approach described above, the NFAT1 reporter was adapted for
incorporation into the NFAT1 locus such that ~1 kbp arms of homology derived from the
sequence surrounding the ATG start codon in the NFAT1 locus were cloned around the
H2B-GFP-T2A-mCh reporter (Figure 4.3A). Additionally, a guide RNA was designed to
target the NFAT1 locus to facilitate homologous recombination and was cloned into the
pX330 vector (Figure 4.3B).
To test whether the CRISPR/Cas9 system can facilitate insertion of the NFAT1
reporter into the NFAT1 locus, J774 macrophages were transfected with NFAT1 DNA
donor vector and associated pX330 vector and cultured for two days. After two days, the
cells were processed for genotyping or fixed for microscopy. Incorporation of the DNA
donor vector into transfected cells was observed by genotyping as a 2 kbp band was
present in transfected J774 macrophage but not wild type controls (Figure 4.3C).
Additionally, by microscopy many cells were observed to be fluorescent and this was
above background levels of incorporation in cells transfected with donor alone (data not
shown).
To determine whether the reporter remains functional when expressed from the
endogenous NFAT1 promoter, J774 macrophages were transfected as indicated above.
Two days post-transfection, the cells were imaged over time in a live cell fluorescent
microscope after the addition of PMA and ionomycin. At time 0, NFAT1 reporter cells
had the proper distribution of H2B-GFP in the nucleus and mCh-NFAT1 in the
cytoplasm (Figure 4.3D). Over time mCh-NFAT1 began to accumulate in the nucleus
resulting in a shift of mCherry fluorescence in the cytoplasm to the nucleus confirming
that the knock-in at the endogenous locus was still responsive (Figure 4.3D and 4.3E). Of
note, nuclear accumulation did not occur unless the cells were stimulated with ionomycin
as unstimulated or LPS stimulation did not result in nuclear accumulation of NFAT1
(Figure 4.3F, bottom) using a protocol that induced robust p65 translocation (Figure 4.3F,
top).
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Figure 4.3. CRISPR/Cas9 mediated editing of the NFAT1 locus
(A) Targeting strategy for inserting the H2B-GFP-T2A-mCherry construct into exon 1 of
the NFAT1 locus. Shown is the DNA donor vector consisting of two ~1 kbp arms of
homology, corresponding to the sequence around the ATG start codon in the NFAT1
locus, surrounds the H2B-GFP-T2A-mCherry DNA construct. Upon recombination with
NFAT1 locus, transcription begins at a new start codon at the start of the H2B gene and
continues through to the NFAT1 gene. (B) Diagram showing the CRISPR/Cas9 cut site.
The guide RNA shown in orange is used to target the NFAT1 locus, the location of the
double stranded break is shown in red, the site of translation initiation is shown in yellow,
and in black is the protospacer associated motif. (C-E) J774 macrophage were transfected
with the NFAT1 DNA donor vector and a pX330 vector containing the Cas9 gene and
sequence for the guide RNA for the NFAT1 locus. Two days post-transfection, DNA was
isolated to detect incorporation of the NFAT1 vector by PCR (C), or live cells were
imaged in the GFP and mCherry channels (D and E). (C) To detect site-specific
incorporation into the NFAT1 locus two primers were used, one specific for the NFAT1
locus and the other specific for the mCherry gene. The negative control is pure NFAT1
donor vector DNA, the positive control is pure NFAT1 donor vector DNA with ~2 kbp
arms of homology, WT is untransfected J774 macrophage, and NFAT1 is J774
macrophage transfected with the NFAT1 donor vector and pX330 vector (representative
of 3 of 4 experiments). (D and E) Transfected cells were stimulated with 1 µg/ml
ionomycin and 0.25 µg/ml PMA then imaged once every minute for 21 mins. (D) GFP
and mCherry fluorescence is shown at the 10 min time point. (E) Quantification of
average mCherry MFI in the nucleus (defined by GFP fluorescence) over the average
mCherry MFI in the cytoplasm at each time point is shown. Data is from a combination
of two independent experiments. A one-way ANOVA was used to compare values at
each time point to time 0, errors bars are SEM, n=7, *p<0.05. (F) J774 macrophage were
transfected with pEGFP-N1 H2B-GFP-T2A-mCh-p65 (top panel) or NFAT1 DNA donor
vector and a pX330 vector containing the Cas9 gene and sequence for the guide RNA for
the NFAT1 locus (bottom panel). Two days post-transfection, live cells were imaged in
the GFP and mCherry channels after stimulation with 1 µg/ml LPS over the course of an
hour (D and E). Representative cells are shown for two individual experiments.
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4.2.4 Generating knock-in mice using the CRISPR/Cas9 system
Having confirmed that the NFAT1 locus can be modified to generate a functional
reporter, I sought to use the CRISPR/Cas9 system to genetically modify mouse zygotes, a
prerequisite to making a reporter mouse. To determine whether mouse zygotes could be
edited to incorporate the NFAT1 reporter, single C57Bl/6 mouse zygotes were given
nuclear microinjections with guide RNA, DNA donor vector, and Cas9 mRNA and
grown in vitro into blastocysts. Individual blastocysts were then processed for
genotyping.
The PCR protocol was first validated to be capable of detecting small amounts of
DNA by detecting the NFAT1 locus in wild type blastocysts and confirmed not to
produce false positives when using primers specific for the NFAT1 reporter (Figure
4.4A). Then, 65 viable blastocysts were genotyped as an initial measure of incorporation
frequency. Unfortunately, there was no evidence of incorporation of the reporter in any of
the blastocysts, suggesting that this approach to insert a large segment of DNA is not
reliable enough to proceed with generating mice (Figure 4.4B). Indeed, in a second
attempt where live blastocysts were implanted to produce pups, no positive mice were
identified by genotyping (data not shown).
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Figure 4.4. Insertion of the NFAT1 reporter into C57Bl/6 blastocysts.
(A) A protocol for detecting DNA from blastocysts was tested on 10 wild type C57Bl/6
blastocysts using a nested PCR approach. Primers specific for either the NFAT1 locus
(left) or specific for a site specific incorporation of our reporter (right) were used. (B)
Incorporation of the NFAT1 reporter into blastocysts injected with the NFAT1 CRISPR
components was assessed using PCR (38 of 65 shown).
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4.2.5 An overexpression-based NFAT1 reporter
As inserting the NFAT1 reporter into the endogenous locus was not viable, I
attempted an alternative approach where a transcriptionally inactive reporter, thus unable
to affect the biology of the cell, would be overexpressed in cells. This was accomplished
by taking advantage of the structure of the NFAT1 protein. The NFAT1 protein has an Nterminal transactivation domain followed by a regulatory domain that contains the
nuclear localization sequence as well as phosphorylation sites that regulate the
availability of the nuclear localization sequence (325). Following this is the Relhomology domain that is responsible for DNA binding and the final domain is the C
terminal domain. Of key significance, the regulatory domain of NFAT1 is entirely
separate from its DNA binding domain. Thus, it is possible to express the regulatory
domain of NFAT1, which is responsible for dictating NFAT1 import and export from the
nucleus, without its DNA binding domain that would be required for this protein to act as
a transcription factor.
To construct this reporter, amino acids 1-399 from NFAT1, corresponding to the
N-terminal transactivation domain and regulatory domains, were used in place of the full
length NFAT1 protein. The NFAT11-399 gene was then combined with mCherry, the H2BGFP gene, and T2A site in a pEGFP-N1 vector (Figure 4.5A). To test whether this form
of the reporter was functional, J774 macrophages were transfected with the NFAT11-399
reporter and then stimulated with PMA and ionomycin for 20 mins prior to fixation for
fluorescent microscopy. Transfected cells that were unstimulated had no evidence of
nuclear accumulation of the NFAT11-399 reporter whereas the reporter accumulated in the
nucleus of stimulated cells confirming the reporter was functional (Figure 4.5B).
To adapt the reporter for insertion into the mouse genome, I took advantage of a
commonly targeted locus known as the Rosa26 locus. This locus constitutively expresses
a non-coding RNA, with no known function, uniformly across the body (326). Genes of
interest can be expressed from this locus by inserting them into the intron between exon 1
and 2 of this locus along with a gene trap (327). A gene trap involves the usage of a
splice acceptor site to ‘steal’ the splice donor site from the previous exon, preventing the
second exon from being spliced into the mRNA transcript, resulting in your gene of
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interest becoming the next exon. To take advantage of this system, the NFAT1-399 reporter
was inserted into the ROSA26TV vector, a plasmid that already contains the splice
acceptor site and arms of homology required for insertion into the Rosa26 locus (Figure
4.5C). Additionally, this plasmid also has a neomycin resistance gene flanked by loxP
sites ahead of the NFAT1 reporter such that expression through the construct will result
in the production of the neomycin resistance protein before production of the NFAT1
reporter. This organization of genes is useful as the expression of the NFAT1 reporter is
inducible in this system through the expression Cre recombinase in cells. When Cre
recombinase is expressed, it will use the LoxP sites to remove the neomycin resistance
gene (328) resulting in the first start codon to then reside at the start of the NFAT1
reporter construct. Thus, this construct not only expresses the NFAT1 reporter, but can do
so in a cell-specific manner depending on Cre recombinase expression.
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Figure 4.5. Construction of an NFAT1 reporter that can be overexpressed.
(A) Schematic of the NFAT11-399-mCherry-T2A-H2B-GFP construct that was inserted
into the pEGFP-N1 vector using the indicated restriction sites. (B) J774 macrophages
were transfected with NFAT11-399-mCherry-T2A-H2B-GFP and then stimulated with
PMA + ionomycin for 20 mins prior to fixation for fluorescent microscopy. Cells were
imaged in the GFP and mCherry channels. Shown are representative images. (C) Shown
is a diagram outlining the targeting strategy for inserting the NFAT11-399-mCherry-T2AH2B-GFP construct into the Rosa26 locus. A donor vector consisting of two arms of
homology, corresponding to the intron sequence in between exon 1 and 2 of the Rosa26
locus, surrounds the DNA construct. The DNA construct contains a splice acceptor (SA)
site, that upon recombination into the locus, interrupts splicing between exon 1 and 2 of
the Rosa26 locus and instead leads to the reporter construct being incorporated into the
mRNA transcript. Ahead of the NFAT1 reporter, a neomycin resistance gene flanked by
LoxP sites is expressed and prevents expression of the NFAT1 reporter. Using Cre-LoxP
mediated recombination, the neomycin gene can be removed allowing expression of the
NFAT1 reporter.
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4.3

Discussion
Our understanding of how intracellular signaling induced through B and T cell

interactions contributes to B cell fate choices is limited by the inability to visualize
signaling as it occurs in vivo. Here, I address this issue by constructing fluorescent
reporters capable of monitoring NFκB and NFAT signaling in vivo, in real-time, and in
individual cells using reporters compatible with intravital imaging. Despite the reporters
being functional, I was unable to generate reporter mice using a knock-in approach to
modify the p65 and NFAT1 loci. Nonetheless, insertion into the Rosa26 locus holds
potential for generating an NFAT1 reporter mouse. This will be accomplished through
either conventional knock-in methods (320) or aided using the CRISPR/Cas9 system
(329).
As the generation of new mouse strains is never guaranteed, additional options
can be explored in the case where a mouse cannot be made. This is easier for the NFAT1
reporter as I have made a form of this reporter that can be overexpressed in cells. Indeed,
the use of a retroviral vector to introduce a transcriptionally inactive NFAT1 reporter into
cells has already been used with success (310, 330). One major limitation to retroviral
vectors however, is that they do not readily transduce quiescent cells such as naïve B and
T cells (310, 330, 331). This problem can be overcome through in vitro activation of cells
and transducing the cells as they begin to proliferate. However, in the context of studying
foreign or autoAg driven GCs, in vitro activation of B and T cells would pose several
problems: First, it is not clear whether in vitro activated cells would behave similarly to
cells activated exclusively in vivo. Second, in vitro activation may allow autoreactive B
and T cells to subvert regulatory pathways that would normally suppress their activation
(332, 333). Lastly, although in vitro activation of T cells is well established (334), in vitro
expansion of B cells is relatively new and is likely to affect the phenotype of the cultured
B cells (335). Thus, to study naive B and T cell responses, a reporter mouse is needed and
may require the use of methods that are less than ideal for generating a transgenic mouse.
Transgenic mice can be generated by injecting zygotes with linear DNA that incorporates
at random into the genome where the linear DNA contains your gene of interest as well
as a promoter to drive its expression (336). This method is quite robust for generating
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founder mice, although, it suffers from several problems: 1st, variable expression of the
transgene; 2nd, loss or gain of function mutations in genes already in the genome as a
result of transgene insertion; and 3rd, insertion of multiple copies of the transgene. The
combination of these problems makes it difficult to be confident that the founder mice
generated are truly correct as these factors could act as confounding factors in
interpreting the data acquired by studies using mice with incorrect transgenes. Thus,
although there are alternative methods available for generating a useable NFAT1
reporter, these methods have significant limitations.
Ideally these studies would be conducted using both the NFAT1 and p65 reporters
as transcription factors do not work alone. Instead, they work in coordination with other
transcription factors influencing their activity (337) and the NFAT1 and p65 proteins are
no exception to this (338-340). For example, NFAT1 induces an anergic transcriptional
program unless it is complemented by other transcription factors (341, 342).
Additionally, as particular transcription factors are preferentially activated by certain
pathways (see Chapter 1.8.2), the usage of multiple reporters of activation would
integrate a greater range of signaling allowing us to more confidently determine whether
signals are being exchanged. I was able to construct a reporter of NFAT1 activity by
taking advantage of the monomeric nature and structure of the NFAT1 protein (325) to
express a transcriptionally inactive reporter. A similar approach is not possible with p65
or the other NFκB proteins as the same domain is responsible for regulating
cytoplasmic:nuclear shuttling and DNA binding making these functions inseparable
(343). Indeed, even if the p65 protein was mutated to abolish its capacity to bind DNA
and act as a transcription factor (344), the transgene would create a dominant negative
mutation. Cytoplasmic and nuclear shuttling of NFκB proteins requires them to form
dimers (304), and given that NFκB proteins form homo- and heterodimers, inactive forms
of p65 would inactivate any other NFκB proteins they dimerized with. Thus, a reporter of
NFκB activity requires modification of the endogenous locus.
The major factor limiting the generation of a p65 reporter mouse was the low
incorporation rate of my p65 donor DNA. In the time since we had completed the
injections, the field of genomic modifications using the CRISPR/Cas9 system has moved
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forward generating several technologies that could have aided my approach. Although I
will not provide an exhaustive list of new methods, the following represent easily
adaptable methods that could be employed in the future. The first is the use of single
stranded DNA donor vectors over double stranded DNA. For some applications, single
stranded DNA donor vectors have been able to achieve high levels of incorporation
relative to double stranded DNA vectors (345). Second, the stability of the guide RNA
can also be limiting (321). The stability of RNAs can be increased by incorporating
chemically modified nucleotides at the ends of the RNA molecules to limit their
degradation and can have substantial effects on incorporation rates (346). Lastly,
inhibition of the non-homologous end joining pathway can promote usage of the
homologous recombination pathway. In this study, I used the SCR7 inhibitor of nonhomologous end joining (347). However, additional small inhibitors of non-homologous
end joining have been identified and could be used to further promote homologous
recombination over non-homologous recombination (348). Thus, there are several
methods that could be used in the future to try to improve incorporation into the p65
locus.
The generation of these reporters is of great interest to us as this will allow us to
answer many basic questions about the GC response. Throughout the GC response B and
T cells form interactions that are essential for GC induction and maintenance (78, 204).
We know that individual interactions can differ substantially in length and this has been
associated with B cells making different fate choices (112, 117, 161). Nonetheless, we
still do not understand at a molecular level what makes a long and short interaction
different. It is for example, unclear whether a short interaction represents a ‘failed’
interaction in which signaling in the B or T cell fails to be induced or is a less potent
version of the longer interaction. Furthermore, although interactions can be quite long at
the pre-GC phase, interactions within the GC are exclusively short. Thus, it is not clear
how signaling in B and T cells has changed between these two time points. Beyond
questions about the basic biology of B and T cell interactions, there are also several
applications of this reporter in our MOG-induced GC model. At the pre-GC phase, it was
observed that B and T cells in MOG-immunized mice form substantially shorter
interactions than those in NPOVA-immunized mice (unpublished observations, Parham
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KA et al.). Currently, it is not clear whether the short interactions in both systems are
equivalent or, perhaps, if the short interactions are unique in each Ag model. Indeed,
using these signaling reporters would give us the first clues for identifying whether the
developing B cell response is controlled through unique signals being exchanged during
interactions to different Ag’s or if perhaps, B cell differentiation is controlled by a
universal code of interaction duration.
In conclusion, the reporters developed here will require additional optimization.
Fortunately, several different avenues are available to address this. By creating
fluorescent mouse strains capable of monitoring the activity of the NFκB and NFAT
proteins, an understanding of the molecular events responsible for directing B cell
differentiation at a cellular level can be defined. This will ultimately give us a more
precise understanding of B cell differentiation that is not currently possible with bulk
analysis of B cells.

4.4

Materials and Methods

4.4.1 Cloning
Primers referenced in Table 4.1 (Integrated DNA Technologies, Carolville, Iowa,
and Sigma, St. Louis, Missouri) were used in PCR reactions using either Pfu polymerase
(Gbiosciences, St. Louis, Missouri) or Phusion polymerase (Thermo Fisher Scientific,
Waltham, Massachusetts). PCR products were run through agarose gel electrophoresis
and bands corresponding to the correct PCR products were purified using either E.Z.N.A.
Gel Extraction Kit (OMEGA Bio-Tek, Norcross, Georgia) or Gel/ PCR DNA Fragments
Extraction Kit (Geneaid, New Taipei City, Taiwan) using manufacturers protocols.
Purified PCRs were digested using combinations of SalI, HindIII, EcoRI, MfeI, NotI,
XmaI, AscI, SacI, XhoI, and BglII (New England Biolabs, Ipswich, Massachusetts) or
BbsI (Thermo Fisher Scientific, Waltham, Massachusetts) then purified using Geneclean
II Kit (MPbiomedicals, Santa Ana, California) according to manufacturers protocol.
Digested products were then ligated into pEGFP-N1 (Clontech, Mountain View,
California), pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene 42230), pCAGGS
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(Belgian Co-Ordinated Collections of Micro-Organisms), or STOP-eGFP-ROSA26TV
vector (Addgene 11739) using T4 DNA ligase (New England Biolabs, Ipswich,
Massachusetts).
The following plasmids were used for PCR templates: pBABE-H2BGFP
(Addgene 26790) was used for amplification of H2B-GFP, RelA cFlag pcDNA3
(Addgene 20012) was used for amplification of the p65 subunit of NFκB, WT NFAT1
(Addgene 11100) was used for amplification of NFAT1, pmCherryN1 (Clontech,
Mountain View, California) was used for amplification of mCherry, RP23-30E22
Bacterial Artificial Chromosome (Invitrogen, Carlsbad, California) containing the p65
locus was used for amplification of arms of homology for the p65 locus, RP23-135N9
Bacterial Artificial Chromosome (Invitrogen, Carlsbad, California) containing the
NFAT1 locus was used for amplification of arms of homology for the NFAT1 locus.
BACs were purified using NucleoBond Xtra BAC (Clontech, Mountain View, California)
as listed in manufacturers protocol.
In brief, the H2B-GFP-T2A-mCh-p65/NFAT1 reporters were constructed by PCR
amplifying H2B-GFP and cutting the PCR transcript with BglII and HindIII. This was
ligated into the pEGFP-N1 vector along with annealed primers corresponding to the T2A
sequence. The mCherry gene was then PCR amplified and cut with SacI and HindIII.
This was cloned into the same pEGFP-N1 vector along with PCR amplified NFAT1 (cut
with HindIII and SalI) or p65 (cut with HindIII and EcoRI).
The p65 donor DNA plasmids were constructed by first modifying the pCAGGs
vector using EcoRI and BglII to incorporate annealed primers encoding a multiple
cloning site. The left arm of homology for the p65 locus was PCR amplified to make a
long version (1938 bp) or a short version (961 bp) and cloned into the pCAGGs vector
using the SalI and MfeI restriction sites. The H2B-GFP-T2A-mCh reporter was PCR
amplified (cut with MfeI and XhoI) and ligated into the same pCAGGs vector. Finally,
the right arm of homology for the p65 locus was amplified to make a long version (1942
bp) or a short version (988 bp) then cut with Xho1 and HindIII before ligation into the
pCAGGs vector. The NFAT1 donor plasmids were similarly constructed by PCR
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amplifying the right arm of homology to make a long version (1999 bp) and a short
version (952 bp) that were cut with NotI and BglII for insertion into the pCAGGs vector.
Then the H2B-GFP-T2A-mCh reporter was PCR amplified and cut with NotI and XhoI
for insertion into the same pCAGGs vector. Lastly, the left arm of homology was PCR
amplified to make a long version (1976 bp) or short version (937 bp) that were cut with
SalI and XhoI before ligation into the pCAGGs vector.
The DNA sequences coding the guide RNAs responsible for targeting the p65 and
NFAT1 locus where generated by annealing DNA primers and ligating them into pX330
vectors cut with BbsI.
Cloning of the NFAT11-399-mCh-T2A-H2B-GFP construct was accomplished by
PCR amplifying NFAT11-399 (cut with SacI and HindIII) and mCherry (cut with HindIII
and AgeI) then ligating them into the pEGFP-N1 vector. Then H2B-GFP (cut with SalI
and NotI) was ligated into the same vector along with two annealed primers forming the
T2A site. This reporter construct was then PCR amplified (cut with AscI and NotI) and
cloned into the STOP-eGFP-ROSA26TV vector along with anneal primers to act as an
adaptor between the XmaI restriction site and the NotI restriction site.
Ligated plasmids were transformed into competent E. coli (DH5α) using standard
techniques (275). Plasmids were collected from these cells using the High-Speed Plasmid
Mini Kit (Geneaid, New Taipei City, Taiwan) according to manufacturers protocol.
Finalized vectors were sent for sequencing (London Regional Genomics Centre, London,
Ontario) and upon confirmation plasmids were purified using Plasmid Maxiprep kit
(Geneaid, New Taipei City, Taiwan).
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Table 4.1. Forward and reverse primers used for cloning
Primer

DNA sequence (5' to 3')

name

Product
size

H2B-GFP 5'-AAA AAA AGA TCT ATG CCA GAG CCA GCG AAG

1137 bp

fwd T-3'
rev 5'-AAA AAA AAG CTT CTT GTA CAG CTC GTC CAT
GCC-3'
T2A fwd 5'-AGC TGG AGG GCA GAG GAA GTC TTC TAA CAT

64 bp

GCG GTG ACG TGG AGG AGA ATC CCG GCC CTG
AGC T-3'
rev 5'-CAG GGC CGG GAT TCT CCT CCA CGT CAC CGC
ATG TTA GAA GAC TTC CTC TGC CCT CC-3'
mCherry 5'-AAA AAA GAG CTC ATG GTG AGC AAG GGC GAG

732 bp

fwd G-3'
rev 5'-TTT TTT AAG CTT CTT GTA CAG CTC GTC CAT
GCC-3'
p65 fwd 5'-AAA AAA AAG CTT ATG GAC GAT CTG TTT CCC

1674 bp

CTC ATC-3'
rev 5'-TTT TTT GAA TTC TTA GGA GCT GAT CTG ACT
CAA AAG AGC AG-3'
NFAT1 fwd 5'-AAA AAA AAG CTT ATG GAC GTC CCG GAG CCG
CAG C-3'
rev 5'-AAA AAA GTC GAC CTA GGT CTG ATT TCG GGA
GGG AG-3'

2808 bp
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p65 guide 5'-CAC CGT CCA TGG TCA GGG TCC CGG-3'

24 bp

RNA fwd
rev 5'-AAA CCC GGG ACC CTG ACC ATG GAC-3'
NFAT1 5'-CAC CGT CCG GGA CGT CCA TGG CTC G-3'

25 bp

guide RNA
fwd
rev 5'-AAA CCG AGC CAT GGA CGT CCC GGA C-3'
multiple 5'-AAT TCC AAT TGC AGG TTC TCG AGT CGT GTG

60 bp

cloning site AGC TCA ACT GAG CGG CCG CAT GTC GA-3'
pCAGGs
fwd
rev 5'-GAT CTC GAC ATG CGG CCG CTC AGT TGA GCT
CAC ACG ACT CGA GAA CCT GCA ATT GG-3'
long left 5'-TTT TTT GTC GAC CTA GCC CCT GCT GGT CCA

1968 bp

arm p65 GAG CTC-3'
fwd
short left 5'-TGC CAC CTG GTC GAC GCC AGA GTC CCC ACA

985 bp

arm p65 CTC AAT CTG CA-3'
fwd
rev 5'-GCT TTT CAA TTG GGT CAG GGT CCC GGG AGC
GGG GCC GGG GT-3'
p65 reporter 5'-AAA AAA CAA TTG ATG CCA GAG CCA GCG AAG
fwd T-3'

1900 bp

141

rev 5'-TTT TTT CTC GAG CTT GTA CAG CTC GTC CAT
GCC GCC GGT GGA G-3'
right arm 5'-GAA CCG CTC GAG ATG GAC GGT GAG GCT GCC
p65 fwd CTC TGG CTC G-3'
long rev 5'-GAA CCC AAG CTT CTT CCC ACT CCT TAC CCA

1966 bp

CTG GCA AGT-3'
short rev 5'-GAT TAC GCC AAG CTT CAA TCC CTA ATC TGG

1012 bp

CTC TTA GAC ACA GGG C-3'
long left 5'-GAA CGC GTC GAC TGT GGG TCA TGA CTG ACC

2000 bp

arm NFAT1 CCT TCG GGT ATG TCA AAA GAC CC-3'
fwd
short left 5'-TGC CAC CTG GTC GAC TCA GGG AGC ACT GCC

961 bp

arm NFAT1 CAT CTC C-3'
fwd
rev 5'-GAA CCG CTC GAG GGC TCG GAG CGT TCG GGA
TGC GGG TTC GTA TAG AG-3'
NFAT1 5'-AAA AAA CTC GAG ATG CCA GAG CCA GCG AAG

1911 bp

reporter fwd T-3'
rev 5'-AAG GAA AAA AGC GGC CGC CCT TGT ACA GCT
CGT CCA TGC CGC CGG TGG AG-3'
right arm 5'-TTT TTT GCG GCC GCA TGG ACG TCC CGG AGC
NFAT1 fwd CGC A-3'
long rev 5'-TTT TTT AGA TCT CAG CAG GAC AGG AGA AGG
GAA TGG CC-3'

2023 bp
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short rev 5'-GAG GGA AAA AGA TCT ATC TGG AAG CTG CCA

976 bp

GCA GGC T-3'
p65 5'-CAT GGA CGA GCT GTA CAA GCT CGA G-3'

1041 bp

genotyping
fwd
rev 5'-CCA AAG TAC AGA GTA CTC TAG TGG CCA G-3'
NFAT1 5'-ATG GAC GTC CCG GAG CCG CA-3'

985 bp

locus
genotyping
fwd
NFAT1 5'-ACG AGC TGT ACA AGG GCG GCC GC-3'

1008 bp

reporter
genotyping
fwd
NFAT1 5'-ACC AGA TGC CCG CAA GCC CGC AG-3'
locus rev
nested fwd 5'-AGA GGT AGA GGG GCG TGT GC-3'

121 bp

rev 5'-AAG TCC CCA ACA ACC GGC TC-3'
NFAT11-399 5'-AAA AAA GAG CTC ATG GAC GTC CCG GAG CCG

1221 bp

fwd CAG C-3'
rev 5'-CAA GGC AAG CTT GAG TGG TGG GAG GGA TGC
AGT C-3'
mCherry 5'-GAA CCG AAG CTT ATG GTG AGC AAG GGC GAG
fwd G-3'

732 bp
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rev 5'-GAA GCC ACC GGT CTT GTA CAG CTC GTC CAT
GCC G-3'
T2A fwd 5'-CCG GAG AGG GCA GAG GAA GTC TTC TAA CAT

60 bp

GCG GTG ACG TGG AGG AGA ATC CCG GCC CT-3'
rev 5'-TCG ACA GGG CCG GGA TTC TCC TCC ACG TCA
CCG CAT GTT AGA AGA CTT CCT CTG CCC TC-3'
H2B-GFP 5'-GAA CGC GTC GAC ATG CCA GAG CCA GCG AAG

1144 bp

fwd TCT G-3'
rev 5'-AAG GAA AAA AGC GGC CGC TTA CTT GTA CAG
CTC GTC CAT GCC GAG AG-3'
reporter 5'-GTC GAA GAG CTC GGC GCG CCA TGG ACG TCC

3117 bp

ROSA26 CGG AGC CGC AGC-3'
fwd
rev 5'-GTA AGC GCG GCC GCA TTA ATT TAC TTG TAC
AGC TCG TCC ATG CCG-3'
ROSA26- 5'-GGC CCA CAC TTG CCT GGT AAG CTG CAC TCT

38 bp

TV adaptor GCT C-3'
fwd
rev 5'-CCG GGA GCA GAG TGC AGC TTA CCA GGC AAG
TGT G-3'
Genotype 5'-GCG AGG GCG ATG CCA CCT ACG GCA-3'
GFP fwd
rev 5'-GGG TGT TCT GCT GGT AGT GGT CGG-3'

450 bp
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4.4.2 Cell culture and transfections
RAW264.7 macrophage or J774 macrophage were cultured in 12-well plates with
1 ml RPMI Medium 1640 with L-glutamine (WISENT, Saint-Bruno, Quebec) and 10%
FBS (WISENT, Saint-Bruno, Quebec) at 37°C, 5% CO2. Cells were plated at 5x105 cells
per well and grown on coverslips overnight until approximately 30-50% confluency at
which point they were transfected with 1 μg of total DNA per well using Fugene HD
(Promega, Madison, Wisconsin) as listed in manufacturer’s protocol (for CRISPR
experiments, cells were transfected at a 3:1 ratio of DNA donor plasmid:pX330 vector).
After 4-5 hours, the media on the transfected cells was replaced by 1 ml of fresh media
and incubated for 1 day for overexpression experiments and 2 days for CRISPR
experiments where the media was supplemented with 0.1 µM SCR7 (Xcessbio, San
Diego, California). For the p65 stimulation experiments, p65 transfected cells were then
stimulated with LPS from S. enterica (Sigma, St. Louis, Missouri) in 10% FBS RPMI
and MEM Non-Essential Amino Acids Solution 100x (Thermo Fisher Scientific,
Waltham, Massachusetts). For NFAT1 stimulation experiments cells were stimulated
with PMA (Tocris Biosciences, Bristol, United Kingdom) and ionomycin (Sigma, St.
Louis, Missouri) in 1 mL serum free RPMI with MEM non-essential amino acids after a
PBS wash.

4.4.3 Fixed and live cell microscopy
Cells were fixed onto coverslips after a PBS wash using a 20 minute incubation in
4% PFA (Electron Microscopy Sciences, Hatfield, Pennsylvania). Fixed cells were then
washed again with PBS and mounted onto glass slides using PermaFluor Mountant
(Thermo Fisher Scientific, Waltham, Massachusetts). These slides were then imaged
using a DM5500B fluorescence microscope (Leica microsystems, Concord, ON, Canada)
with a 40x objective lens in the Bright Field, GFP, and mCherry filters.
For live cell experiments, coverslips with transfected macrophage (described in
4.4.2) were transferred to a Leiden chamber in a Leica DM16000B microscope equipped
with a 37°C heated stage perfused with 5% CO2, a 40x objective, photometrics Evolve512 delta EM-CCD camera, Chroma Sedat Quad filter set, and the Leica Application
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Suite X software platform (Leica microsystems, Concord, ON, Canada). The locations of
2-3 reporter positive cells were tracked using the mark-and-find feature then the Leiden
chamber was opened to add PMA + ionomycin to a final concentration of 0.25 µg/ml
PMA and 1 µg/ml ionomycin in serum free RPMI. Cells were then imaged once every
minute for 22 minutes in the GFP and mCherry channels.

4.4.4 Genotyping of CRISPR transfected cells and mouse pups
Two days post-transfection, J774 macrophage were scraped off the bottom of 12well plates then centrifuged at 1500 rpm for 8 minutes at 4°C. The pellet was then
suspended in permeabilization buffer (50 mM Tris, 50 mM KCl, 2.5 mM EDTA, 0.45%
Igepal, 0.45% Tween-20 (Bioshop, Burlington, Ontario), and 0.15 mg/ml proteinase K
(Biobasic, Markham, Ontario)) and incubated overnight at 55°C then frozen at -20°C
until needed. To set up the genotyping reactions, Phusion polymerase (Thermo Fisher
Scientific, Waltham, Massachusetts) was used with 2% DMSO and either 1 µl of
genomic DNA or 0.5 µg of purified donor DNA plasmids were used as templates. The
cycler conditions used were: 98°C for 3 mins then 45 cycles of (0.5 mins 98°C, 0.5 mins
62°C, and 3 mins 72°C) followed by 10 mins 72°C. Finished PCR reactions were then
loaded onto a 1% agarose gel. For the genotyping of mouse pups, small tail snips were
used instead of transfected cells.

4.4.5 Guide RNA design
Suitable guide RNAs were identified for both the p65 and NFAT1 loci using the
CRISPR design tool provided at (http://crispr.mit.edu/) which is described in (323).
Guide RNAs were selected based on specificity where the p65 guide RNA had a score of
82 and the NFAT1 guide RNA had a score of 94.

4.4.6 Nuclear injections
The protocol for nuclear injections was based on (349). In brief, 4 week old
C57Bl/6 females were injected with pregnant mare serum gonadotrophin (Sigma, St.
Louis, Missouri) and two days later mice were injected with human chorionic
gonadotrophin (Sigma, St. Louis, Missouri) then mated with male C57Bl/6 mice. Single
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embryos were then collected from female mice, washed, then cultured briefly in M2
media (Millipore, Burlington, Massachusetts) at 37°C and 5% CO2. An injection mixture
of 100 ng/µl Cas9 mRNA (TriLink Biotechnologies), 50 ng/µl guide RNA (Integrated
DNA Technologies, Carolville, Iowa), and 200 ng/µl donor DNA was mixed at a 1:3:3
ratio with M2 media supplemented with Cytochalasin B 10 µg/ml (Sigma, St. Louis,
Missouri) and M2 media supplemented with 10% (wt/vol) Polyvinylpyrrolidone 360 kDa
(Sigma, St. Louis, Missouri). Zygotes were then injected with this mixture and cultured
in KOSM media (Millipore, Burlington, Massachusetts) supplemented with 0.1 µM
SCR7 until the two cell stage for transfers into pseudopregnant females to generate whole
mice, or cultured to the blastocyst stage for genotyping.

4.4.7 Blastocyst genotyping
To isolate DNA from blastocysts a DNeasy blood and tissue kit (Qiagen, Hilden,
Germany) was used. To detect blastocysts DNA, an initial set of primers specific for the
NFAT1 locus or specific for a site-specific insertion of the NFAT1 reporter was used in
combination with Q5 high-fidelity polymerase (New England Biolabs, Ipswich,
Massachusetts) according to the manufacturer’s protocol. Then, 1 µl of the PCR was used
to seed a second PCR reaction using two primers that formed a nested PCR within the
first set of primers. Again the PCR reaction was conducted with Q5 high-fidelity
polymerase according to the manufacturer’s protocol. Once complete, the PCRs were run
on a 2% agarose gel.

4.4.8 Image analysis
Tiled images from microscopy were analyzed using the ImageJ program. The cell
counter add-on for this program was used to quantify the number of cells in a tiled image
that displayed a nuclear translocation of a transcription factor where a nuclear
translocation was defined as visible fluorescence in the area defined by the nuclear
marker. The nuclear to cytoplasmic fluorescence ratio was calculated by measuring the
fluorescence in the nuclei of cells defined by the nuclear marker and dividing this by the
fluorescence measured in a representative portion of cytoplasm near the nucleus.
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4.4.9 Statistical analysis
Prism software (Graphpad, La Jolla, California) was used to graph the data and
for calculation of statistical significance. A student’s T test was used to compare two
groups, while multiple comparisons were compared using an ANOVA followed by a T
test with a Bonferroni correction.
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Chapter 5

5

Overall discussion and future directions
In this thesis, I describe factors that influence the initiation and progression of

GCs directed against the autoAg MOG. The hypothesis that the MOG-induced GC would
be short-lived and less productive than foreign-Ag driven GCs is addressed.

5.1

Summary of the major findings of this thesis
In Chapter 2 of this thesis, I developed a novel protein expression system to

express large amounts of mMOGtag protein. I show that the mMOGtag expression system
is amenable to manipulation through the generation of haMOGtag, which alters T cell Agaffinity and induces accelerated proliferation of MOG-specific T cells. Both mMOGtag
and haMOGtag were confirmed to be capable of inducing EAE incorporating autoreactive
B and T cells confirming that these Ags can induce GC responses in the context of
relevant autoimmune disease. In Chapter 3, I used the tools developed in Chapter 2 to
determine factors that influence B cell differentiation in the context of autoimmune GC
responses. I found that immunization with MOG protein results in a short-lived GC that
produces few plasma cells relative to the model foreign-Ag, NPOVA. Instead, the MOGinduced immune response produces predominantly memory B cells; however, these cells
are short-lived. I then showed that the collapse of the MOG-induced GC response is
instructed by the autoreactive T cell and could be attributed to their low-affinity for Ag.
However, the short-lived nature of MOG-specific memory B cells was not under T cell
control. Despite evidence of T cells contributing to B cell fate choices in these Agmodels, I saw no evidence that TFH cells are differentially expressing molecules
associated with B cell differentiation. Instead, TFH cells differed only in absolute number,
a property that appears to be instructed by the Ag itself. Increases in TFH cell numbers
were also associated with an expansion of DZ B cells suggesting that absolute TFH cell
numbers influence the fate decision between staying in the GC and memory B cell
differentiation. Altogether, the MOG-induced autoreactive GC response is limited by
properties of the MOG-autoAg including low T cell Ag-affinity. One hypothesis that
could link the fate choices B cells make in immune responses to the properties of Ags, is
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that Ag-properties influence how signals are exchanged during B and T cell interactions.
This hypothesis was addressed in Chapter 4 by developing a tool to investigate the
kinetics of signal exchange between B and T cells during their interactions. I showed that
I can monitor the activation status of cells by monitoring the cytoplasmic to nuclear
translocations of the NFAT1 and p65 proteins. The reporter of NFAT1 activity was
successfully adapted for insertion into the endogenous NFAT1 locus using the
CRISPR/Cas9 system; however, this did not translate into successful generation of a
reporter mouse. The NFAT1 reporter has since been adapted for insertion into the Rosa26
locus and this construct should generate a functional reporter mouse.

5.2

A model of the autoreactive germinal center
Overall, the results of this thesis reinforce the current models of GC initiation and

progression but also extend them. One of the key findings in Chapter 3 was that MOGinduced GCs are biased towards centrocytes over centroblasts as a result of not
maintaining a DZ in the GC. Indeed, the lack of a DZ in the MOG-induced GC response
can potentially explain why I do not see efficient plasma cell production and why there is
preferential memory differentiation. In particular, differentiation into plasma cells is
favored in B cells that acquire a high-affinity BCR, where the acquisition of a highaffinity BCR is facilitated by SHM, whereas memory B cell differentiation is favored by
low-affinity BCRs (58, 108, 128, 152). As SHM occurs in the DZ of the GC (108), it
seems likely that the lack of selection of centrocytes to enter the DZ of the MOG-induced
GC would contribute to preferential memory B cell differentiation although, further
analysis of SHM in the MOG-induced GC would be required to validate this.
I also showed that when immunizing with haMOGtag instead of mMOGtag, which
incorporates a high-affinity T cell epitope, MOG-specific B cells favored staying in the
GC over memory B cell differentiation and this was associated with an expansion in the
DZ of the GC and increased proliferation. This result is also supported by the cyclic reentry model of the LZ and DZ of the GC and by studies looking at how Ag-presentation
affects B cell differentiation. In particular, several reports have shown that when
additional Ag is targeted towards a population of GC B cells, that population is
preferentially selected to enter the DZ of the GC over memory B cell differentiation (112,
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127). This is similar to my experiments with haMOGtag, where manipulation of T cell
Ag-affinity promoted the transition of GC B cells to enter the DZ, opposed to Ag-avidity
that was used in the studies mentioned above. One key difference between our model and
the studies mentioned above, is that in my experiments all GC B cells are presenting a
higher-affinity Ag whereas in their experiments they are targeting Ag towards a small
population of GC B cells within the GC. Thus, in their studies they are manipulating the
competitiveness of a specific population of GC B cells whereas in my experiments I am
manipulating the whole GC, as all GC B cells would present the exact same Ag. Indeed,
my results would suggest that B cell fate choices are influenced by not only competition
between B cells for Ag, but also that presentation of higher-affinity Ags can affect B cell
fate choices across the entire GC.
While I was able to show that T cell Ag-affinity affected the balance between
memory B cells and GC B cells, manipulation of T cell Ag-affinity in our MOG system
did not affect plasma cell generation unlike the manipulation of Ag-avidity in other
studies (112, 127). However, it should be noted that, although haMOGtag does contain a
higher-affinity peptide than mMOGtag, the affinity of this peptide is still much lower than
the affinity of many foreign Ag-derived peptides typically used in such studies (261,
350). Furthermore, the NF-M18-30 peptide used in haMOGtag has a relatively low affinity
for MHC class II molecules resulting in incomplete presentation of this peptide (351).
Thus, it is likely that haMOGtag only partially enhanced T cell Ag-affinity in B-T
interactions, perhaps explaining its modest effects. Consistent with this, in our
experiments using NPOVA and NPMOG, where there is a substantial difference in T cell
affinity, the results were more striking. Relative to NPOVA, NPMOG was characterized
by reduced early plasmablast expansion and reduced long-lived plasma cell generation.
Based on these results and the results of others (112), it seems likely that there is a
continuum where low levels of T cell help promotes memory B cell differentiation, while
intermediate levels of T cell help promotes GC maintenance and T cells imparting the
highest level of help promote plasma cell expansion.
An unexpected finding in this thesis was that TFH cells in the NPOVA, mMOGtag,
and haMOGtag responses had the same expression of cytokines and surface receptors
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known to influence B cell fate choices, despite clear evidence of B cells making different
fate decisions. The only major difference between these Ags, was the absolute number of
TFH cells that each Ag could induce. It is possible however, that the differing numbers of
TFH cells may alone be sufficient to change B cell fate choices. In all of the experiments
conducted in this study, the ratio of GC B cells to TFH cells remained the same, a finding
also supported by the results of others (170, 352), suggesting that the absolute numbers of
TFH cells by itself may determine the size of the GC B cell response. Furthermore, based
upon the experiments in this thesis and the results of others (170), Ag can be a limiting
factor in GCs by controlling the maintenance of TFH cells (170). In particular, Agpresentation by GC B cells is required for TFH cells to maintain PD-1 expression. This is
important because PD-1 signaling is required to suppress the expression of the CXCR3
chemokine receptor that normally directs TFH cells to leave the GC environment (180).
Thus, it seems likely that a combination of Ag-affinity and Ag-avidity may influence the
number of TFH cells that can be maintained in the GC, which in turn may determine the
number of GC B cells that can be supported. Nonetheless, it should be noted that Agaffinity can also affect the initial differentiation of pre-TFH cells (353, 354) and thus,
increased initial differentiation of pre-TFH cells could contribute to my findings.
Based upon the literature cited above, there are general rules established for how
B cell differentiation is instructed during GC responses: first, low BCR-affinity promotes
memory differentiation over GC B cell or plasma cell differentiation and high-BCR
affinity promotes plasma cell differentiation over GC B cell or memory B cell
differentiation; second, the acquisition of a high-affinity BCR is dependent on acquiring
high-affinity mutations through SHM that is largely influenced by the time GC B cells
stay within the DZ of the GC; lastly, presentation of larger amounts of Ag leads to
preferential plasma cell expansion and increased LZ to DZ transitions leading to better
GC retention of particular B cell clones in increased DZ dwell time. I have contributed to
these rules by expanding the last point. In particular, I have shown that in addition to the
absolute amount of Ag being presented, it is important to consider the cumulative
affinities of those Ags as this functions similarly to the presentation of more Ag.
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Altogether, these results suggest a model where the absolute number of TFH cells
controls LZ to DZ transitions. In particular, when TFH cells are limited, TFH cell help
would also be limited making it difficult for GC B cells to gain access to the DZ of the
GC (112). However, when TFH cells are in abundance, TFH cell help would be expected to
be plentiful resulting in many B cells being selected to enter the DZ of the GC. As
discussed above, how T cell Ag-affinity and the absolute number of TFH cells would
affect plasma cell differentiation is less clear. The decision to become a plasma cell is B
cell intrinsic (128). However, T cells can influence plasmablast proliferation (128, 156)
and influence the long-term production of plasma cells indirectly by maintaining GCs
over a longer period of time (126). Thus, the absolute number of TFH cells may influence
plasmablast proliferation or the accumulation of plasma cells over time; however,
additional experiments will be required to determine how this occurs. Putting all of these
ideas together, a model was generated and is summarized and described in Figure 5.1. In
the next sections I will address unresolved questions and the significance of this research.
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Figure 5.1. A model of how T cell antigen-affinity affects germinal center progression
Based on the results of this thesis, the initiation of GC responses is similar regardless of
the T cell controlling the GC. However, for low-affinity Ags, the low number of TFH cells
is limiting leading to fewer B cells acquiring sufficient T cell help. This leads to
inefficient plasma cell expansion and failure of centrocytes to be selected to enter the DZ
of the GC. Furthermore, this leads to B cells accumulating and persisting in the LZ of the
GC leading to preferential memory B cell differentiation. Limited interactions between B
and T cells also limits the maintenance of TFH cells, resulting in TFH cells losing their PD1high phenotype and leaving the GC. Then at the mature GC time point, an equilibrium is
reached between the small number of GC B cells and TFH cells allowing the maintenance
of a small GC response. In contrast, high-affinity Ags maintain themselves over longer
periods of time by maintaining a larger TFH cell pool that can support plasma cell
differentiation and LZ to DZ transitions in the GC.
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5.3

Future directions

5.3.1 Somatic hypermutation in the MOG-induced germinal center
One of the main functions of the GC, in particular the DZ of the GC, is to drive
SHM (58). Differences in SHM between the NPOVA and MOG GC responses could
potentially partially explain the collapse of MOG-induced GCs and inefficient plasma
cell differentiation. However, SHM was not addressed in this thesis. Studying SHM is
complicated by the need to sequence individual BCRs of GC B cells to identify mutations
in their BCRs. These mutations also need to be mapped, cloned, and expressed to test
how each mutation contributes to the affinity of the antibody/BCR. Mutations and their
affinities have been mapped for the NP system using B1-8 mice, indeed, the NP-system
has been used extensively for the study of SHM (355). In this study, we could not
conduct similar research as mutations in the IgHMOG BCR have not been mapped, which
requires a significant amount of work and was beyond what could be accomplished in
this thesis. Nonetheless, preliminary experiments to determine how autoreactive T cells
affect SHM could make use of the NPOVA and NPMOG systems, as the tools for
analyzing the NP response are already available (274).
This avenue of research would be of interest in the future as this could help
solidify the GC model I suggested above. In particular, I would expect that the MOGinduced GC would be characterized by low SHM and that SHM would be restored upon
immunizing with haMOGtag, as haMOGtag could support a sizable DZ. Presumably,
centroblasts would have a sufficiently longer DZ dwell time to permit efficient induction
of SHM (112). It should be noted however, that in some scenarios excessive TFH cell
support can inhibit SHM as a result of excessive selection of centrocytes for entry into
the DZ of the GC making it difficult to specifically expand high-affinity B cell clones
(356). Thus, it possible that additional T cell help would not promote SHM. Nonetheless,
based upon the results of Chapter 3, immunization with haMOGtag approached but did not
exceed the DZ proportions of the NPOVA GC, which effectively supports SHM and the
selection of high-affinity GC B cells (123), suggesting that immunization with haMOGtag
would not represent excessive T cell help.
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Another unresolved finding of this thesis is that although MOG-specific GCs start
as being predominantly MOG-specific, over time MOG-specificity appears to decrease,
something that is not seen with the NPOVA system. A similar phenomenon has been
described before where GC B cells undergo SHM to mutate their autoreactive BCRs to
become non-autoreactive (104, 357-359). In these scenarios, autoreactive B cells first
mutate their BCR to decrease their affinity for epitopes on the endogenously expressed
autoAg, then mutate their BCRs towards any foreign-epitopes on the immunizing-Ag. Of
key significance, as this process had been described to be dependent on the endogenous
expression of the autoAg, we can test whether this process is occurring in our
autoreactive GCs by taking advantage of MOG deficient mice (351), thereby eliminating
the endogenous Ag.
Another scenario where using MOG-deficient mice would be useful is in
understanding why MOG-specific memory B cells have a short life-span. In Figure 3.9, I
showed that autoreactive T cells were not responsible for programming unstable B cell
memory suggesting that the reduced life-span of autoreactive memory B cells was due to
some factor intrinsic to the autoreactive B cell or its environment. Using MOG-deficient
mice, we could determine whether endogenously expressed MOG, available in tissues
such as the deep cervical LNs (69, 70), is leading to activation-induced cell death of
MOG-reactive B cells as I would expect MOG-specific memory to be more stable in a
setting where no endogenous MOG is available. Additionally, if the MOG-deficient
background was crossed onto the IgHMOG mouse to generate MOG-specific B cells that
pass through immune tolerance unaffected, we could assess whether the reduced life-span
of MOG-specific memory B cells is as a result of anergy induced during development
(30). Indeed, we cannot be sure at this time that MOG-specific B cells do not start in an
anergic state and that being drawn into an immune response would reverse anergy in
these cells.

5.3.2 T cell antigen-affinity and the germinal center
In Chapter 3 of this thesis, there were unaddressed confounding factors
influencing the interpretation of how T cell Ag-affinity affects the GC: 1st, Many of my
experiments make use of two different T cells that differ in autoreactivity making it
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unclear whether autoreactivity or low T cell Ag-affinity was affecting my results; 2nd, in
my experiments using haMOGtag the differences in affinity were not substantial and lead
to only modest changes in the GC response. Thus, to more firmly establish how T cell
Ag-affinity affects the GC response, I would need to make use of an Ag-model system
that eliminates autoimmunity and has a greater range of T cell Ag-affinities that can be
manipulated. Both of these issues could be addressed using the NPOVA system using
B1-8 B cells and OTII T cells. The NP-based system is useful as NP can be attached to
any protein allowing for the B cell side of the immune response to be standardized to any
protein (360). The OTII T cell is also useful as it recognizes the OVA323-339 peptide with
a high-affinity (250) and it is easier to design mutated peptides (known as altered peptide
ligands) that lower T cell Ag-affinity than it is to increase T cell Ag-affinity. Indeed,
several altered peptide ligands of the OVA323-339 peptide have been described making it
possible to clone and express a series of OVA proteins exhibiting a gradient of T cell Agaffinities (250, 251). Overall, this system would not only provide more precise control of
T cell Ag-affinity, but it will also eliminate the confounding factor of autoreactivity.
Nonetheless, these results could also be validated using the haMOGtag system if done on
a MOG-deficient background to eliminate autoreactivity in IgHMOG B cells, 2D2 T cells,
and eliminate endogenous MOG-expression in the recipient environment.

5.3.3 Signal exchange and interaction duration of B and T cell conjugates
As I elaborated on in Chapter 4 of this thesis, there are several basic aspects of the
B and T cell interaction that are still not understood. In particular, it is not known what
the kinetics of signal exchange between B and T cells is during their interactions. This is
important as interactions can differ substantially in duration (78). Thus, it is not clear
whether signals can be effectively exchanged within a short-interaction or that signals
continue to be exchanged during long-interactions. This question requires the usage of
reporters such as the ones I had attempted to make in Chapter 4 of this thesis, which
would allow for real-time quantification of signaling in B and T cells as they interact in
living tissue. Indeed, if these reporter mice are successfully generated in the future, they
will be used to answer these questions.
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Beyond understanding the basic rules that govern B cell differentiation during B
and T cell interactions, these results are also likely relevant to the GC responses I have
characterized in this thesis. A promising explanation for how Ag-properties influence B
cell fate choices is that Ag-properties affect signal exchange between B and T cells
during their interactions. Indeed, the Kerfoot laboratory has found that during the pre-GC
phase of the immune response, B and T cells form shorter interactions in response to
MOG relative to NPOVA (Figure 5.2A). Furthermore, when we immunize with
NPMOG, we get an intermediate phenotype consistent with the intermediate phenotype I
saw in Chapter 3. Consistent with our results, others have seen that increased interaction
duration promotes GC B cell differentiation over memory B cell differentiation and
promotes ASC differentiation over GC B cell differentiation (112, 127). Thus, interaction
length may play a key role in determining B cell differentiation to these different Ags.
The maintenance of physical interactions between B and T cells is dependent on the
expression of SLAM proteins and ICAMs (160). Preliminary evidence suggests that
SLAM and ICAM-1 are upregulated on B cells when immunizing with NPOVA;
however, this fails to occur on MOG specific B cells and NPMOG immunization results
in an intermediate phenotype (Figure 5.2B). Thus, differential expression of ICAM-1
molecules and SLAM receptors that modify cellular adhesion may be responsible for the
differences in interaction length that we have seen. Further work will need to characterize
explicitly how Ag-properties influence the upregulation of these molecules on B cells,
whether these differences in receptor expression on B cells are truly determining
interaction length, and by extension, influencing how B cells are differentiating.
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Figure 5.2. Pre-GC B and T cell interactions are influenced by properties of immunizing
Ags.
(A and B) Fluorescent protein-marked Ag-specific B and T cells were transferred into
non-fluorescent protein-marked SMARTA recipient mice then immunized with the
indicated Ag two days post-transfer. Two days post-immunization, the popliteal LN was
exposed for intravital two-photon microscopy to track Ag-specific B and T cell
interactions over time (A) or LNs were processed for flow cytometry analysis (B). (B) N
is IgD- CD19+ GFP- B cells, Ag is IgD- CD19+ GFP+ B cells. *p<0.05, **p<0.01,
****p<0.0001. Data courtesy of Dr. Parham.
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5.4

B cells in MS and EAE
In addition to acquiring a better understanding of the basic biology of GC

responses, the results of this thesis have important implications to the autoimmune
disease MS and its animal model EAE. In particular, there is the idea that myelin-specific
B cells are activated in the deep cervical LNs and that these cells are fueling a myelinspecific B cell response in the CNS (68-70). Nonetheless, despite evidence of myelinspecific GCs occurring in MS (62), no other study beyond the work in this thesis has
characterized a myelin-specific GC. Indeed, the short-lived nature of myelin-specific GCs
is likely to have several implications in how we look at MS.
Currently, the memory B cell subset appears to be a promising candidate for the
pathogenic subset in MS (5, 361). In this thesis, I found MOG-specific GCs produced
memory B cells in abundance at the early stages of the GC response; however, these cells
were short-lived. Given that memory B cells have recently been shown to be potent
inducers of myelin-specific T cell responses (361), then it would be expected that their
short life span would represent a major limitation in driving the disease. Indeed, this
would suggest that myelin-specific B cells would need constant replenishment to
continue to fuel the autoimmune response and thus, would be therapeutically targetable
throughout MS. Consistent with the idea autoreactive GCs require replenishment, MS
relapses are associated increased numbers of circulating memory TFH cells, that are
generated during the initiation of GCs and throughout GCs (94), suggesting the induction
of autoreactive GCs coincides with disease progression (362, 363).
One possibility that was not fully addressed in this thesis or in the MS literature in
general, is that some of the cells that we are defining as memory B cells may actually be
ABCs. This population is produced from GC responses to most Ags (166) and has a
tendency to localize to the B cell follicle-T cell zone border where they can interact with
T cells and promote T helper 17 cell differentiation (148), a T cell subset associated with
the promotion of MS and EAE (364-367). Indeed, when looking at GC histology, many
GFP+ B cells can be seen at the B cell follicle-T cell zone interface although presently it
cannot be definitively determined whether these cells are ABCs. Nonetheless, knowing
whether ABCs are being generated in GCs would be of interest as this population appears
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to be expanded in MS patients and also shows evidence of disproportionate
representation in the cerebral spinal fluid of MS patients relative to peripheral blood
suggesting these cells actively accumulate in the inflamed CNS (141).
Beyond my analysis of GCs and memory B cells, I also found that when
immunizing with our MOG Ag, I could induce Ag-specific plasma cell responses
including the generation of long-lived plasma cells that could be detected as late as d39
post-immunization. This would suggest that even a single GC response directed against a
myelin autoAg is sufficient to drive an antibody response including the generation of
long-lived cells that can maintain antibody production over time. Although antibodies are
not the main driving factor in MS (368), they can exacerbate damage (61-63) and thus,
should ideally be suppressed. However, if these plasma cells are actually long-lived, then
halting their production is unlikely to appreciably affect their numbers as it would require
a great deal of time for the long-lived plasma cells to die off. Altogether, these results
would suggest that the therapeutic targeting of autoreactive GCs to induce a full collapse
would quickly lead to the deterioration of myelin-specific memory B cells as these cells
would not be renewed; however, long-lived plasma cells would persist.

5.5

Concluding remarks
The focus of the research conducted in the Kerfoot laboratory is to understand the

basic rules governing B cell differentiation and establishing the role of B cells in MS. The
work in this thesis bridges the gap between these two goals by establishing the rules that
govern myelin-specific GC development, but also doing this in a model that is relevant to
CNS autoimmune disease. Indeed, relative to the development of GCs towards foreignAgs, the GC response against MOG diverges significantly from the expected trajectory of
a foreign-Ag resulting in plenty of opportunities to look at factors that influence B cell
differentiation. This thesis focused predominantly of how T cells contribute to the
collapse of autoreactive GCs. However, as shown in the above sections, there may also
be differences between MOG and foreign-Ag specific B cells that may be contributing to
the differential GC progression I have seen. Furthermore, I do not know how the
autoreactive origins of the B and T cells I studied or how the expression of endogenous
autoAg may be contributing to GC progression. Both of these issues will need to be
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studied in more detail. Thus, the results of this thesis points to several different avenues
of research on basic B cell biology that will need to be addressed in the future.
Additional work is also needed to characterize how myelin-specific B cells
contribute to EAE. I have shown that MOG-specific B cells can be expanded through
immunization with MOG and I and others have shown that MOG-specific B cells
contribute to EAE. Nonetheless, it is still not known how or where MOG-specific B cells
contribute to EAE. Thus, future research will need to characterize how the subsets of B
cells produced in MOG-specific GCs, are contributing to EAE. Overall, the research in
this thesis into the manipulation of B cell responses may be valuable in vaccine design,
but also for understanding how autoreactive B cell responses initiate and progress.
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